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ABSTRACT 
 
Sirisha Pochareddy 
TRANSCRIPTIONAL REGULATION OF THE HUMAN ALCOHOL 
DEHYDROGENASES AND ALCOHOLISM 
 
Alcohol dehydrogenase (ADH) genes encode proteins that metabolize 
ethanol to acetaldehyde. Humans have seven ADH genes in a cluster. The 
hypothesis of this study was that by controlling the levels of ADH enzymes, cis-
regulatory regions could affect the risk for alcoholism. The goal was thus to 
identify distal regulatory regions of ADHs. To achieve this, sequence 
conservation across 220 kb of the ADH cluster was examined. An enhancer (4E) 
was identified upstream of ADH4. In HepG2 human hepatoma cells, 4E 
increased the activity of an ADH4 basal promoter by 50-fold. 4E was cell specific, 
as no enhancer activity was detected in a human lung cell line, H1299. The 
enhancer activity was located in a 565 bp region (4E3). Four FOXA and one 
HNF-1A protein binding sites were shown to be functional in the 4E3 region. To 
test if this region could affect the risk for alcoholism, the effect of variations in 
4E3 on enhancer activity was tested. Two variations had a significant effect on 
enhancer activity, decreasing the activity to 0.6-fold. A third variation had a small 
but significant effect. The effect of variations in the ADH1B proximal promoter 
was also tested. At SNP rs1229982, the C allele had 30% lower activity than the 
A allele. 
 vii 
 
In addition to studying the regulatory regions of ADH genes, the effects of 
alcohol on liver-derived cells (HepG2) were also explored. Liver is the primary 
site of alcohol metabolism, and is highly vulnerable to injuries due to chronic 
alcohol abuse. To identify the effects of long term ethanol exposure on global 
gene expression and alternative splicing, HepG2 cells were cultured in 75 mM 
ethanol for nine days. Global gene expression changes and alternative splicing 
were measured using Affymetrix GeneChip® Human Exon 1.0 ST Arrays. At the 
level of gene expression, genes involved in stress response pathways, metabolic 
pathways (including carbohydrate and lipid metabolism) and chromatin regulation 
were affected. Alcohol effects were also observed on alternative transcript 
isoforms of some genes. 
 
                                                                                    Howard J. Edenberg, Ph.D.  
                                                                                      Committee Chair.                            
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I. INTRODUCTION 
 
1. Alcohol dehydrogenases 
Medium-chain alcohol dehydrogenases (ADH) catalyze the reversible 
oxidation of ethanol and other alcohols to acetaldehyde (Edenberg and Bosron, 
1997; Zakhari, 2006). ADHs are dimeric proteins that utilize NAD+ as the 
coenzyme. Each ADH subunit is 40 kDa, binds two zinc ions and has catalytic 
and coenzyme binding domains (Hurley et al., 2002).  
 
 
 
Figure 1. The primary pathway of alcohol metabolism. ADH, alcohol 
dehydrogenase; ALDH, aldehyde dehydrogenase 
 
 
Based on their sequence homology and kinetic properties, ADHs have 
been classified into different classes. In vertebrates, eight classes (I to VIII) have 
been identified, with no species encoding all eight classes (Duester et al., 1999; 
Peralba et al., 1999). Enzymes in classes I to V are present in multiple species 
including humans. Class VI is found only in rats and the deer mouse (Hoog and 
Brandt, 1995; Zheng et al., 1993). Classes VII and VIII are found in the chicken, 
and the amphibians, respectively (Kedishvili et al., 1997; Peralba et al., 1999). 
Less than 70% sequence homology has been observed between different 
classes, and only proteins within a class form dimers. The class III enzyme is the 
only ADH enzyme seen in invertebrates and thus is considered the ancestral 
Ethanol Acetaldehyde Acetate 
NAD+ NADH NAD + NADH
ADH ALDH
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form that gave rise to other isozymes (Cederlund et al., 1991; Danielsson and 
Jornvall, 1992). 
In humans there are seven ADH isozymes including three class I proteins. 
Class I proteins α, β and γ share greater than 90% similarity and can form homo- 
or heterodimers (Edenberg, 2000). The Class II ADH includes the π polypeptide; 
the class III includes the χ polypeptide; the Class IV, has the σ polypeptide 
isozyme, and no endogenous protein has been reported for class V.
 3 
 
 
 
Table 1. Tissue distribution and substrate specificity of human ADH 
isozymes. HMGSH is S-(hydroxymethyl) glutathione and GSNO is S-
nitrosoglutathione  
 
1(Smith et al., 1971) 
2(Smith et al., 1972) 
3(Smith, 1986) 
4(Duley et al., 1985) 
5(Allali-Hassani et al., 1997) 
6(Estonius et al., 1996) 
7(Yin et al., 1990) 
8(Yokoyama et al., 1995) 
  9 (Zgombic-Knight et al., 1995) 
10(Dong et al., 1996) 
11(Yin et al., 1993) 
12(Edenberg and Bosron, 1997) 
13(Yang et al., 1994) 
14(Kaiser et al., 1991) 
15(Koivusalo and Uotila, 1991) 
16(Staab et al., 2008) 
 
 
 
 
Class Gene Protein Tissue distribution Common substrates 
I ADH1A α 
fetal and adult liver1,2, 
adult kidney3, adrenal 
gland6 
ethanol12, retinol13 
I ADH1B β  
fetal and adult liver1,2, 
adult kidney1,4, lung1,4 , 
blood vessels5, adrenal 
gland6 
ethanol12, retinol13 
I ADH1C γ adult liver
2, fetal 
kidney1, adrenal gland6 ethanol
12, retinol13 
II ADH4 π 
fetal and adult liver1,6, 
stomach6, intestine6, 
pancreas6 
ethanol12, retinol13 
III ADH5 χ ubiquitous in adult
4,6 
and fetus6 HMGSH
14,15, GSNO16 
IV ADH7 σ adult stomach
7,8, upper 
GI tract10,11, fetal liver6 retinol
13, ethanol12 
V ADH6 None as mRNA in fetal and adult liver6 ethanol
12 
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The seven ADH isozymes have overlapping substrate specificities (Table 
1). All isozymes are active with ethanol, albeit with different Vmax and Km values 
(Edenberg and Bosron, 1997; Hurley et al., 2002). Class I enzymes have the 
lowest Km for ethanol and account for approximately 70% of alcohol metabolism 
in the liver (Hurley et al., 2002). Class II π- ADH, which has a Km of 34 mM for 
ethanol, contributes to most of the remaining 30% of alcohol metabolism in the 
liver (Hurley et al., 2002; Li et al., 1977). Class IV ADH has an intermediate Km 
value but the highest Vmax for ethanol (Kedishvili et al., 1995). It contributes 
mostly to alcohol metabolism in the stomach, where it is present at maximum 
concentration (Yin et al., 1990; Yokoyama et al., 1995). Class III ADH is a 
glutathione-dependent formaldehyde dehydrogenase that metabolizes 
glutathione adducts such as S-(hydroxymethyl) glutathione (HMGSH) and S-
nitrosoglutathione (GSNO) more efficiently than primary alcohols and aldehydes 
(Kaiser et al., 1991; Koivusalo and Uotila, 1991; Staab et al., 2008). 
 In addition to dietary alcohol, other physiological substrates of ADH 
enzymes have been identified. One important substrate is retinol (vitamin A). 
Class I, II, and IV enzymes catalyze the oxidation of retinol to retinaldehyde, the 
first step in the synthesis of retinoic acid (Yang et al., 1994). Class IV ADH is the 
most active form of retinol dehydrogenase (Zgombic-Knight et al., 1995). Gene 
deletion studies in mice have shown that the Class IV ADH is protective against 
retinol deficiencies in the diet (Deltour et al., 1999; Molotkov et al., 2002). Other 
physiological substrates of ADHs include cytotoxic aldehydes generated during 
lipid peroxidation (Boleda et al., 1993), ω-hydroxy fatty acids (Boleda et al., 
 5 
 
1993), 3β-hydroxy-5β steroids (McEvily et al., 1988), 4-hydroxy-3methoxyphenyl 
ethanol (Mardh and Vallee, 1986) and 4-hydroxy-3methoxyphenyl glycol (Mardh 
et al., 1986; Mardh et al., 1985). 
 
2. Human ADH cluster 
In humans the seven ADH isozymes are encoded by seven genes  
ADH1A (encodes α), ADH1B (β), ADH1C (γ), ADH4 (π), ADH5 ( χ), ADH6 (no 
protein; only mRNA), ADH7 (σ) (Table 1 ). The seven genes are present as a 
cluster spanning approximately 365 kb on chromosome 4q23 (Figure 2); a similar 
clustering of ADH genes is also observed in other mammals. In humans, all the 
seven genes have nine exons and eight introns (Edenberg, 2000). The direction 
of transcription is also the same and is from qter to pter (shown in the reverse 
orientation in Figure 2).  
 
 
 
 
Figure 2. Diagram of the human ADH cluster. Seven alcohol dehydrogenase 
genes are shown in their transcriptional orientation (they are oriented on the 
chromosome 4q in the opposite direction). Arrows mark the genes and depict the 
direction of transcription. The genes range in size from 14.5 kb to 23 kb; 
intergenic distances are given in kb.  
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All ADH genes except ADH7 are expressed at the highest levels in the 
liver; ADH7 is highly expressed in the stomach and the upper gastrointestinal 
tract (Edenberg, 2000). In other tissues they are expressed to lower levels and 
each class has a distinct pattern of expression. ADH5 is ubiquitously expressed 
and thus is the only ADH present in the brain. Tissue distribution of ADHs is 
summarized in Table 1. 
With the exception of ADH1C, all ADHs are detected in fetal liver 
(Estonius et al., 1996). Class I ADHs exhibit temporal expression patterns during 
development. ADH1A and ADH1B are expressed in early (second trimester) and 
late (third trimester) fetal liver, respectively (Smith et al., 1971, 1972). Expression 
of ADH1C is observed only after birth (Smith et al., 1972). Once expressed, 
ADHs are expressed constitutively in adult organisms. 
 
3. Additional pathways of alcohol metabolism 
In humans, alcohol is metabolized predominantly in the liver by ADHs. 
Besides ADHs, oxidative metabolism of alcohol is also catalyzed by cytochrome 
P450 enzymes including (CYP2E1, CYP1A2 and CYP3A4) and hydrogen 
peroxide-dependent catalase (Handler et al., 1986; Handler and Thurman, 1988; 
Lieber, 2004; Lieber and DeCarli, 1968; Salmela et al., 1998; Zakhari, 2006). 
These three enzyme systems are localized to different sites within a cell; ADHs 
are present in the cytosol. CYP2E1 and catalase are present in microsomes and 
peroxisomes, respectively (Handler and Thurman, 1988; Lieber, 2004; Zakhari, 
2006). The contribution of CYP2E1 to alcohol metabolism is minor because 
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CYP2E1 is induced only at elevated concentrations (Badger et al., 1993; Zakhari, 
2006). Catalase also has a small role as it is limited by the availability of 
hydrogen peroxide (Lieber, 1984; Zakhari, 2006). Acetaldehyde generated from 
alcohol by any of these enzymes is further metabolized to acetate by aldehyde 
dehydrogenases (ALDH) (Hurley et al., 2002). 
 
4. Alcoholism 
Alcoholism is a complex disease affecting millions in the world, including 4 
to 5% of the population in the United States at any given time (Li et al., 2007). 
Chronic alcohol abuse is associated with numerous health risks such as liver 
cirrhosis, cancer and cardiovascular disease (Cargiulo, 2007; Rehm et al., 2003). 
In addition, it has undesirable social consequences: traffic accidents, domestic 
violence, sexual assault and child malnutrition; it is the third leading cause of 
preventable deaths in the United States (Mokdad et al., 2004). 
Diagnostic criteria for alcoholism have been defined in Diagnostic and 
Statistical Manual of Mental Disorders (DSM) and International Classification of 
diseases (ICD). According to the most recent DSM criteria (DSM-IV), a person is 
said to be alcohol dependent if he or she exhibits a maladaptive pattern of 
drinking with three or more of the following symptoms occurring at any time in a 
period of one year: tolerance, withdrawal, impaired control, neglect of activities, 
excessive time spent in alcohol-related activity and/or continued use despite 
knowledge of the problem (Grant, 1996; Hasin, 2003).  
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Alcoholism is influenced by both genetic and environmental factors. 
Evidence for genetic risk was obtained from family, twin and adoption studies 
(Birley et al., 2005; Goodwin et al., 1973; Goodwin et al., 1974; Kendler et al., 
1997; Mayfield et al., 2008; McGue, 1997; McGue, 1999; Nurnberger et al., 2004; 
Prescott et al., 1999; Prescott and Kendler, 1999). Monozygotic twins of 
alcoholics exhibit greater risk for alcoholism whereas dizygotic twins of alcoholics 
are at approximately the same risk as full siblings (Kendler et al., 1997; Prescott 
et al., 1999). Children adopted away from alcoholic parents exhibit the same risk 
as the children brought up by their biological parents, further supporting the role 
of genetics in the risk for alcoholism (Goodwin et al., 1973; Goodwin et al., 1974). 
Together these studies suggest that greater than 50% of the risk for the disease 
is from genetic factors.  
Several studies have been carried out to identify genes associated with 
the risk for alcoholism. ADH and ALDH were the first genes to be associated with 
alcoholism (Bosron and Li, 1986). Gamma-aminobutyric acid A receptor, alpha 2 
(GABRA2) (Edenberg et al., 2004), cholinergic receptor, muscarinic 2 (CHRM2) 
(Luo et al., 2005; Wang et al., 2004), cholinergic receptor, nicotinic, alpha 5 
(CHRNA5) (Wang et al., 2009), opioid receptor, kappa 1 (OPRK1) (Edenberg et 
al., 2008a; Xuei et al., 2007; Zhang et al., 2008a), nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1 (NFKB1) (Edenberg et al., 2008b) are 
some of the genes that have been reported recently in genome-wide association 
studies.  
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5. ADHs and alcoholism 
The effects of ethanol on liver and other organs in the body are dependent 
on the concentrations of ethanol (Gronbaek, 2009). The rate at which ethanol is 
metabolized influences the concentrations of ethanol and acetaldehyde. Two 
important factors that could determine the rate of ethanol metabolism are (1). the 
kinetic properties of ADH enzymes, and (2). the levels of ADH enzymes. Several 
studies have reported association of variations in the coding and non-coding 
variations of ADHs with the risk for alcoholism (Birley et al., 2009; Edenberg and 
Foroud, 2006; Edenberg et al., 2006; Reich et al., 1998; Williams et al., 1999).  
Functional variations in the class I ADHs have been studied extensively. 
There are three known alleles of ADH1B that vary at a single nucleotide position 
(Edenberg, 2007; Hurley et al., 2002). These single nucleotide polymorphisms 
(SNP) lead to non-synonymous changes in the amino acid sequence. The β1 
subunit encoded by ADH1B*1 has arginine (Arg) at positions 48 and 370. In the 
β2 subunit encoded by ADH1B*2 subunit Arg at position 48 is changed to 
histidine (His) whereas in the β3 subunit encoded by ADH1B*3, Arg at position 
370 is changed to cysteine (Cys). These substitutions result in enzymes with 
turnover rates 80- to 90-fold greater than ADH1B*1(Hurley et al., 2002). The 
protective effect of these variations was studied in the Asian populations where 
the ADH1B*2 allele is most commonly seen. In Chinese men living in Taiwan, the 
frequency of the ADH2*2 allele was 0.73 in the non-alcoholic population but 
reduced to 0.48 in alcoholics suggesting a protective effect (Thomasson et al., 
1994; Thomasson et al., 1991).  
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Two alleles that alter the kinetic properties of the ADH1C enzyme have 
also been identified. The two alleles differ in two amino acid positions; the 
ADH1C*1 allele has an Arg and isoleucine (Ile) at positions 272 and 350, 
respectively. The ADH1C*2 allele instead has glutamine (Gln) and valine (Val) at 
the same positions. The protein encoded by ADH1C*1 has 2.2-fold greater 
turnover rate than ADH1C*2 and shown to be protective in Asian population 
(Hurley et al., 2002).  
Besides ADH coding variations, variations in cis-regulatory elements that 
affect the levels of ADH enzymes have been associated with alcoholism. A SNP 
at position -136 (relative to the +1 translational start site) in the promoter of the 
ADH4 gene affects the promoter activity in hepatoma cells, with the A allele 
having 2-fold higher activity than the C allele (Edenberg et al., 1999). This SNP 
has been associated with alcohol dependence in a Brazilian population 
(Guindalini et al., 2005). In the Japanese population, lower blood alcohol levels 
were observed in people with this regulatory variation in people with 
ALDH2*487Glu/Glu genotype (Kimura et al., 2009).  
Regulatory polymorphisms that affect the expression levels were also 
identified in a distal regulatory element 3 kb upstream of ADH1C promoter (Chen 
et al., 2005). The effect of various haplotypes of this region on basal promoter 
activity was studied. The haplotypes carried a combination of three SNPs and 
one 66 bp insertion / deletion. Insertion or deletion alone did not have any effect 
on the promoter function. However, a significant difference in activity was 
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observed in two haplotypes that differed at all four positions; one haplotype 
decreased the promoter activity by 57% whereas another had no effect  
Because regulatory polymorphisms may play a critical role in affecting the 
genetic risks for alcoholism, a comprehensive knowledge of ADH transcriptional 
regulation is necessary.  
 
6. Transcriptional regulation of ADHs 
Regulation of transcription is accomplished through the complex 
interaction of cis-acting regulatory elements, proteins that bind these elements 
and the chromatin structure. Cis-elements that regulate gene expression include 
proximal promoters, enhancers, silencers, locus control regions (LCR), and 
insulators (Maston et al., 2006; West and Fraser, 2005). Enhancers, silencers 
and LCRs can control gene expression in an orientation-independent and 
position-independent way, and from locations as remote as 80 kb from the gene 
(Bondarenko et al., 2003; Maston et al., 2006). Enhancers bind activator proteins 
that activate transcription by recruiting general transcription factors and RNA 
polymerase II and/or by recruiting chromatin remodeling complexes that render 
the chromatin accessible to general transcription factors and RNA polymerase II. 
Silencers function by binding repressor proteins that inhibit assembly of general 
transcription factors and thereby repress expression. LCRs are complex 
regulatory modules with the ability to regulate transcription of multiple genes in 
the locus (Dean, 2006). Insulators are boundary elements that protect a gene 
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from the influence of neighboring cis-regulatory elements like enhancers or 
silencers (Bushey et al., 2008). 
To understand the regulation of ADH expression the proximal promoter 
regions of ADHs have been studied extensively. In addition distant regulatory 
enhancer for class I ADH genes has been identified. However, distal regulatory 
mechanisms for the other classes of ADH genes have not been addressed yet.  
Proximal promoters of the ADH genes have binding sites for multiple 
proteins (Figure 3). The transcription factors that are important for expression of 
ADHs include CCAAT/enhancer-binding protein (C/EBP) family, Specificity 
protein 1 (Sp1), CCAAT transcription factor (CTF), upstream stimulatory factor 
(USF), hepatocyte nuclear factor-1 (HNF-1) and Activator protein-1 (AP-1) 
(Edenberg, 2000). 
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Figure 3. Schematic representation of cis-acting elements in the proximal 
promoters of ADH genes.  Transcription factors known to bind a given site are 
shown above the site. Numbering is relative to the +1 transcription start site. 
Please refer to the text for references.  
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The human class I ADH genes share 80-90% identity in the region 
extending 270 bp upstream of the transcription start site (Brown et al., 1996). 
Two C/EBP sites flank the TATA box and both sites are bound by proteins 
(C/EBPα, C/EBPβ or Albumin D-site binding protein, DBP) in ADH1B and 
ADH1C. In ADH1A only the downstream site is bound by these proteins (Brown 
et al., 1994, 1996; Carr and Edenberg, 1990; Stewart et al., 1990a; Stewart et al., 
1990b; van Ooij et al., 1992). Binding sites for USF, Sp1, HNF-1 and CTF are 
also present in the proximal promoters. Sp1, USF and HNF-1 enhance the 
expression, whereas CTF decreases the expression of ADH1B in transient 
transfection assays in hepatoma cells (Brown et al., 1996). In addition to these 
elements, ADH1B and ADH1C have a glucocorticoid response element (GRE) 
and a retinoic acid responsive element (RARE), respectively (Duester et al., 
1991; Winter et al., 1990). The glucocorticoid response element (GRE) in ADH1B 
overlaps with the HNF-1 site and can bind purified glucocorticoid receptor (Winter 
et al., 1990). Dexamethasone, a synthetic glucocorticoid, can induce two- to four-
fold expression from ADH1B promoters with GRE (Winter et al., 1990). A similar 
increase in endogenous expression of ADH1 was observed in H4IIE-C3 rat 
hepatoma cells upon treatment with dexamethasone (Dong et al., 1988).  
The retinoic acid responsive element (RARE) element in ADH1C is 
created by tandem duplication of 29 bp found in all class I ADH promoters. The 
duplicated downstream sequence can bind retinoic acid receptor and induce 
expression in the presence of retinoic acid (Duester et al., 1991; Harding and 
Duester, 1992).  
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ADH4 proximal promoter has nine protein binding sites, of which seven 
(sites 1 to 7) are bound by proteins present in liver extract (Li and Edenberg, 
1998). Sites 8 and 9 are protected by extracts from kidney and spleen, 
respectively. C/EBP proteins bind to sites 2 and 4 and AP-1 binds to sites 1, 2 
and also 4. Sites 2 to 7 act as positive regulators in rat hepatoma cells, but with 
different strengths. Site 8 acts as a negative element, decreasing the activity of 
the basal promoter by 21%. 
ADH5 promoter is G-C rich and unlike other ADH genes, lacks a TATA 
box. There are ten (A to J) protein binding sites in the proximal 400 bp region 
(Hur and Edenberg, 1995). Minimal promoter with sites A through C is functional 
in H4IIE-C3 rat hepatoma cells, CV-1 African green monkey kidney cells, and 
HeLa cells. Sp1 binds to all three sites and activates expression. Binding of Sp1, 
however, is modulated by other members of Sp family and FB-1 transcription 
factor. Sp3, Sp4 and FB-1 compete with Sp1 to bind to site C and therefore 
decrease the activity of the promoter (Kwon et al., 1999; Lee et al., 2002). Sites 
E, G, H and I decrease activity in all cells studied. Sites D and F exhibit cell-
specific activity; site D has a positive effect in H4IIE-C3 cells but no effect in the 
other cells. Conversely, site F acts a positive element in CV-1 and HeLa cells but 
as a weak negative element in H4IIE-C3 cells (Hur and Edenberg, 1995).  
Post-transcriptional regulation, by two upstream AUG codons in the 
mRNA, of ADH5 has also been reported. Mutation at one or both of the upstream 
AUG codons increased gene expression by two-fold in examined cells (Kwon et 
al., 2001).  
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The ADH6 promoter has nine (A to I) protein binding sites within 300 bp of 
the transcription start site (Zhi et al., 2000). All sites are bound by liver extract 
and act as positive elements in rat hepatoma cells. Sites C, D and E are 
recognized by C/EBPα. Two cell-specific elements are present further upstream, 
between -1.2 kb and -2.3 kb. Site 1 decreased the activity of the promoter in non-
hepatoma cells while site 2 increased the activity in hepatoma cells.  
The ADH7 proximal promoter has four (A to D) protein binding sites, three 
of which are bound by proteins in the nuclear extract of different cells tested 
(Kotagiri and Edenberg, 1998). AP-1 binds strongly to site A and weakly to site 
C. Mutation in site A disrupts AP-1 binding and leads to a decrease in promoter 
activity, highlighting the importance of this site. C/EBP binds strongly to site B but 
decreases the activity of the promoter as observed in C/EBP overexpression 
studies. This effect could be one of the reasons why ADH7 is not expressed in 
liver, where C/EBP proteins are present at high levels.  
Known cis-regulatory elements in the proximal promoter regions do not 
entirely explain the tissue specific expression of ADHs in adults and the temporal 
expression of class I ADH genes in the fetus. In mice, 12 kb upstream and 23 kb 
downstream regions of ADH1 were inadequate to induce ADH1 expression in 
liver (Szalai et al., 2002). However, 110 kb upstream and 104 kb downstream 
regions were able to induce expression (Szalai et al., 2002). This indicates the 
presence of regulatory regions far from the promoter. In humans an HNF-1 
binding site, 51 kb away from the class I ADH cluster, was identified (Su et al., 
2006). This region was shown to regulate tissue specific expression of all the 
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class I genes and when deleted repressed the expression of each of the class I 
ADH genes in transgenic mice. The HNF-1 binding site was also shown to 
interact with the class I ADH promoters suggesting a DNA looping mechanism of 
activation. 
 
7. Identification of cis-regulatory regions 
In humans, 95% of the genome is non-coding sequence, and cis-
regulatory regions are only a small part of this. Therefore, identifying cis-
regulatory sequences like enhancers or silencers that can work from hundreds of 
kb away is a difficult task. Many approaches have been explored in the literature 
(Elnitski et al., 2006). The classical approach to search for regulatory regions of a 
gene of interest is to make deletion constructs of proximal regions and test these 
in reporter gene assays. However, this approach becomes cumbersome to 
identify distal regulatory regions. A more useful technique to identify distal 
regulatory regions has been the DNaseI hypersensitivity assay (Gazit and Cedar, 
1980). It is based on the principle that the chromatin in the regulatory regions is 
more accessible to proteins and as a result, more sensitive to DNaseI, a non-
specific endonuclease. Another technique that has been widely used in recent 
years for identifying or characterizing regulatory regions is chromatin 
immunoprecipitation (ChIP) (Dedon et al., 1991; Kuo and Allis, 1999). The 
function of regulatory regions is mediated via the binding of trans-acting 
transcription factors; thus studying DNA-protein interactions in vivo leads to 
identification of regulatory regions. Recently high-throughput versions of DNaseI 
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hypersensitive site assays and ChIP assays have been developed and used to 
identify regulatory regions on a genome-wide scale (Crawford et al., 2006a; Ren 
et al., 2000; Robertson et al., 2007; Sabo et al., 2006; Song and Crawford, 
2010). However, these are still not cost-effective approaches for many research 
labs. 
A computer based approach for identifying regulatory regions in the 
genome is comparative genomics (King et al., 2007; Miller et al., 2004). 
Comparative genomics involves cross-species sequence comparisons to identify 
evolutionarily conserved sequences. The underlying assumption for this strategy 
is that if a region is evolutionarily conserved, it implies a functional role 
(Hardison, 2000). Or if a region has a critical functional role, like gene regulation, 
then it is protected from mutations in the sequence. One of the first cellular 
enhancers discovered was identified through sequence conservation (Emorine et 
al., 1983). With the availability of genome sequences from increasing number of 
organisms, identifying regulatory regions through sequence conservation is a 
powerful tool.  
 
8. Transcription factors 
Transcriptional regulation is achieved through interaction of cis-regulatory 
regions with the trans-acting proteins. There are three kinds of transcription 
factors (Martinez, 2002; Tjian, 1996):  
1. general transcription factors including RNA polymerase and 
transcription factor II family of proteins that are involved in initiation, 
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elongation and termination of transcription (Sikorski and Buratowski, 2009; 
Thomas and Chiang, 2006). 
 2. sequence-specific DNA binding proteins that bind cis-regulatory 
regions in the genome and control the expression of the corresponding 
genes; activator and repressor proteins fall under this group. 
3. transcription cofactors mediate interactions between the basal 
transcription factors and sequence specific effectors. These include 
mediator complexes and chromatin remodeling complexes (Casamassimi 
and Napoli, 2007; Clapier and Cairns, 2009; Thomas and Chiang, 2006).  
 
Activator proteins that are involved in regulatory mechanisms in this study are 
discussed below. 
 
8.a. FoxA family 
FoxA (previously known as Hepatocyte nuclear factor-3) transcription 
factors are a sub-family of forkhead box (Fox) proteins, which contain a 110 
amino acid forkhead DNA binding domain (Weigel and Jackle, 1990). There are 
three FoxA proteins, FoxA1, FoxA2, and FoxA3, and they share 95% sequence 
identity in the forkhead domain. Forkhead domain has a ‘winged helix’ structure 
where three helices are arranged in a helix-turn-helix core, and flanked by loops 
(Clark et al., 1993). FoxA proteins also have trans-activation and histone 
interaction domains at the N and C-termini of the protein, respectively (Pani et 
al., 1992; Qian and Costa, 1995). FOXA proteins recognize VAWTRTTKRYTY 
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sequence, where V is A/C/G nucleotide, W is A/T, R is A/G, K is G/T and Y is C/T 
(Overdier et al., 1994) 
FoxA proteins are highly expressed in the liver and regulate many liver-
specific genes in adult organisms (Friedman and Kaestner, 2006; Schrem et al., 
2002). Albumin (Herbst et al., 1991), aldoalse B (Gregori et al., 1994), 
transerythrin (Herbst et al., 1991) are some of the genes that are regulated by 
FOXA proteins. FOXA proteins play essential roles during development. They 
are expressed sequentially during development; FoxA2 appears by embryonic 
day 6.5 (E6.5), followed by FoxA1 and FoxA3 (Sasaki and Hogan, 1993). FoxA2 
null mutations are embryonic lethal while FoxA1 and FoxA3 are postnatally lethal 
(Lee et al., 2005).  
FoxA proteins belong to a class of transcription factors that function as 
pioneer factors, proteins that can bind highly compacted chromatin and alter the 
chromatin structure and enhance transcription (Zaret et al., 2008). During 
development, FoxA proteins have been shown to bind the enhancer of the 
albumin gene and open the chromatin (Chaya et al., 2001; Cirillo et al., 2002). 
FoxA1 has also been shown to act as pioneer factor in adult tissues (Carroll et 
al., 2005; Gao et al., 2003; Zhang et al., 2005). 
 
8.b. HNF-1A  
Hepatocyte nuclear factor -1α (HNF-1A) is a liver enriched transcription 
factor with POU and homeodomain DNA binding domains (Baumhueter et al., 
1990). It also has three transactivation domains and a myosin-like dimerization 
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domain (Mendel et al., 1991a). It recognizes a consensus sequence 
GTTAATNATTAAC and binds to DNA as a dimer (Courtois et al., 1988; Frain et 
al., 1989). HNF-1A homodimers are stabilized by the protein dimerization 
cofactor of HNF-1 (DCoH). DCoH does not bind DNA nor does it interfere with 
the binding of HNF-1A to DNA (Mendel et al., 1991b). Like FoxA proteins, HNF-
1A transcribes many liver specific genes like albumin (Lichtsteiner et al., 1987), 
α-antitrypsin (Courtois et al., 1987), α- and β-fibrinogen (Courtois et al., 1987), 
and others (Schrem et al., 2002). 
 
9. Alcohol and the liver 
In addition to understanding the genetic risk factors of alcoholism, it is also 
important to gain knowledge on the pathogenesis of the disease. Alcohol is 
chiefly metabolized in hepatocytes, parenchymal cells which form 85% of the 
total volume of a healthy liver (Tsukamoto and Lu, 2001). Liver is the most 
susceptible organ for alcohol induced injuries. Chronic alcohol abuse leads to 
alcoholic liver diseases, ALDs (Fleming and McGee, 1984; MacSween and Burt, 
1986; Mann et al., 2003; McCullough and O' Connor, 1998). The most prevalent 
ALD is alcoholic steatosis or fatty liver, which is characterized by fat deposition in 
the liver and hepatomegaly (MacSween and Burt, 1986). Fatty liver, upon further 
exposure to alcohol, develops alcoholic hepatitis, where there is inflammation of 
the liver. The most severe form of ALD is cirrhosis in which fibrotic tissue 
replaces the normal liver tissues and leads to liver dysfunction. In a small 
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percentage (1- 2%) of people, cirrhosis leads to hepatocellular carcinoma (Seitz 
and Stickel, 2006). 
Several molecular mechanisms have been implicated in the development 
and progression of ALD. Acetaldehyde, the break down product of alcohol, forms 
adducts with proteins, and disrupts their function (Niemela, 2001; Niemela et al., 
1998; Worrall et al., 1990). Another key effect of alcohol metabolism is the 
altered energy state of the cell. In both ADH and ALDH catalyzed reactions, 
NAD+ is reduced to NADH, increasing the NADH/NAD+ ratio in cells 
(Cunningham et al., 1986). This change in the redox state leads to inhibition of 
activity of many enzymes that are involved in metabolic pathways like 
carbohydrate metabolism (Badawy, 1977) . NADH also enters the electron 
transport chain and leads to the generation of reactive oxygen species (ROS) 
(Albano, 2006; Bailey et al., 1999; Wu and Cederbaum, 2009). ROS cause 
damage to mitochondrial membrane and also induce oxidative stress within the 
cell (Bailey and Cunningham, 2002; Bailey et al., 1999; Cunningham and Bailey, 
2001). Upon chronic alcohol abuse, this oxidative stress overwhelms the cellular 
redox system and leads to the depletion of antioxidants such as reduced 
glutathione (Bai and Cederbaum, 2006; Garcia-Ruiz et al., 1994; Hirano et al., 
1992). ROS also cause peroxidation of lipids which further increases the 
oxidative stress in the cell (Niemela, 2001; Niemela et al., 1998; Worrall et al., 
1990). 
 Alcohol metabolism affects some of the key enzymes involved in lipid 
metabolism. Acetaldehyde decreases the DNA binding ability of the heterodimer 
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of proliferator-activated receptor-α (PPARα) and retinoid X receptor (RXR) (Galli 
et al., 2001). PPARα-RXR dimer is involved in the transcription of many fatty acid 
oxidation enzymes including carnitine palmitoyl transferase-1 (CPT1A), a rate 
limiting enzyme in the pathway (Aoyama et al., 1998; Zammit, 2008). 
Another protein that is affected by ethanol is AMPK (AMP- activated 
protein kinase). Activation of AMPK leads to fatty acid oxidation and concurrent 
inhibition of fatty acid synthesis (Hardie et al., 1998). AMPK mediated regulation 
of the fatty acid oxidation is brought about by inhibition of acetyl-CoA carboxylase 
(ACC), and activation of malonyl Co-A decarboxylase (MCD). The activity of 
these two enzymes leads to a decrease in the concentration of malonyl Co-A and 
activation of CPT-1A. Ethanol decreases the activity of AMPK, thus inhibiting 
fatty acid oxidation and promoting fatty acid synthesis (You et al., 2004). 
Sterol regulatory element-binding proteins (SREBPs) are a family of 
transcription factors involved in the transcription of many genes involved in fatty 
acid synthesis (Eberle et al., 2004). They play an important role in the 
development of alcohol induced fatty liver (You and Crabb, 2004a; You et al., 
2002). Ethanol activates transcription from SREBP regulated promoters and 
leads to an increase in the expression of lipogenic enzymes (You et al., 
2002).Thus, the combined effects of ethanol on PPARα and AMPK lead to the 
inhibition of fatty acid oxidation, increase in the fatty acid synthesis in the liver 
and development of fatty liver (Purohit et al., 2009; You and Crabb, 2004b). 
Chronic alcohol abuse damages the lining of the intestine, ultimately 
exposing the liver to gut-derived bacterial endotoxins (Bode and Bode, 2005; 
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Keshavarzian et al., 1999). These endotoxins activate the liver macrophages, 
Kupffer cells, which release ROS and cause more damage to hepatocytes (Bode 
and Bode, 2005; Thurman, 1998). Kupffer cells also produce inflammatory 
cytokines such as TNF-α that contribute to liver inflammation. Acetaldehyde 
adducts, cell death seen in hepatocytes due to ROS also trigger an immune 
response against the alcohol-injured liver.  
In addition, ROS and cytokines from hepatocyte and Kupffer cells, activate 
the hepatic stellate cells (HSC) (Nieto et al., 2002; Siegmund and Brenner, 2005; 
Wheeler et al., 2001). Upon activation HSC proliferate and increase the synthesis 
and secretion of extracellular matrix (ECM) proteins, particularly collagen 
(Cubero et al., 2009; Rojkind and Martinez-Palomo, 1976; Siegmund and 
Brenner, 2005). Accumulation of the ECM proteins alters the morphology of the 
liver, leading to the development of fibrotic liver. 
 
10. Alternative transcript isoforms and diseases 
One of the post-transcriptional processes that regulate gene function is 
splicing. In splicing, introns are removed and the remaining exons are spliced to 
form the mature protein coding or functional RNA (Wang et al., 2008). Exons or 
introns can be spliced in different arrangements and this process is termed 
alternative splicing. Diverse mRNA or proteins known as alternative isoforms can 
be generated from same gene by alternative splicing. Alternative splicing 
generates another layer of gene regulation and recent estimates suggest that 92-
94% of the human genes are alternatively spliced (Wang et al., 2008). One-third 
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of alternative splicing events are cassette exons (exons that can be included or 
excluded in the transcript). Another type of alternative splicing event is where an 
alternative donor or acceptor splice site is used, generating a different 5’ and 3’ 
end of the exon. An intron can also be included during splicing to synthesize an 
alternatively spliced form. Alternative isoforms can also be generated by using an 
alternative transcription start site, alternative poly (A) site (alternate poly 
adenylation site that signals transcription termination) (Chen and Manley, 2009). 
Different ways in which alternative isoforms could be generated are shown in 
Figure 4. In this dissertation, all events mentioned above, that generate 
alternative isoforms will be referred to as alternative splicing events. 
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Figure 4. Generation of alternative transcript isoforms. Multiple ways in 
which alternative isoforms of a transcript can be synthesized are shown. (A) 
Inclusion or exclusion of a cassette exon. (B) Use of alternate acceptor site 
during splicing. (C) Use of alternate donor site during splicing. (D) Retention of 
an intron. (E) Use of alternate start site (indicated by an arrow) and (F) Use of 
alternate poly(A) site (indicated by a red line ending with a circle). Exons are 
shown as boxes. Dashed lines indicate splicing events and dark lines indicate 
introns.  
A
B
C
D
E
F
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Splicing defects can be the primary cause of a disease, as seen in spinal 
muscular atrophy (Zhang et al., 2008c), tauopathies (Gallo et al., 2007), atypical 
Cystic fibrosis (Buratti et al., 2001), Hutchinson-Gilford progeria syndrome (De 
Sandre-Giovannoli and Levy, 2006) and others (Garcia-Blanco et al., 2004; 
Orengo and Cooper, 2007). Alternative splicing has also been implicated in 
cancer, where key cancer genes like BRCA-1 have been shown to be 
alternatively spliced (Hoffman et al., 1998). One of the aims of this study was to 
examine the effects of alcohol on alternative splicing to gain insight into the 
molecular mechanisms of alcohol induced liver injuries. 
 
11. Global transcriptional profiling 
One of the aims of this study was to examine global effects of alcohol on 
gene expression and alternative transcript isoforms. The most popular approach 
to study these genome-wide changes is to use microarrays. Microarray 
technology allows the hybridization, in parallel, of thousands of labeled molecules 
in a sample to surface bound nucleic acid probes and the subsequent 
quantitation of bound molecules.  
Recently Affymetrix GeneChip® Human Exon 1.0 ST Arrays (for simplicity 
these will henceforth be referred to as Exon arrays) have been developed. Unlike 
the traditional 3’ arrays that have probes targeting only the 3’ end of a transcript 
(Affymetrix, 2003), exon arrays have probes against the entire length of the 
transcript (Affymetrix, 2005a). Therefore, exon arrays can be used to not only 
quantitate gene expression, but also identify alternative isoforms. On average, 
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each exon in a transcript has one probe set and each probe set has four perfect 
match probes. In genes with only one exon, such as histones or CEBP family of 
transcription factors, more than one probe set is present per exon. There are a 
total of 1.4 million probe sets. From highest to lowest levels of confidence of 
annotation, probe sets are classified into core, extended or full probe sets 
(Affymetrix, 2005a). Core probe sets are supported by the RefSeq and full length 
mRNA GenBank records with full coding sequence (CDS) information. Extended 
probe sets, on the other hand, come from other cDNA evidence, including other 
human mRNA, EST sequences, ENSEMBL gene collections, syntenically 
mapped mRNA from mouse, rat and human, mitoMap mitochondrial genes, 
microRNA registry genes, vegaGene , and vegaPseudoGene records 
(Affymetrix, 2005a). Full probe sets are based on computational gene predictions 
like Genescan (Affymetrix, 2005a).  
General work flow for exon array analysis includes the following steps: 
data normalization, summarization for each probe set, present/absent filtering, 
statistical analysis of differential gene expression and alternative splicing and 
finally biological significance of the affected genes in the experiment. Quantile 
normalization of the data is carried out because signals from different 
hybridizations may be at different scales. Data summarization generates a 
summary measure for a probe set from the signals of all of the (usually 4) probes 
in the set. Robust multi-array analysis (RMA) and the probe logarithmic intensity 
error (PLIER) are two of the commonly used approaches for data summary 
(Affymetrix, 2005c; Irizarry et al., 2003). Both algorithms use an error model-
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based approach to summarize signals. RMA assumes that the error is 
proportional to the normalized and background-adjusted probe intensity. On the 
other hand, PLIER assumes that the error is proportional to the probe intensity 
without background correction.  
After the probe set summary signals are obtained, it is necessary to 
remove signals that are not significantly different from the background. Pre-
analysis filtration of absent probe sets decreases the noise and enhances the 
ability to detect real differences (McClintick and Edenberg, 2006). A detection 
above background correction was proposed for exon arrays to remove probe 
sets with signals near background (Clark et al., 2007). In addition to removing 
probe sets based on signal, other filtering steps have also been shown to 
decrease the noise and improve detection of alternative splicing events. Filtering 
probe sets based on hybridization specificity (bind to unique or more regions), or 
by fraction present (a probe set should be present in a pre-defined fraction of 
arrays used in the experiment) has been shown to improve the ability to detect 
real differences (McClintick and Edenberg, 2006; Mieczkowski et al., 2010; Xing 
et al., 2008).  
Once probe set signals are obtained, signals from all the present probe 
sets in the gene are summarized to estimate the expression level of the gene of 
which they are part. Many approaches have been proposed for estimating gene 
expression. PLIER can be used to generate gene level estimates in a manner 
similar to probe set summarization (Affymetrix, 2005b). A simpler approach is to 
use median intensity of all the probe sets in a transcript (Clark et al., 2007). Clark 
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et al. reported that, in their data, median intensity of all core probe sets was a 
good estimate of gene expression. Once the probe set and gene signals are 
estimated, standard statistical tests like Student t-test can be used to look for 
genes or probe sets that have significantly different expression values between 
the test conditions. When the p-value is below the pre-defined threshold, for 
example, 0.05, the difference is said to be significant. Because of the large 
number of tests carried out in microarrays, multiple testing corrections are 
applied to the analyses to control the false positive rate. A false discovery rate 
(FDR) method of correction for multiple testing was proposed by Benjamini and 
Hochberg (1995). FDR estimates the number of false positives that can be 
expected at a particular p-value, although it does not identify which results are 
false positives. Similar to p-value, a threshold for FDR can be used to identify 
significantly affected genes 
Analysis of the Exon array data to identify differentially expressed genes 
or alternatively spliced exons is challenging because exons and genes are not 
independent elements and cannot be treated so for statistical analysis. Therefore 
it is difficult to differentiate gene expression and alternative splicing. The 
estimation of overall expression of a gene is affected by the number of 
alternatively spliced probe sets or exons in the gene. For example, in the 
absence of any alternative splicing, comparison of gene expression values in two 
conditions should detect differentially expressed genes. However, if an exon is 
alternatively spliced, this also influences gene expression estimates and the 
gene could be falsely detected as differentially expressed. Equally, the detection 
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of alternative splicing in exons is dependent on the gene expression levels. It is 
not possible to use probe set expression values in two conditions to compare and 
detect alternative spliced exons, because if a gene is differentially expressed, 
then levels of all probes are affected and simply comparing the probe set 
expression values could lead to all probe sets detected as differentially spliced.  
The goal is to detect differential gene expression as well as alternatively 
spliced exons. Two common approaches are used in the literature to detect 
alternative splicing. In the splicing index approach, probe set values are 
normalized to the gene signals (Clark et al., 2007; Srinivasan et al., 2005). 
Dividing probe set values by gene values should account for differential gene 
expression. It is, however, dependent on how the gene expression values are 
estimated. The second approach to analyze exon array data is two-way ANOVA. 
The two-way ANOVA model for alternative splicing includes experimental 
conditions and probe sets within the transcript as factors. The interaction 
between the probe set and experimental factors (like treatment condition) is used 
to identify probe sets that are alternatively spliced in the experimental conditions. 
However, both splicing index and two-way ANOVA do not overcome the effect of 
alternative splicing on differential gene expression. Also, both assume that all 
probe sets across a gene will have a similar response to changes in gene 
expression. This has been shown not to be true: one common observation is that 
the ends of the transcripts respond differently than the probe sets away from the 
ends (Bemmo et al., 2008; Whistler et al., 2010). This leads to an edge bias 
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effect in which many probe sets towards 5’ and 3’ ends are detected falsely as 
alternatively spliced (Bemmo et al., 2008; Whistler et al., 2010).  
In this dissertation, exon arrays were used to study the effects of alcohol 
on gene expression and alternative splicing. 
 
12. Research objectives 
There are three main objectives of this research. The first objective was to 
investigate the transcriptional regulation of the ADH genes. Understanding the 
regulation of ADH genes is important because of the key role they play in alcohol 
metabolism and risk for alcoholism. A sequence conservation approach was 
taken to identify putative distal regulatory elements in the ADH cluster. These 
putative regions were tested for activity in vitro and a strong enhancer was 
identified and characterized. 
The second objective was to study the effects of variations on the cis-
regulatory regions in the ADH cluster. Many variations in the ADH cluster have 
been associated with the risk for alcoholism. Since most do not affect the 
structure of the encoded proteins; they could either affect gene regulation or 
merely be associated (in linkage disequilibrium) with variants that affect function 
in some way. The effect of variations on the activity of two cis-regulatory regions 
of ADH cluster was examined in this study. The first region that was examined 
was the enhancer identified in this study. Two variations greatly affect activity 
and we hypothesize that these could affect the risk for the disease. The second 
region that was examined was the ADH1B proximal promoter. There was already 
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evidence of association of two SNPs in this region with alcoholism (Edenberg et 
al., 2006). We examined the functional effects of variations in this region and 
observed that one variation decreases the activity of the promoter.  
The third objective was to understand the effects of chronic alcohol 
exposure on global gene expression and alternative splicing in HepG2 human 
hepatoma cells. Microarray technology allowed us to explore the effects of 
ethanol at a global level and to gain more insight into the alcohol-induced liver 
injuries observed in chronic alcoholics. This was the first study to explore the 
effects of ethanol on alternative splicing. 
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II. MATERIALS AND METHODS 
 
1. Identification of putative distal regulatory elements 
To identify putative distal regulatory regions in the ADH cluster, 
comparative genomics approach was taken. University of California, Santa Cruz 
(UCSC) genome browser (March 2006, NCBI36/hg18 assembly) 28-Way Cons 
Track was used to identify evolutionarily conserved regions (Blanchette et al., 
2004; Chiaromonte et al., 2002; Kent et al., 2003; Siepel et al., 2005). As 
sequence conservation was absent or not reported in the non-placental 
vertebrates at the time, only the placental mammals for which multiple 
alignments were available were used for this study: Rhesus, bushbaby, tree 
shrew, rat, mouse, guinea pig, rabbit, shrew, hedgehog, dog, cat, horse, and 
cow. If at least 50% sequence conservation was observed, the region was 
considered a putative regulatory region.   
 
2. Cloning of test fragments 
For testing putative distal regulatory elements, proximal promoters of 
ADH4 (4Basal; −41 to −299 bp relative to ADH4 +1 CDS) and ADH1B (1Basal; 
−10 to −169 bp relative to ADH1B +1 CDS) were amplified by PCR from human 
DNA using R-Taq polymerase (Midsci, St. Louis, MO). SV40 promoter was 
amplified from the pGL3 control vector (Promega, Madison, WI). 
Oligonucleotides used in PCR are listed in Table 2. All promoters were 
subcloned into KpnI and XhoI sites in the pXP2 luciferase reporter plasmid 
(Nordeen, 1988). Putative regulatory elements were cloned upstream of the 
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4Basal promoter; the position of each fragment relative to the nearest CDS and 
restriction sites are given in Table 3. Subfragments of 4E were cloned into 
BamHI and SalI sites of pXP2, upstream of 4Basal.  
To test ADH1B proximal promoter haplotypes, the region extending to 
1484 bp upstream of ADH1B +1 CDS was PCR amplified using high fidelity 
platinum Pfx polymerase (Invitrogen, Carlsbad, CA). Primers used are listed in 
Table 2. PCR cycle conditions were as follows: 94 0C/ 5 min, (94 0C/15 s, 62 
0C/20 s, 68 0C/ 90 s)x 10 cycles, (94 0C/15 s, 60 0C/20 s, 68 0C/ 90 s)x 30 cycles, 
68 0C/ 7 min. DNA from five different individuals was used as a template. All test 
fragments were cloned into KpnI and BglII sites in pXP2 luciferase reporter 
vector (Nordeen, 1988). Clones were sequenced by ABI BigDye terminator v3.1 
cycle sequencing kit and five different haplotypes were obtained (Table 10). 
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Primer  Sequence Description 
HE3475 GTGGTACCGGGCTTTTCTCTATTATTTTA 4Basal _F 
HE2492 CCCTCGAGAAGCTTCAAACTCCTACCCA 4Basal _R  
HE3639 GTGGTACCAATCCAGTGGGTGTGGC 1Basal _F  
HE3640 CCAAGCTTGTCTTCTCTGCCCACCAG 1Basal _R  
HE3641 GTGGTACCCTGCGATCTGCATCTCAATTA SV40 Basal _F 
HE3642 CCAAGCTTAGTACCGGAATGCCAAGC SV40 Basal _R 
HE3481 CGGGATCCCAAGCCAGAATGAAAAGGTAGAC 4E _F  
HE3482 CCAAGCTTAGCCAGAGCACAAATAATGGAG 4E _R  
HE3623 CGGGATCCCCAAGCCAGAATGAAAAGGTA 4E1 _F  
HE3633 GCGTCGACTTGCGATTTCTCTGGGATG 4E1 _R  
HE3627 CGGGATCCTCAGGTCCATTCTGTGAACG 4E2 _F  
HE3635 GCGTCGACTGTAGTCTCCCCTCTCTTGCTG 4E2 _R  
HE3629 CGGGATCCCAGATAACAGCAAGAGAGGGG 4E3 _F  
HE3636 GCGTCGACCAGCCAGAGCACAAATAATGG 4E3 _R  
HE3530 CGGGATCCGCAGTCTCTATGTATTCTCTTGCC 4-5-a_F 
HE3531 CCCCGGGGCTCAGTGGGCTTGTAAACG 4-5-a_R 
HE3477 CGGGATCCTGAGGTGATAGATACCCTATTTA 6-4-a_F 
HE3478 CCAAGCTTTTTGAGAACTGGGTTAGGTT     6-4-a_R 
HE3526 CCCAAGCTTTTACAGAAAAGCCAACGCTG 1A-6-a_F 
HE3527 CCCGGGGTCACCAGAGGGATGTGTTTG 1A-6-a_R 
HE3524 CGGGATCCCTGTGATTGATTGGGTGTCG 1A-6-b_F 
HE3525 CCCCGGGGGGGGAGGATTTAGCACCTATT 1A-6-b_R 
HE3528 CGGGATCCAATAGGTGCTAAATCCTCCCC 1A-6-c_F 
HE3529 CCCGGGGTCAAGAGATGTCTGGCTGTGAC 1A-6-c_R 
HE3483 CGGGATCCAACCAATCTGCCCTGTG 1A-6-d_F 
HE3484 CCAAGCTTGGAAGGAGGGGGTGAGATAG 1A-6-d_R 
HE3485 CGGGATCCGTTTTCTGAGGCTTCCC 1A-6-e_F 
HE3486 CCAAGCTTCCCTGATGTGATTATTGTGC     1A-6-e_R 
HE3116 GTGGTACCCTGGGGCTATCTTCTTTCCG 
ADH1B 
proximal 
promoter_F 
HE3003 CGAGATCTGTCTTCTCTGCCCACCAGC 
ADH1B 
proximal 
promoter_R 
 
Table 2. Primers used to clone test fragments. Forward (F) and reverse (R) 
primers used for amplification of promoters and test regions are given.  
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Fragment Nearest + 1 CDS Location 
Restriction 
sites 
4-5-a ADH5 -24,880 to -23,299 BamHI & Smal 
4E ADH4 -14,506 to -13,003 BamHI & HindIII 
6-4-a ADH4 -20,549 to -19,471 BamHI & HindIII 
1A-6-e ADH6 -32,319 to -31752 BamHI & HindIII 
1A-6-d ADH6 -34,944 to -33,238 BamHI & HindIII 
1A-6-c ADH6 -46,988 to -45,523 BamHI & Smal 
1A-6-b ADH6 -48,607 to -46,968 BamHI & Smal 
1A-6-a ADH6 -49,682 to -48,534 HindIII & SmaI 
4E1 ADH4 -14,506 to -13,973 BamHI & SalI 
4E2 ADH4 -14,057 to -13,539 BamHI & SalI 
4E3 ADH4 -13,567 to -13,003 BamHI & SalI 
 
Table 3. Putative distal regulatory elements. The putative distal regulatory 
fragments that were tested in this study are listed along with the nearest (with 
respect to the direction of transcription in the cluster) +1 CDS. Location is relative 
to the nearest +1 CDS based on the human genome NCBI build 36.
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3. Transient transfections and reporter gene assays 
HepG2 human hepatoma cells (HB-8065; ATCC, Manassas, VA) were 
cultured in MEM (ATCC) with 10% FBS (Invitrogen, Carlsbad, CA), 4 mM 
glutamine (Thermo Scientific Hyclone, Waltham, MA) and 1X Penicillin and 
Streptomycin (Thermo Scientific Hyclone) on cell bind surface plates (Corning 
Inc, Corning, NY) at 37 0C. For transient transfection assays of putative distal 
regulatory elements, 3 x 105 cells were seeded per well in 12-well plates. 24 h 
after seeding, cells were transfected in complete media with 500 ng of test DNA, 
along with 15 ng of pCMV β-galactosidase plasmid (Clontech, Mountain View, 
CA) and 485 ng of pUC19 DNA, using 2  µl of Fugene HD (Roche, Indianapolis, 
IN) per 1 µg of DNA. Cells were harvested 30 h after addition of DNA by scraping 
into ice-cold 1X PBS, pelleted by centrifugation and suspended in 100 µl of 1X 
Reporter lysis buffer (Promega, Madison, WI). Cell extracts were prepared by 
repeated cycles of freeze-thawing; 5 µl of the extract was used for each assay. 
Luciferase assays were carried out using the Luciferase assay system (Promega, 
Madison, WI), with activity measured on a Spectromax LS (Molecular devices, 
Sunnyvale, CA). β-galactosidase assays were carried out using the Galacto-Light 
System (Tropix, Benford, MA). 
For transfection assays with ADH1B proximal promoter haplotypes, 8 x 
105 cells were seeded per well in 6-well cell binding surface plates. 24 h after 
seeding, cells were transfected in serum free media with 2 µg of test DNA, along 
with 140 ng of CMV-galactosidase plasmid (Clontech, Mountain View, CA) and 
1.2 µg of pUC19 DNA using 3 µl Fugene HD. Complete medium was added 5 h 
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after addition of DNA and cells were cultured for another 24 h. Cells were 
harvested 30 h after addition of DNA, and processed and assayed as described 
above. 20 µl and 5 µl of the extract were used for Luciferase and β-galactosidase 
assays, respectively; activity was measured on a Lmax Plate Luminometer 
(Molecular Devices).  
H1299 human lung carcinoma cells (ATCC CRL-5803) were cultured in 
high glucose DMEM (Sigma- Aldrich, St. Louis, MO) with 10% FBS, 2 mM 
glutamine and 1X Penicillin and Streptomycin on plastic plates (BD Biosciences, 
San Jose, CA) at 37 0C. Cells were seeded at 7 x 105 per well in 6-well plates 
(BD biosciences, San Jose, CA). 24 h after seeding, cells were transfected in 
complete media with 2 µg of test DNA, along with 135 ng of β-galactosidase 
plasmid and 1.1 µg of pUC19 DNA using 3 µl of Fugene HD per 1 µg of DNA. 
Cells were harvested 30 h after addition of DNA, and processed and assayed as 
described above. 15 µl and 2.5 µl of the extract were used for Luciferase and β-
galactosidase assays, respectively; activity was measured on a Monolight 2010 
Luminometer (Analytical Luminescence Laboratory, Sparks, MD).  
All test constructs were transfected at least in triplicate in each individual 
experiment, with experiments repeated at least three times. Promoter activity 
was defined as luciferase activity normalized to β-galactosidase activity, to 
correct for the transfection efficiency. A t-test assuming unequal variances was 
carried out in Microsoft Excel, considering each individual transfection as an 
independent data point.  
 40 
 
4. Electrophoretic mobility shift assays (EMSA) 
EMSAs (Sambrook et al., 1989) were carried out with double-strand 
oligonucleotides designed to span the putative transcription factor binding sites 
(Table 4). Oligonucleotides were synthesized (Integrated DNA Technologies, 
Coralville, IA) with a 5′ 6-FAM label on one of the strands, which was annealed to 
the complementary unlabeled oligonucleotide. For annealing, the two single-
stranded oligonucleotides were diluted to 5 µM in annealing buffer (10 mM Tris 
(pH 8.0), 1 mM EDTA (pH 8.0) and 50 mM NaCl) and mixed in a 1:1 ratio. 
Oligonucleotides were heated to 95 0C for 3 min, cooled to 5 0C above their 
melting temperature over a period of 5 min, cooled further to 5 0C below melting 
temperature over a 1 h period. They were finally allowed to cool to 20 0C over a 
period of 3 h.  
Nuclear extracts were prepared from HepG2 cells using NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Thermoscientific Pierce, Waltham, MA), 
following the manufacturer's protocol. Protein concentrations were measured by 
Bio-Rad protein assay (Bio-Rad, Hercules, CA). Protein binding reactions were 
carried out with 0.2 or 0. 4 pmol of the annealed oligonucleotides and 10 µg of 
the nuclear extracts in 10 mM Tris-HCl (pH 7.5), 60 mM potassium chloride, 2.5 
mM magnesium chloride, 1 mM EDTA, 1 mM DTT, 750 ng of poly (dIdC) and 7% 
glycerol. Oligonucleotides were incubated with the nuclear extract for 30 min at 
25 0C. In competitor assays, unlabeled competitor oligonucleotides in 50-fold 
molar excess to the labeled oligonucleotides were added to the reaction before 
addition of the probe. For supershift assays, 2 µg of the antibody was added to 
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each reaction. FOXA1 (sc-9186x), FOXA2 (sc-9187x) and IgG (sc-2028) 
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
DNA-protein complexes were electrophoresed on 6% polyacrylamide Novex 
DNA Retardation Gels (Invitrogen) in 0.5 x TBE running buffer (45 mM Tris-
borate and 1 mM EDTA, pH 8.3) and scanned with fluorescent image analyzer 
FLA-5100 (Fujifilm, Valhalla, NY) at 473 nm with the LPB filter. 
 
 
Oligonucleotide Sequence Description 
HE3781 5’6-FAM-TTTCAAGATCAGCAATTT GACAGCAAACATGAACTTTGTA EMSA Oligo 1 
HE3782 5’6-FAM-CTGCTTCCCTAACAAAC ACTGAAAAGATCAA EMSA Oligo 2 
HE3941 5’6-FAM-TAAGCATGTTGTCTTAT TTGTTAATATGTTACATAATAC EMSA Oligo 3 
HE3784 5’6-FAM-TTAGTTTCTTCCCACTA AATAAAAACAAACAGAAGTTTTC EMSA Oligo 4 
HE3918 GCCCATTGTTTGTTTTAAGCC FOXA consensus 
HE3829 TCCCATACCCCCATTTAAGCC FOXA consensus mutated 
HE4017 AAGTTAATGATTAAC HNF-1A consensus 
 
Table 4. Oligonucleotides used in EMSA.  Only the sense strand is shown; 
complementary oligonucleotides were annealed to these and double stranded 
oligonucleotides were used in EMSA. 
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5. Site directed mutagenesis 
Mutants of the potential transcription factor binding sites in fragment 4E3 were 
generated by overlap extension PCR (Sambrook et al., 1989). Oligonucleotides 
in which the potential transcription factor binding sites were mutated (Table 5) 
were synthesized by Integrated DNA Technologies (Coralville, IA). In the first 
step of the PCR, two fragments were generated such that they overlap at the 
mutated sequence. Products were gel extracted and 75 ng of each product was 
used as template in the extension step. Products with overlapping ends were 
mixed with R-Taq polymerase and 10 PCR cycles were run without primers. 
HE3629 and HE3636 were then added and PCR was continued for another 25 
cycles to amplify the full-length fragment. Products of the extension step were 
column purified and cloned into BamHI and SalI sites in the pXP2 vector, 
upstream of the ADH4 promoter.   
 
6. Generation of the 4E haplotypes 
Different haplotypes of the 4E3 region were generated by site-directed 
mutagenesis with the Quick change site-directed mutagenesis kit (Stratagene, La 
Jolla, CA). Primers were designed with the SNP at the center (Table 5). The 
amplified products were digested with DpnI to remove the template plasmid, and 
then transformed into DH5α competent cells (Invitrogen). Transformants were 
sequenced to confirm the presence of the SNP at the desired site.  
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Oligonucleotide Sequence Description 
HE3825 TTCAAGATCAGCAATTTGACACACCCGTTGAACTTTGTAATCAAACAGAC Site 1 mutant 
HE3843 AATCAAACCTCTGCTTCCCTACACCCGTCTGAAAAGATCAAACGGG Site 2 mutant 
HE3876 GCACAGCCCCTAATTTGTTAATATGTTACATAATACTTACCTCACAGGGTT Site 3 mutant 
HE3872 GCATGTTGTCTACCCCCATAATATGTTACATAATACTTACCTCACAGGGTT Site 4 mutant 
HE3874 GTAAGCATGTTGTCTTATTCACCCGTATGTTACATAATACTTACCTCAC Site 5 mutant 
HE3823 AGTTTCTTCCCACTAAATAAAACACCCGTGAAGTTTTCTCTTAGCTAACA Site 6 mutant 
HE3881 CACAGCCCCTAACCCCCATAATATGtTACATAATACTTACCTCACAGGGTT 
Sites 3 and 4 
mutant 
HE3817 CCCAAATTTCATCGAACATCCTAAAACTTTCAAGATC 
rs7678936 T 
allele 
HE3819 GTTGTCTTATTTGTTAATATGGTACATAATACTTACCTCACAG 
rs7678890 G 
allele 
HE3821 GTCTCTTTTCTGGAAAATCAGAGATCTGTCATTG 
rs11401494 T 
allele 
 
Table 5. Primers used in site-directed mutagenesis. Only the forward primer 
is listed, with the mutated site bold and underlined. Complementary 
oligonucleotides were used as reverse primers. 
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7.  Long-term treatment of HepG2 cells with ethanol 
Two million HepG2 cells were seeded per 75 cm2 flask (Corning Inc., 
Corning, NY). Six hours after seeding, ethanol was added to a final concentration 
of 75 mM to one set of flasks. Every 24 h, media was replaced in both control 
and ethanol treatment flasks with fresh media, without or with ethanol, 
respectively. Four days after seeding, cells were trypsinized and seeded into new 
flasks at two million viable cells per flask, with media changes continuing daily as 
before. Five days after the split (a total of 9 days without or with ethanol), cells 
were collected by trypsinization. Four independent experiments were carried out.  
The numbers of viable cells in the control and ethanol treatment flasks 
were measured by trypan blue exclusion. Briefly, 0.1 ml of 0.4% Trypan blue 
stain (Sigma T8154) was added to 0.5 ml of trypsinized cells, and allowed to 
stand at room temperature for 5 min. Cells that were not stained by the dye were 
counted as viable. 
 
8. RNA extraction, labeling and hybridization 
Trypsinized cells were pelleted by centrifugation at 2500 rpm for 3 min. 
The cell pellet was suspended in 5 ml of Trizol (Invitrogen, Carlsbad, CA) and 
total RNA was extracted following the manufacturer’s protocol. RNA was further 
purified on RNeasy Mini kit columns (Qiagen, Valencia, CA). The quality of the 
RNA was tested on a Bioanalyzer (Agilent Technologies, Palo Alto, CA), with 
RNA integration numbers (RIN) from 9.6 to 10. Starting with 1 µg of total RNA, 
ribosomal RNA (rRNA) was reduced from the total RNA using RiboMinus 
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Human/Mouse Transcriptome Isolation Kit (Invitrogen, Carlsbad, CA). cDNA was 
synthesized with random primers tagged with the T7 promoter. This cDNA was 
used as template for cRNA synthesis by T7 RNA polymerase, using the 
GeneChip Whole Transcript Sense target labeling assay kit (Affymetrix, Santa 
Clara, CA). The sense strand of cDNA was then synthesized from cRNA, 
fragmented and terminally labeled with biotin. Fragmented and labeled cDNAs 
were subsequently hybridized to GeneChip Human Exon 1.0 ST Arrays 
(Affymetrix). Chips were stained, washed and scanned following the standard 
Affymetrix protocols. Two technical replicates (processed in separate batches) of 
each of the 8 independent samples (4 control, 4 ethanol treated) were used.  
 
9. Exon array data analysis 
Affymetrix CEL files were imported into Expression console software 
(Affymetrix) and analyzed at the core exon level (HuEx-1_0-st-v2.na28.hg18 
annotation) using the PLIER algorithm (Affymetrix, 2005c). For further steps, 
control probe sets (e.g. those against intron regions) were excluded. Because 
cross-hybridizing probe sets were shown to be a major cause of false predictions 
of differential alternative splicing (Xing et al., 2008), only unique probe sets (a 
probe set in which all probes perfectly match only one sequence) were included. 
Thus 228,871 PLIER probe set signal estimates representing 17,881 genes were 
imported into Partek® Genomics Suite software version 6.4 (Partek, St. Charles, 
MO), quantile normalized, and log2 transformed. Technical replicates were 
normalized and transformed independently. 
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To remove signals that were not significantly different from the 
background, “detection above background” (DABG) p-value was calculated. 
Exon arrays have 25,000 background probe sets that do not match any 
sequence in the genome. Detection above background p-value was calculated by 
comparing the signal from each probe to the median intensity of background 
probes with the same GC content (Affymetrix, 2005b; Clark et al., 2007). Probe 
sets were also filtered based on fraction present (McClintick and Edenberg, 
2006). This approach was shown to reduce false positives (McClintick and 
Edenberg, 2006) and to improve correlation between fold changes obtained in 
array data and quantitative reverse transcription PCR (qRT-PCR) data 
(Mieczkowski et al., 2010). In fraction present filtering, a probe set was 
considered to be present if it had a detection above background p-value ≤ 0.05 in 
all the arrays in at least one of the treatment conditions (ethanol or control, in this 
case).  
A group of probe sets covering all the known isoforms for a given gene are 
referred to as a Transcript cluster; however, for simplicity these will be called 
genes. In addition to probe sets, genes were also subjected to present/absent 
filtering (McClintick and Edenberg, 2006). A gene was considered to be present if 
at least 50% of its probe sets were called present in all the samples in at least 
one treatment group (Clark et al., 2007). In the genes that were called present, 
only probe sets that were present were analyzed. After filtering steps, 127,805 
representing 10,738 genes were included for further analysis.  
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To determine if a gene is differentially expressed or alternatively spliced or 
both, two-way analysis of variance (ANOVA) was carried out in Partek ® 
Genomics Suite (St. Louis, MO). The ANOVA model included experimental 
factors [treatment condition (ethanol vs. control) and batch ID (technical 
replicate)] along with the probe sets in each gene. With this model, p-values for 
differential expression and alternative splicing were obtained and based on these 
p-values, false discovery rate (FDR) (Benjamini and Hochberg, 1995) was 
calculated for differential gene expression and alternative splicing.  
In this study, a gene was detected as differentially alternatively spliced if 
the alternative splicing FDR was ≤ 3%. If a gene meets this cutoff for differential 
alternative splicing, it means that one or more of the probe sets are affected by 
ethanol differently from other probe sets in the gene. However, this does not 
indicate which probe set was affected. Thus, differentially alternatively spliced 
genes were visually inspected to determine which probe set was differentially 
alternatively spliced. To assist in this closer examination, the effects of ethanol 
on each probe set in the gene were studied. One-way ANOVA was carried out to 
estimate the fold change and significance of this change (p-value) for each probe 
set. Fold change of each probe set was compared to the other probe sets in the 
gene to determine if the probe set was responding to alcohol differently from 
other probe sets.  
Based on visual inspection, genes that were detected as differentially 
alternatively spliced (FDR ≤ 3%) were classified into three groups- probably 
differentially alternatively spliced, probably not differentially alternatively spliced 
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and uncertain. A gene was called probably differentially alternatively spliced if a 
probe set in the gene displayed a fold change significantly different in magnitude 
or direction from other probe sets in the gene. For example, C1R gene had a 
FDR of 0.3% for differential alternative splicing and thus was inspected for further 
analysis. In this gene four probe sets had a fold change in the range of 1.4 to 1.6 
while another probe set had a 2.5-fold change. Because of this difference, the 
probe set and the gene were considered probably differentially alternative 
spliced.  
To qualify as differentially alternatively spliced in the presence of ethanol, 
at least one exon had to be significantly different from the others (p-value > 0.05 
in one-way ANOVA). For example, ACAD11 was identified as differentially 
alternatively spliced with FDR of 0.001%. It had 18 probe sets that were included 
in the analysis. Most of these probe sets were affected by only a small magnitude 
by ethanol. One probe set however, was apparently increased in expression by 
3-fold but the change was not significant (p-value for that probe set was 0.1). 
Therefore this gene was grouped under probably not differentially alternatively 
spliced. A gene was also considered probably not differentially alternatively 
spliced if the probe sets towards the 5’ or 3’ end were exhibiting probable edge 
effects (refer to Figure 19); these could represent real biological effects but 
because they are also artifactually produced (Bemmo et al., 2008; Whistler et al., 
2010) we chose not to further examine them. A gene was classified as uncertain, 
if it was difficult to say if the gene had an alternative isoform with ethanol or 
which probe set in the gene was alternatively spliced. An example is shown in 
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Figure 20. A gene was also grouped as uncertain if the adjacent probe set in the 
same exon did not behave the same way. In the absence of known alternative 
events, it was not possible to say if these are alternate donor and acceptor sites 
or technical artifacts.  
To identify biological pathways or processes affected by ethanol 
treatment, differentially expressed genes were analyzed by Ingenuity Pathway 
Analysis software (Ingenuity® Systems, www.ingenuity.com). Steps in the exon 
data analysis are shown in Figure 5. 
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Figure 5. Exon array data analysis. The workflow of exon array data analysis is 
shown. 
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10. Validation of differential gene expression by qRT-PCR 
Quantitative real time RT-PCR assays (Taqman gene expression assays) 
were carried out to confirm differential gene expression changes that were 
observed in microarray data. The synthesis of the first strand of cDNA was 
carried out using Superscript First-Strand Synthesis System (Invitrogen, 
Carlsbad, CA) or High-capacity cDNA Reverse Transcription kit (Applied 
Biosystem, Foster City, CA) following manufacturer’s directions. For seven genes 
(FGG, GCLC, IDH2, TGFBR3, HK2 and CPT1A) 2 µg of total RNA was used as 
a template and the first strand of cDNA was synthesized with Superscript First-
Strand Synthesis System. For the remaining genes (HTR3B, SREBF1, BHMT, 
CHRNA5, PCK1, TGFB1), the High-capacity cDNA Reverse Transcription kit was 
used with 1 µg or 1.5 µg of total RNA. Two independent cDNA synthesis 
reactions were carried out on each sample from the four independent 
experiments. Aliquots of the cDNA were used in real time PCR reactions with 
Taqman Gene expression assays (Applied Biosystems). Real time PCR 
reactions were carried out in triplicate on each of the two independently 
synthesized cDNAs from each sample. Mitochondrial ribosomal protein L3 
(MRPL3) was used as an endogenous control, because our microarray data 
demonstrated that MRPL3 had very low variation among samples and between 
control and ethanol conditions. Fold change for ethanol over control was 
calculated by delta delta Ct method (Livak and Schmittgen, 2001). 
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11. Validation of alternative splicing by qRT-PCR 
To identify if there are alternative isoforms of the gene with respect to the 
test exon, PCR was carried out with primers flanking the test exon (Table 6). The 
High-capacity cDNA Reverse Transcription kit was used with 1.5 µg of total RNA 
and random primers (Invitrogen, Carlsbad, CA). For each condition (control or 
ethanol) cDNA from each of the four independent experiments was pooled and 
PCR was carried out using R-Taq polymerase (Midsci). PCR products were 
visualized on a 1.5% agarose gel to determine if the exon was alternatively 
spliced. 
Quantitative real time RT-PCR assays (SYBR green assays) were carried 
out to confirm differential alternative splicing changes that were observed in 
microarray data. For BPGM and CD55 1.5 µg of total RNA from each of the four 
independent experiments was used as a template and the first strand of cDNA 
was synthesized with Superscript First-Strand Synthesis System and oligo d(T) 
primers (Promega, Madison, WI). For MBD5 the High-capacity cDNA Reverse 
Transcription kit was used with 1.5 µg of total RNA and random primers 
(Invitrogen, Carlsbad, CA). Primers used to amplify each gene are listed in Table 
6. Real time PCR reactions were carried out in duplicate on cDNA from each of 
the four independent experiments. For each experiment sample, the mean of Ct 
for control was subtracted from the mean of the Ct for ethanol and fold change 
was calculated by 2-(delta Ct). 
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Primer  Primer sequence Gene 
HE3679 ATGGAGTGCTTTATGTCAGTCCCAGTG MBD5 
HE3680 ACATCTTCTGCGGTTCTCTGTTTCACA MBD5 
HE3687 CCGAGGAAGGGAAGGTGGAGC MBD5 
HE3689 CACCCTGTGGGATTTGGTGTACAGTC MBD5 
HE3695 GGTATGCGGTGGTGTGATCGTA CD55 
HE3697 AACGTGAAACACGTGTGCCCTG CD55 
HE3768 TTGACAGGTTTGCTTGGGACGC CD55 
HE3769 GACTGCCTTTTTTCTCCTTGCTCTG CD55 
HE3694 CACTTCAGGTACTACCCGTCTTCTATCTGG CD55 
HE3711 CCAGAGGTGTGGGGTGGAAGT ACSL1 
HE3712 GGTGAGTGACCATTGCTCCTTTGG ACSL1 
HE3690 TGCTGCTGCTGCTGGTGGC BPGM 
HE3693 TTCAAATGGGCTAATATTCAAGGACAGC BPGM 
HE3691 ACTTTCTGTTTACACAAGAGTTGCCTCC BPGM 
HE3704 GATGGGAATGTGATGCTGCCTTCTAGTA NR2C1 
HE3705 CCCAGTGCTGGCAAGTGATGAA NR2C1 
 
Table 6. Primers used for validation of alternative splicing. 
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III. RESULTS 
 
1. Identification of an enhancer in the ADH cluster 
A comparative genomics approach was used to identify distal regulatory 
elements that affect expression of the ADH genes. Using the UCSC 
Conservation track, conservation in the intergenic regions between ADH4 and 
ADH5, ADH4 and ADH6, and ADH6 and ADH1A was explored. Conservation in 
placental mammals, Rhesus, bushbaby, tree shrew, rat, mouse, guinea pig, 
rabbit, shrew, hedgehog, dog, cat, horse, and cow, was studied and regions with 
at least 50% conservation were identified as putative cis-regulatory regions. Eight 
putative regions were identified and their effect on the activity of the ADH4 Basal 
promoter (4Basal) was tested in transient transfection assays in the HepG2 
human hepatoma cells. The position of tested fragments in the ADH cluster is 
shown in Figure 6. 
Six of the eight regions tested decreased the activity of the promoter 
(Figure 7), while another had no effect. Among these six negative regulatory 
regions, the greatest effect was observed at site 4-5-a which is 23 kb upstream of 
ADH5. It decreased the promoter activity to 0.26-fold. The region 6-4-a, 19.5 kb 
upstream of the ADH4 also decreased the promoter activity by 70%. A similar 
effect was observed with 1A-6-d but other regions (1A-6-a, 1A-6-c , 1A-6-e) 
between ADH1A and ADH6 had modest effects. 
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Figure 6. Location of the tested putative regulatory regions.  Eight regions 
that were conserved in the 220 kb of the ADH cluster (Figure 2) studied are 
shown. The direction of the arrows represents the direction of transcription. 
Location relative to the nearest +1 CDS (in the direction of transcription) based 
on the human genome NCBI build 36 is also indicated. 
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Figure 7. Six putative regulatory regions decrease transcription.   
Conserved regions were subcloned into pXP2 reporter vector upstream of 
4Basal, and transiently transfected into HepG2 cells (n = 12). Transcription was 
determined as luciferase activity normalized to the internal control β- 
galactosidase. Fold change was calculated as ratio of the activity of each 
construct to the activity of 4Basal (set to one and therefore not shown); bars 
indicate the standard errors of the mean. *p-value ≤ 1 x 10-5. 
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In contrast to these negative elements, a 1504 bp conserved region 13 kb 
upstream of the ADH4 translation start site, (4E), caused a 50-fold increase in 
activity (p-value = 6 x 10-15; Figure 8). In the absence of a promoter, the 4E 
fragment had weak activity, only 80% of the activity of the 4Basal promoter (p-
value = 9 x 10-4; Figure 8). Because of its strong enhancer effect, further studies 
were carried out with 4E. 
 
 
 
 
Figure 8. 4E enhances the activity of the ADH4 promoter.  Test plasmids with 
only the promoter (4Basal), 4E upstream of the promoter (4E+4Basal) and 4E in 
the absence of any promoter (4E only) were transiently transfected into HepG2 
cells (n = 16). Promoter activity was determined as luciferase activity normalized 
to the internal control β-galactosidase. Fold change was calculated as ratio of the 
promoter activity of each construct to the promoter activity of 4Basal (set to one 
and therefore not shown); bars indicate the standard errors of the mean.  
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2. Characterization of the enhancer element 4E 
2.a. Effect of 4E on heterologous promoters 
To determine if the enhancer acts specifically on the ADH4 promoter, it 
was tested in combination with two heterologous promoters. 4E increased the 
activity of another ADH promoter, the ADH1B basal promoter (1Basal), by 180-
fold (p-value = 2 x 10-12) in HepG2 cells. It increased the activity of the SV40 
promoter (SV40Basal) by 56-fold (p-value = 8 x 10-10).  
2.b. Function of 4E in non-hepatoma cells 
Cell specificity of 4E was tested in H1299 cells, a lung carcinoma cell line. 
Of the seven ADHs, only ADH1B is known to be expressed in lungs. However, 
the transfected minimal promoters of both ADH4 and ADH1B did show activity 
above the vector-only background. Therefore, the enhancer activity of 4E was 
tested upstream of ADH4, ADH1B and SV40 promoters. No enhancer activity 
was detected with any of the three promoters (Table 7). These results suggest 
that 4E shows cellular specificity.  
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Promoter Fold change in hepatoma cells (mean ± Std error) 
Fold change in lung 
cells  
(mean ± Std error) 
4Basal 50.2 ± 2.2 * 0.64 ± 0.1 * 
1Basal 180 ± 5.3 * 0.97 ± 0.2 
SV40Basal 56 ± 2.9 * 0.80 ± 0.1 * 
 
Table 7. Cell specific activity of 4E.  4E was subcloned upstream of ADH4, 
ADH1B, and SV40 promoters and activity of each construct was normalized to 
the activity of the respective promoter to obtain the fold change (mean ± standard 
error). *p-value ≤ 0.05. 
  
 
2.c. Localization of sequences required for 4E enhancer activity  
To localize functional elements within the 1504 bp 4E region, the region 
was subdivided into three fragments, 4E1, 4E2 and 4E3 (Figure 9). The 
enhancer effect of 4E was contained within the 4E3 fragment, which enhanced 
the activity of 4Basal by 46-fold (p-value = 5 x 10-15) (Figure 9). 4E1 repressed 
the activity of 4Basal by 50% (p-value < 0.001), whereas 4E2 increased the 
activity by 1.2-fold (p = 0.05). As the activity of 4E3 was not different from the 
parent fragment 4E (p-value = 0.13), further characterization was focused on the 
4E3 fragment.  
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Figure 9. The enhancer function of 4E is located in a 565 bp region. (A) 
Position of 4E relative to flanking genes; the direction of the arrows represents 
the direction of transcription. This region is enlarged below, along with sub-
fragments tested for activity. (B) The effects of subfragments of 4E upon the 
ADH4 basal promoter were tested in transient transfections in HepG2 cells (n = 
16). Fold change was calculated as ratio of the normalized luciferase activity of 
each construct to that of 4Basal; bars indicate the standard errors of the mean.  
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2.d. Identification of potential protein binding sites in 4E 
Five potential Forkhead box protein A (FOXA, previously known as 
hepatocyte nuclear factor 3 binding sites and one hepatocyte nuclear factor 1-α 
binding site (HNF-1A; Figure 10) were identified using transcription factor 
prediction software Promo (Courtois et al., 1988; Farre et al., 2003; Messeguer et 
al., 2002; Overdier et al., 1994). Oligonucleotides were synthesized to cover 
these potential FOXA binding sites (Table 4, Materials and Methods) and tested 
in electrophoretic mobility shift assays (EMSA) with HepG2 nuclear extract. With 
all four oligonucleotides, at least two high-molecular weight DNA-protein 
complexes were observed (Figure 11). Competitor assays were carried out with 
unlabeled FOXA specific and non-specific oligonucleotides to determine if it is a 
FOXA specific complex. Unlabeled FOXA consensus oligonucleotide (Verschuur 
et al., 2005) disrupted the strong, high molecular weight complex. On the other 
hand, the complex was intact when a mutated FOXA consensus oligonucleotide 
was added, confirming that it is a FOXA-specific complex. A non-specific 
competitor oligonucleotide also had no effect on these complexes (Figure 11). 
The FOXA-specific complex was also perturbed in supershift assays with FOXA1 
and FOXA2 antibodies, while it was unaffected with control IgG antibody (Figure 
11).  
 62 
 
 
 
 
Figure 10. Annotated genomic sequence of the 4E3 region.  Six potential 
transcription factor binding sites, identified using Promo (Farre et al., 2003; 
Messeguer et al., 2002), are shown in bold along with the site name above the 
sequence. Sites 1 to 4 and site 6 were identified as putative FOXA sites where 
as site 5 was identified as putative HNF-1A site. Two nucleotides shared by sites 
4 and 5 are shown in italics. Oligonucleotides used in EMSA are underlined.  
Known variations within the sequence are represented with an arrow. 
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Figure 11. FOXA proteins bind to putative sites in 4E3. Electrophoretic 
mobility shift assays were carried out with 5′FAM labeled oligonucleotides of 
interest and 10 µg of HepG2 nuclear extract. Competition experiments were 
carried out in the presence of 50-fold molar excess of either a FOXA consensus 
(C), FOXA consensus mutant (M), or a non-specific (N) oligonucleotide. In 
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supershift assays, 2 µg of either FOXA2 antibody (A2), FOXA1 antibody (A1) or 
goat IgG (Ig) antibody was added. (A) Gel shifts with Oligos 1 and 2 that span 
sites 1 and 2, respectively, are shown. (B) Gel shifts in which Oligo 3 (sites 3, 4, 
and 5) and Oligo 4 (site 6) were used as probes are shown. FOXA specific bands 
are indicated by arrows, other bands were non-specific. 
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In Oligonucleotide 3, Site 5 was predicted to be a HNF-1α site; it overlaps 
with site 4 by two nucleotides. In EMSA assays with Oligonucleotide 3, multiple 
high molecular weight bands were observed, but the FOXA specific complex was 
the most prominent (indicated by an arrow on Figure 11). While none of the 
bands were disrupted by HNF-1A competitor (Su et al., 2006), increasing 
concentrations of the HNF-1A competitor led to a stronger FOXA specific 
complex (Figure 12). 
 
 
 
 
Figure 12. HNF-1A competitor increases FOXA binding. EMSA assays with 
Oligonucleotide 3 were carried out in the presence of increasing concentrations 
(5 to 50-fold molar excess) of HNF-1A consensus oligonucleotide. (A) Short 
exposure of the gel. (B) Longer exposure of the gel. FOXA specific bands are 
indicated by arrows, other bands were non-specific. 
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2.e. Effect of mutations on enhancer activity 
To test the functional role of the putative FOXA sites in the 4E3 region, 
each of these sites was mutated and tested in transient transfections of HepG2 
cells. Mutation of sites 1 and 4 decreased the activity by 60% and 65%, 
respectively (Figure 13), whereas mutations at sites 2, 3, and 5 reduced the 
activity by at least 40%. Disruption of site 6 did not have a significant effect.  
To test the function of these sites in a combinatorial fashion, multiple sites 
were mutated. A double mutant of sites 1 and 4 lost most of the activity, 
exhibiting only 0.2-fold of the wild type enhancer. The activity was further 
decreased to 0.1-fold when multiple sites were mutated in conjunction with site 1 
(Figure 13).   
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Figure 13. Effects of site-directed mutations on enhancer function. Potential 
FOXA and HNF-1α sites were mutated in 4E3 and tested in transient 
transfections of HepG2 cells (n = 16). Fold change was calculated as ratio of the 
enhancer activity of each mutated construct to the wild type; bars indicate the 
standard errors of the mean. (A) Activity of single site mutants. (B) Activity of 
double or multiple site mutants. *p-value ≤ 1.5 x 10-7. 
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3. Effects of regulatory variations on gene expression 
One of the hypotheses of this study is that variations in the regulatory 
regions of the ADH genes could lead to different levels of expression, thereby 
affecting the risk for alcoholism. Therefore, the effects of variations in two key 
regulatory regions, enhancer 4E3 and ADH1B proximal promoter, in the ADH 
cluster were studied.  
 
3.a. Effects of natural variations on 4E3 enhancer activity 
There are three known SNPs in the 4E3 enhancer region (NCBI dbSNP 
Build 130). The position of each SNP is shown in Figure 10. The genotype and 
allele frequencies for rs7678936 and for rs7678890 are shown in Table 8. Data 
for rs11401494 are unavailable.  
In transient transfections, four different haplotypes of 4E3, cloned 
upstream of the ADH4 promoter, were tested. The activities of all haplotypes 
were normalized to the activity of the most common haplotype in most 
populations: rs7678936 G, rs7678890 T, and rs11401494 del, which is denoted 
as haplotype 1. The activity of haplotype 2 (T, T, del) was only 60% that of 
haplotype 1. Haplotype 3 (G, G, del) displayed a similar decrease in activity. 
Insertion of A at position -13,058 (Haplotype 4: G, T, A) had a very small but 
significant effect (0.9-fold change relative to the haplotype 1, p-value = 0.02; 
Figure 14). 
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A      
  rs7678936 
  Allele Genotype 
Hapmap 
Population T G T/T T/G G/G 
CEU 0.1 1   0.1 0.9 
CHB   1     1 
JPT   1     1 
YRI 0.3 0.7 0.1 0.4 0.5 
ASW 0.3 0.7 0.1 0.4 0.5 
CHD 0 1 0 0 1 
GIH  0 1 0 0 1 
LWK  0.3 0.7 0.1 0.4 0.5 
MEX  0 1 0 0.1 0.9 
MKK  0.3 0.7 0.1 0.4 0.5 
TSI 0.1 0.9 0 0.1 0.9 
 
B      
  rs7678890 
  Allele Genotype 
Hapmap 
Population T G T/T T/G G/G 
CEU 1 0.1 0.9 0.1   
CHB 1   1     
JPT 1   1     
YRI 0.7 0.3 0.5 0.4 0.1 
 
 
Table 8. Allele and genotype frequencies of SNPs in the 4E3 region.  Allele 
and genotype frequencies in different populations for the two SNPs in the 
enhancer region 4E3 were obtained from HapMap (release 27, Phase II and III; 
hapmap.ncbi.nlm.nih.gov). Data for rs11401494 are not available. (A) Data for 
rs7678936. (B) Data for rs7678890. Populations are Utah residents with ancestry 
from northern and western Europe (CEU), Han Chinese in Beijing, China (CHB), 
Japanese in Tokyo, Japan (JPT), Yoruba in Ibadan, Nigeria (YRI), African 
ancestry in Southwest USA (ASW), Chinese in Metropolitan Denver, Colorado 
(CHD), Gujarati Indians in Houston, Texas (GIH), Luhya in Webuye, Kenya 
(LWK), Mexican ancestry in Los Angeles, California (MEX), Maasai in Kinyawa, 
Kenya (MIKK), and Toscans in Italy (TSI). 
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Figure 14. Effects of polymorphisms on enhancer function.  Four different 
haplotypes of the 4E3 region were tested in transient transfections in HepG2 
cells (n = 20). Alleles of rs7678936, rs7678890 and rs11401494, respectively are 
shown on the x-axis. The error bars indicate standard errors of the mean. The 
promoter activity of each haplotype was normalized to the promoter activity of 
Haplotype 1 (G,T, del). *p-value = 0.02; **p-value ≤ 8 x 10-13. 
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3.b. Effects of polymorphisms on ADH1B promoter activity 
In association studies of alcohol dependence (defined as meeting alcohol 
dependence criteria by DSM-IIIR (American Psychiatric Association, 1987) plus 
Feighner definite alcoholism (Feighner et al., 1972), three SNPs in the ADH1B 
region were significantly associated (Edenberg et al., 2006). Two of these 
variations (rs1229982 and rs1159918) are located in the proximal promoter 
region, while rs1353621 is in the first intron. Allele and genotype frequencies of 
rs1229982 and rs1159918 are shown in Table 9.  
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  rs1229982 
  Allele Genotype 
Hapmap 
Population A C A/A C/A C/C 
CEU 0.2 0.8 0.0 0.3 0.7 
CHB 0.0 1.0 0.0 0.1 0.9 
JPT 0.0 1.0 0.0 0.1 0.9 
YRI 0.6 0.4 0.3 0.5 0.2 
ASW 0.5 0.5 0.2 0.5 0.2 
CHD 0.1 0.9 0.0 0.1 0.9 
GIH  0.1 0.9 0.0 0.2 0.8 
LWK  0.5 0.6 0.2 0.6 0.3 
MEX  0.2 0.8 0.0 0.3 0.7 
MKK  0.4 0.6 0.2 0.5 0.3 
TSI 0.2 0.8 0.1 0.3 0.6 
 
  rs1159918 
  Allele Genotype 
Hapmap 
Population T G T/T T/G G/G 
CEU 0.3 0.7 0.1 0.4 0.5 
CHB 0.2 0.8 0.0 0.3 0.6 
JPT 0.2 0.8 0.0 0.3 0.7 
YRI 0.9 0.1 0.8 0.2 0.0 
ASW 0.7 0.3 0.5 0.4 0.1 
CHD 0.1 0.9 0.0 0.3 0.7 
GIH  0.3 0.7 0.1 0.5 0.4 
LWK  0.7 0.3 0.5 0.4 0.2 
MEX  0.7 0.3 0.5 0.4 0.1 
MKK  0.7 0.3 0.5 0.4 0.1 
TSI 0.3 0.7 0.1 0.4 0.6 
 
Table 9. Allele and genotype frequencies for two SNPs in the ADH1B 
proximal promoter region. Allele and genotype frequencies in different 
populations for the two SNPs that were associated with alcoholism were obtained 
from HapMap (release 27, Phase II and III; hapmap.ncbi.nlm.nih.gov). 
Populations are as in Table 8.  
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The effects of rs1229982 and rs1159918 SNPs, along with the other 
natural variations in the region of -1484 bp to -10 bp (with respect to the coding 
sequence start site were tested). The Single Nucleotide Polymorphism database 
(dbSNP; www.ncbi.nlm.nih.gov/projects/SNP/) reports 12 SNPs in this region 
(Figure 15). The region was PCR amplified from DNA of various individuals to 
generate the natural haplotypes, and cloned into the pXP2 reporter plasmid. Five 
different haplotypes, haplotype 1 to haplotype 5 (Table 10), were obtained. The 
five haplotypes had the same allele for five SNPs (rs28913901, rs28913903, 
rs28913904, rs3076071 and rs28913905) but differed in the remaining seven 
positions. 
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 Figure 15. Variations in the ADH1B proximal promoter region.  Twelve 
variations in the proximal promoter are shown as vertical lines with the two 
alleles and the SNP ID (rs number) at the end. Filled circles represent those 
variations that were tested in the transfection assays. For some variations 
(shown as open circles), the same allele was present in all the haplotypes tested. 
Rectangular boxes represent SNPs that were associated with alcoholism in 
European Americans. Position is relative to the ADH1B + 1 translational start 
site.  
 
 
 
 
 
Haplotype 1229982 28913902 6810842 2070897 2070898 1159918 5860575 
1 A - A C C T - 
3 C T C T T G - 
4 C T C C C T - 
2 A T C T C G - 
5 C T A C C T G 
 
Table 10. Tested haplotypes of the ADH1B proximal promoter. Five 
haplotypes with seven SNPs that were obtained from cloning the proximal 
promoter region are shown; they were identical at all other positions. Alleles of 
the two SNPs that were associated with alcoholism are shown in bold.  
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Five haplotypes were tested in HepG2 cells by transient transfections. The 
activity of each was normalized to that of haplotype 1, which had the sequence 
closest to the reference sequence in Genbank (accession number 
NT_016354.17). A significant (p-value ≤ 5.4 x 10-7) decrease in the promoter 
activity relative to haplotype 1 was observed in haplotypes 3, 4 and 5, whereas 
no difference in activity was seen with haplotype 2 (p-value = 0.39; Figure 16). 
Analysis of the combination of SNPs in the five haplotypes suggested that SNP 
rs1229982 at -1444 position might be responsible for the decrease in the activity. 
The promoter with the rs1229982 C allele at this position leads to a 30% 
decrease in the promoter activity. 
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Figure 16. Variations in the ADH1B promoter affect activity. Five different 
haplotypes of the ADH1B proximal promoter region were tested in transient 
transfections in HepG2 cells (n = 12). The promoter activity of each haplotype 
was normalized to the promoter activity of Haplotype 1. Alleles of rs1229984, and 
rs1159918, respectively are shown on the x-axis. The error bars indicate 
standard errors of the mean. * p-value ≤ 6.6 x 10-4.
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4. Effects of alcohol on gene expression  
To determine the effects of long term ethanol exposure on global gene 
expression, human hepatoma cells (HepG2) were exposed to 75 mM (0.34%) 
ethanol for nine days, with fresh media daily. To investigate the effect of ethanol 
on cell growth, the number of viable cells was counted by trypan blue exclusion. 
After the initial four day exposure to 75 mM ethanol, there were only 48% as 
many viable cells as in the control cultures. Two million viable cells were again 
seeded in new flasks and cultured in ethanol for the next five days. There were 
again 48% as many viable cells in the ethanol-treated cultures as in the control 
cultures. The decrease in viable cell number could be due to a longer lag phase, 
or a reduced rate of cell growth, or cell death. However, before trypsinization, 
cells appeared to be similar in morphology in both ethanol and control conditions. 
We did not observe many floating or dead cells in the presence of ethanol.  
Effects of ethanol on gene expression were studied using Affymetrix 
GeneChip® Human Exon 1.0 ST Arrays. Among the 17,881 genes represented 
by main and unique probe sets, 10,738 genes (60%) were reliably detected in at 
least one of the treatment conditions, and only those were used for further 
analysis. Genes with just one probe set reliably detected were also excluded 
(516 genes). Two-way ANOVA was applied to identify genes that were 
differentially expressed. Steps in the data analysis are shown in Materials and 
Methods (Figure 5).  
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Of the 10,222 genes that were analyzed many were differentially 
expressed (Table 11). Most of the expression differences were modest, with 
absolute fold change between 1.1 and 1.3 (Figure 17).  
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Number of genes affected by ethanol 
FDR 15% FDR 10% FDR 3% 
3242 2423 1093 
 
Table 11. Effects of ethanol on gene expression at different false discovery 
rates.  Number of genes significantly differentially expressed by ethanol at three 
levels of False Discovery Rate are shown. FDR was calculated by Benjamini and 
Hochberg method (1995). 
  
 
 
 
Figure 17. Distribution of fold changes of differentially expressed genes. 
Distribution of fold changes of differentially expressed genes (FDR ≤ 15%). Each 
bin represents number of genes that have absolute fold change equal to or less 
than the given value, but greater than the previous bin value (e.g. bin 1.1 shows 
the number of genes with absolute fold change between 1.0501 and 1.1000). 
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At a stringent false discovery rate (FDR) of 3% a total of 1,093 genes were 
differentially expressed due to chronic exposure to ethanol. To assess biological 
pathways affected by chronic ethanol treatment, differentially expressed genes 
(FDR ≤ 3%) that had a minimum of 10% change in expression level (991 genes) 
were analyzed. Once the pathways were identified using this stringent FDR, 
genes associated with these pathways were added that were at a relaxed FDR (≤ 
15%) and with at least 10% fold change. This provided more insight into the 
effects of the alcohol on these pathways. Canonical pathways that were 
significantly affected by chronic ethanol treatment (p ≤ 0.05) are listed in Table 
12.
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Ingenuity Canonical 
Pathways p-value Molecules 
Arginine and Proline 
Metabolism 0.0001 
ALDH1B1, SAT2, PRODH2, ODC1, BCKDHB, CKB, DAO, C22ORF30, 
ALDH3A2, AGMAT, ALDH3B1, GATM, ASL, P4HA2 
Acute Phase Response 
Signaling 0.0001 
ECSIT, ITIH3, HAMP, SERPING1, AMBP, SERPINA3, SERPIND1, C1R, 
SHC1, HMOX1, JUN, MRAS, CFB, SERPINE1, AGT, HPX, TTR, C1S, 
IL6R, STAT3, CEBPB, PLG, HP, RBP5, FGA 
Pyruvate Metabolism 0.0001 NKD1, ALDH1B1, PC, ACSS1, PCK1, BCKDHB, C22ORF30, PCK2, ALDH3A2, ACSS2, ALDH3B1, RWDD2B, UEVLD, ACSL1 
Fructose and Mannose 
Metabolism 0.0002 
GMPPB, PFKFB3, HK2, PFKFB1, PFKFB4, DUSP18, PFKP, PFKL, 
ALDOC, MPI 
Glycolysis/Gluconeogenesis 0.0003 ALDH1B1, ENO2, ACSS1, PFKP, PFKL, HK2, ALDH3A2, ACSS2, ALDH3B1, RWDD2B, UEVLD, PTGR1, ACSL1, ALDOC 
Glycine, Serine and 
Threonine Metabolism 0.0006 
GNMT, BHMT, GLYCTK, AGXT, SARDH, DAO, C22ORF30, CBS, 
GCAT, SARS2, GATM, SHMT2, ETNK2 
Ascorbate and Aldarate 
Metabolism 0.0019 ALDH1B1, C22ORF30, CYP24A1, ALDH3A2, ALDH3B1, BCKDHB 
Estrogen-Dependent Breast 
Cancer Signaling 0.0019 
JUN, TERT, IGF1R, MRAS, CREB3L4, HSD17B1, HSD17B2, HSD17B8, 
EGFR 
Renin-Angiotensin Signaling 0.0024 PTK2B, GNAQ, SHC3, STAT3, SHC1, PAK1, JUN, ADCY1, ITPR3, MRAS, PRKCE, PRKD1, AGT 
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Ingenuity Canonical 
Pathways p-value Molecules 
Propanoate Metabolism 0.0025 ALDH1B1, ALDH3A2, ACSS2, ACSS1, ALDH3B1, UEVLD, ALDH6A1, CCBL1, ACSL1, GCDH, ACADS 
IL-3 Signaling 0.0045 SHC1, STAT6, PAK1, JUN, FOXO1, MRAS, PRKCE, STAT3, PRKD1 
Glycerolipid Metabolism 0.0060 ALDH1B1, GPAM, LIPC, PNPLA3, GLYCTK, ALDH3A2, DGKG, ALDH3B1, LIPG, LPIN2, AGPAT3, PTGR1 
Prolactin Signaling 0.0065 SHC1, JUN, MRAS, PRKCE, NMI, STAT3, CEBPB, PDK1, PRKD1 
Thrombopoietin Signaling 0.0089 SHC1, THPO, JUN, MRAS, PRKCE, STAT3, PRKD1 
Urea Cycle and Metabolism 
of Amino Groups 0.0093 CKB, SARDH, AGMAT, GATM, ASL, ODC1 
T Helper Cell Differentiation 0.0117 TGFBR2, STAT6, IL4R, TGFB1, IL6R, IL10RB, RORC, STAT3 
Nitrogen Metabolism 0.0117 SARDH, CA9, PTPRG, HAL, TGM4, GLS2, CCBL1 
Oncostatin M Signaling 0.0126 SHC1, TIMP3, EPAS1, MRAS, STAT3 
FXR/RXR Activation 0.0138 LIPC, UGT2B4, PCK2, FOXO1, NR0B2, SREBF1, FOXA1, FASN, HNF4A, VLDLR, MTTP 
Citrate Cycle 0.0151 PC, PCK2, IDH2, PCK1, OGDH 
PPARα/RXRα Activation 0.0166 ACOX1, TGFBR3, GNAQ, NR2C2, MAP4K4, NCOA3, ABCA1, TGFBR2, SHC1, JUN, NR0B2, TGFB1, FASN, ADCY1, MRAS 
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Ingenuity Canonical 
Pathways p-value Molecules 
Glycerophospholipid 
Metabolism 0.0166 
NAPEPLD, PNPLA3, PLA2G15, HMOX1, GPAM, GDE1, LPCAT2, 
C22ORF30, DGKG, LIPG, LPIN2, PLA2G12B, AGPAT3, ETNK2 
Bile Acid Biosynthesis 0.0191 ALDH1B1, SOAT2, ALDH3A2, ALDH3B1, PTGR1, HSD3B7 
D-glutamine and D-
glutamate Metabolism 0.0200 TGM4, GLS2 
PXR/RXR Activation 0.0209 CPT1A, PCK2, FOXO1, NR0B2, CES3, ALDH3A2, HNF4A 
Cholecystokinin/Gastrin-
mediated Signaling 0.0263 
SHC1, JUN, PTK2B, ITPR3, MRAS, GNAQ, PRKCE, FNBP1, PRKD1, 
EGFR 
GNRH Signaling 0.0269 MAP3K15, EGR1, GNAQ, CREB3L4, PAK1, JUN, ADCY1, ITPR3, MRAS, PRKCE, PRKD1, DNM2, EGFR 
Cell Cycle: G1/S Checkpoint 
Regulation 0.0288 HDAC6, CCNE1, TGFB1, HDAC11, CDK4, ABL1, BTRC, HDAC5 
TR/RXR Activation 0.0347 F10, SLC16A3, HP, UCP2, LDLR, SREBF1, FASN, PFKP, PCK1, FGA, AKR1C2, NCOA3 
NRF2-mediated Oxidative 
Stress Response 0.0355 
DNAJC3, GCLC, HERPUD1, TXNRD1, HMOX1, JUN, GPX2, MRAS, 
PRKCE, DNAJA3, JUND, PRKD1, ACTA1, EPHX1 
Glycosaminoglycan 
Degradation 0.0355 MGEA5, KLB, NAGLU, GALNS, SULF2 
Coagulation System 0.0355 PLG, F10, SERPINA5, F7, SERPINE1, FGA, SERPIND1 
  
 
84 
Ingenuity Canonical 
Pathways p-value Molecules 
Androgen and Estrogen 
Metabolism 0.0380 
UGT2B4, STS, SULF2, METTL7B, HSD3B7, HSD17B1, HSD17B2, 
HSD17B8 
Fatty Acid Metabolism 0.0407 ALDH1B1, CPT1A, ALDH3A2, ACOX1, ALDH3B1, CYP4F11, PTGR1, ACSL1, GCDH, ACADS 
Glutathione Metabolism 0.0417 ACSS2, GPX2, GCLC, IDH2, RAB15, ANPEP 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 0.0447 
IL4R, CTGF, LEPR, FGFR1, IL6R, FGFR2, TGFBR2, TGFB1, TIMP1, 
IGF1R, PDGFRB, AGT, EGFR 
Fcγ Receptor-mediated 
Phagocytosis in 
Macrophages and 
Monocytes 
0.0468 MYO5A, HMOX1, NAPEPLD, PAK1, PTK2B, LYN, PRKCE, ACTA1, PRKD1 
G Beta Gamma Signaling 0.0468 SHC1, PAK1, ADCY1, MRAS, GNAQ, PRKCE, PRKD1, DNM2, EGFR 
Phospholipase C Signaling 0.0468 
NAPEPLD, GNAQ, CREB3L4, HDAC5, HDAC6, SHC1, HMOX1, 
HDAC11, ITPR3, ADCY1, LYN, MRAS, PRKCE, ARHGEF3, PLA2G12B, 
FNBP1, PRKD1 
C21-Steroid Hormone 
Metabolism 0.0479 CYP21A2, HSD3B7, HSD17B2 
  
Table 12. Pathways affected by chronic ethanol exposure.  Genes that were differentially expressed (FDR ≤ 3%; 
difference ≥ 10%) with chronic exposure to ethanol were analyzed by Ingenuity Pathway Analysis. Pathways (and genes 
in them) that were significantly affected (p ≤ 0.05) are shown.  
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An overlap between significant pathways was observed. For example, 
most of the genes in the Pyruvate metabolism pathways were also present in 
Glycolysis/ Gluconeogenesis pathway. Similarly, many signaling molecules like 
SHC1, GNAQ, ADCY1 were present in multiple pathways. Due of this overlap 
between pathways, we studied pathways with similar functions together. 
Therefore, pathways like glycolysis/ gluconeogenesis, citrate cycle, fructose and 
mannose metabolism were considered under effects of alcohol on carbohydrate 
metabolism. We also focused our analysis on liver associated functions like 
acute phase response pathways, or on pathways that are known to play a role in 
alcohol induced liver injury like the oxidative stress response.  
Alcohol affected many genes in stress response pathways. Acute phase 
proteins like fibrinogen (FGA) and hemeoxygenase1 (HMOX1), were changed by 
1.2 and 1.3-fold, respectively. Multiple genes associated with the Nrf2-mediated 
oxidative stress response were also affected by chronic ethanol treatment. Nrf2-
regulated proteins including glutamate-cysteine ligase, catalytic subunit (GCLC), 
glutathione peroxidase 2 (GPX2), thioredoxin reductase (TXNRD1) were 
upregulated by at least 20%. Superoxide dismutases were also upregulated, but 
modestly (1.13-fold; Table 13).  
 Several genes involved in hepatic fibrosis were affected by ethanol. 
Fibroblast growth factor receptor family members FGFR1 and FGFR2 were 
upregulated by 1.49- and 1.53-fold, respectively. Transforming growth factor B 
(TGFB1) and its receptor TGFBR2 were increased by 23% and 12% 
respectively. Other receptors that were affected include insulin-like growth factor 
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receptor (IGFR1, 1.29-fold), epidermal growth factor receptor (EGFR, 1.12-fold), 
platelet derived growth factor beta polypeptide (PDGFRB,-1.3-fold) and 
Interleukin-4 receptor (IL-4R, -1.19-fold). Alcohol also had an effect on cell cycle 
genes. Cyclin D1 (CCND1), Cyclin E1 (CCNE1) increased in expression. Ethanol 
had opposing effects on cyclin dependent kinase 4 and 6 (CDK4 and CDK6); 
CDK4 decreased in expression while CDK6 increased in expression. 
Chronic ethanol treatment affected genes encoding proteins involved in 
cellular metabolism (Table 13). Several genes involved in the metabolism of 
amino acids were affected by ethanol. Genes encoding urea cycle enzymes 
arginase (ARG2) and arginosuccinate lyase (ASL) were changed by -1.17 and -
1.15-fold. Prolyl 4-hydroxylase, alpha polypeptide II (P4HA2), an enzyme 
involved in the formation of 4-hydroxyproline increased in expression whereas 
pyrroline-5-carboxylate reductase (PRODH2) decreased in expression. Multiple 
genes in the metabolism small amino acids (glycine, serine, threonine) were also 
affected. Mitochondrial serine and threonine t-RNA synthetases (SARS2, 
TARS2) decreased in expression with ethanol.  
The expression of many genes related to carbohydrate metabolism 
decreased upon ethanol treatment. Transcript level of phosphofructokinase 
(PFKL), which catalyzes the irreversible conversion of fructose-6-phosphate to 
fructose-1, 6-bisphosphate in the glycolytic pathway, was decreased by 1.25 fold. 
Pyruvate carboxylase (PC) enzyme that plays a crucial role in gluconeogenesis 
and lipogenesis was also decreased by 1.22-fold. Enzymes involved in fructose 
metabolism were also affected by ethanol. Liver isozyme 6-phosphofructo-2-
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kinase/fructose-2,6-biphosphatase 1 (PFKFB1) which catalyzes both the 
synthesis and degradation of fructose-2,6-biphosphate increased by 1.41-fold 
with ethanol.  
Glycerolipid metabolism, glycerophospholipid metabolism and fatty acid 
metabolism pathways were considered as effects of alcohol on lipid metabolism. 
Key fatty acid oxidation enzymes carnitine palmitoyltransferase 1A (CPT1A) and 
acyl-Coenzyme A dehydrogenase (ACADS) were decreased by 50% and 24%, 
respectively. Most of the enzymes involved in glycerolipid metabolism were 
upregulated by ethanol. Mitochondrial glycerol-3-phosphate acyltransferase 
(GPAM) and 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3) 
increased in expression by 1.3- and 1.5-fold, respectively. Choline kinase alpha 
(CHKA) and ethanolamine kinases (ETNK1, ETNK2) were also upregulated. 
Genes regulated by nuclear receptors, including farnesoid X receptor 
(FXR) and retinoid X receptor (RXR), were affected by chronic ethanol treatment. 
Nuclear receptor subfamily 0, group B, member 2 (NROB2) was downregulated 
by 1.3-fold, whereas very low density lipoprotein receptor (VLDLR), and ATP 
binding cassette members (ABCB1 and ABCB4) were upregulated by 1.4 and 
1.16-fold respectively. 
In addition to identifying pathways that were affected by ethanol, changes 
in the expression of genes of interest, including those involved in alcohol 
metabolism, transcription factors, chromatin regulation or those that have been 
associated with the risk for alcoholism, were also examined. Of genes involved in 
alcohol metabolism, three aldehyde dehydrogenase genes were affected by 
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ethanol. The expression of ALDH3B1 and ALDH2 was decreased by 1.32-fold 
and 1.12-fold, respectively, whereas ALDH1B1 increased by 1.13-fold. Histone 
acetyltransferase and deacetylases, MYST4 and HDAC11 were also affected by 
ethanol. 
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Transcript 
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Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
Amino acid metabolism 
2623441 ACY1  aminoacylase 1  -1.19 0.03 0.07 
2397732 AGMAT  agmatine ureohydrolase (agmatinase)  -1.15 0.00 0.65 
2535976 AGXT  alanine-glyoxylate aminotransferase  -1.19 0.00 0.84 
3638607 ANPEP  alanyl (membrane) aminopeptidase  1.17 0.01 0.04 
3722182 AOC2  amine oxidase, copper containing 2 (retina-specific)  1.27 0.09 0.76 
3541383 ARG2  arginase, type II  -1.17 0.06 0.87 
3005363 ASL  argininosuccinate lyase  -1.15 0.00 0.38 
2914820 BCKDHB 
 branched chain keto acid dehydrogenase E1, beta 
polypeptide  -1.20 0.00 1.00 
2817251 BHMT  betaine-homocysteine methyltransferase  1.46 0.00 0.98 
2817212 BHMT2  betaine-homocysteine methyltransferase 2  1.23 0.00 0.16 
3958005 C22orf30  chromosome 22 open reading frame 30  1.19 0.03 0.60 
3933923 CBS  cystathionine-beta-synthase  -1.12 0.00 0.83 
3476330 CCDC92  coiled-coil domain containing 92  1.80 0.06 0.72 
3580769 CKB  creatine kinase, brain  -1.42 0.00 0.75 
3430868 DAO  D-amino-acid oxidase  1.20 0.00 0.81 
2864118 DMGDH  dimethylglycine dehydrogenase  1.14 0.11 1.00 
3845175 GAMT  guanidinoacetate N-methyltransferase  -1.11 0.06 0.63 
3622386 GATM 
 glycine amidinotransferase (L-arginine:glycine 
amidinotransferase)  -1.40 0.00 0.64 
3945014 GCAT 
 glycine C-acetyltransferase (2-amino-3-ketobutyrate 
coenzyme A ligase)  -1.40 0.00 0.93 
3955185 GGT5  gamma-glutamyltransferase 5  -1.28 0.12 0.92 
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3903598 GGT7  gamma-glutamyltransferase 7  1.11 0.04 0.22 
3457891 GLS2  glutaminase 2 (liver, mitochondrial)  -1.14 0.00 0.93 
2623611 GLYCTK  glycerate kinase  -1.23 0.00 0.95 
2907513 GNMT  glycine N-methyltransferase  -1.56 0.00 0.64 
3466687 HAL  histidine ammonia-lyase  -1.57 0.00 0.99 
3638760 IDH2  isocitrate dehydrogenase 2 (NADP+), mitochondrial  -1.27 0.00 0.68 
2720145 LAP3  leucine aminopeptidase 3  1.12 0.13 0.14 
3621140 LCMT2  leucine carboxyl methyltransferase 2  1.11 0.11 0.65 
2956438 MUT  methylmalonyl Coenzyme A mutase  -1.22 0.06 0.96 
3031711 NOS3  nitric oxide synthase 3 (endothelial cell)  -1.17 0.06 0.87 
2540157 ODC1  ornithine decarboxylase 1  1.15 0.00 0.63 
3158060 OPLAH  5-oxoprolinase (ATP-hydrolysing)  -1.14 0.09 0.91 
2875193 P4HA2  prolyl 4-hydroxylase, alpha polypeptide II  1.17 0.00 0.25 
3860003 PRODH2  proline dehydrogenase (oxidase) 2  -1.23 0.00 0.38 
3175971 PSAT1  phosphoserine aminotransferase 1  1.22 0.06 0.27 
2626802 PTPRG  protein tyrosine phosphatase, receptor type, G  1.20 0.01 0.11 
2458607 PYCR2  pyrroline-5-carboxylate reductase family, member 2  -1.15 0.06 0.85 
3157647 PYCRL  pyrroline-5-carboxylate reductase-like  -1.22 0.06 0.74 
3228813 SARDH  sarcosine dehydrogenase  -1.15 0.00 0.82 
3861738 SARS2  seryl-tRNA synthetase 2, mitochondrial  -1.16 0.00 0.95 
3743883 SAT2  spermidine/spermine N1-acetyltransferase family member 2  -1.19 0.01 0.51 
3418007 SHMT2  serine hydroxymethyltransferase 2 (mitochondrial)  -1.12 0.00 0.95 
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2786322 SLC7A11 
 solute carrier family 7, (cationic amino acid transporter, y+ 
system) member 11  1.54 0.00 0.12 
2358320 TARS2  threonyl-tRNA synthetase 2, mitochondrial (putative)  -1.12 0.06 0.94 
2620348 TGM4  transglutaminase 4 (prostate)  1.47 0.01 0.00 
Carbohydrate metabolism 
3218077 ALDOB  aldolase B, fructose-bisphosphate  -1.24 0.04 0.99 
3750767 ALDOC  aldolase C, fructose-bisphosphate  -1.29 0.00 0.91 
3458700 B4GALNT1  beta-1,4-N-acetyl-galactosaminyl transferase 1  1.36 0.01 0.11 
3957486 DUSP18  dual specificity phosphatase 18  1.33 0.02 0.42 
3403015 ENO2  enolase 2 (gamma, neuronal)  -1.30 0.00 0.92 
2342176 FPGT  fucose-1-phosphate guanylyltransferase  1.18 0.13 0.15 
3667241 FUK  fucokinase  -1.19 0.04 0.84 
3540552 FUT8  fucosyltransferase 8 (alpha (1,6) fucosyltransferase)  1.43 0.00 0.27 
3770923 GALK1  galactokinase 1  -1.16 0.06 0.87 
3704513 GALNS  galactosamine (N-acetyl)-6-sulfate sulfatase  1.21 0.01 0.00 
3784602 GALNT1 
 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 1 (GalNAc-T1)  1.31 0.02 0.02 
2684187 GBE1  glucan (1,4-alpha-), branching enzyme 1  -1.21 0.02 0.97 
3596147 GCNT3  glucosaminyl (N-acetyl) transferase 3, mucin type  1.39 0.00 0.92 
3972929 GK  glycerol kinase  -1.31 0.04 0.35 
2674653 GMPPB  GDP-mannose pyrophosphorylase B  -1.25 0.02 0.98 
2691014 GSK3B  glycogen synthase kinase 3 beta  1.14 0.13 0.98 
3867538 GYS1  glycogen synthase 1 (muscle)  -1.16 0.00 0.00 
2489545 HK2  hexokinase 2  -1.33 0.00 0.82 
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3601955 MPI  mannose phosphate isomerase  -1.26 0.00 0.64 
2999948 OGDH 
 oxoglutarate (alpha-ketoglutarate) dehydrogenase 
(lipoamide)  -1.24 0.00 0.67 
3378541 PC  pyruvate carboxylase  -1.22 0.00 0.80 
3890640 PCK1  phosphoenolpyruvate carboxykinase 1 (soluble)  -1.35 0.00 0.94 
3529508 PCK2  phosphoenolpyruvate carboxykinase 2 (mitochondrial)  -1.13 0.01 0.19 
2515707 PDK1  pyruvate dehydrogenase kinase, isozyme 1  -1.19 0.02 0.10 
3667093 PDPR  pyruvate dehydrogenase phosphatase regulatory subunit  1.19 0.00 0.75 
4009811 PFKFB1  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1  1.41 0.01 0.57 
2377094 PFKFB2  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2  -1.15 0.05 0.56 
3233605 PFKFB3  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3  -1.29 0.00 0.86 
2673312 PFKFB4  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4  -1.18 0.00 0.94 
3923632 PFKL  phosphofructokinase, liver  -1.25 0.01 0.27 
3232349 PFKP  phosphofructokinase, platelet  -1.16 0.01 0.88 
3928040 RWDD2B  RWD domain containing 2B  -1.32 0.00 0.99 
2798538 SDHA 
 succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp)  -1.10 0.14 0.53 
3365487 UEVLD  UEV and lactate/malate dehyrogenase domains  1.13 0.02 0.52 
Lipid metabolism 
3434594 ACADS  acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain  -1.24 0.01 0.15 
3543673 ACOT2  acyl-CoA thioesterase 2  -1.21 0.04 0.13 
3771215 ACOX1  acyl-Coenzyme A oxidase 1, palmitoyl  -1.25 0.00 1.00 
2796553 ACSL1  acyl-CoA synthetase long-chain family member 1  1.42 0.00 0.00 
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3901696 ACSS1  acyl-CoA synthetase short-chain family member 1  1.17 0.03 0.00 
3883064 ACSS2  acyl-CoA synthetase short-chain family member 2  -1.18 0.00 0.92 
3923426 AGPAT3  1-acylglycerol-3-phosphate O-acyltransferase 3  1.49 0.00 0.52 
2734047 AGPAT9  1-acylglycerol-3-phosphate O-acyltransferase 9  1.28 0.06 0.94 
3274758 AKR1C2 
 aldo-keto reductase family 1, member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, ty 1.25 0.00 0.51 
3714068 ALDH3A2  aldehyde dehydrogenase 3 family, member A2  1.19 0.01 0.29 
2898499 ALDH5A1  aldehyde dehydrogenase 5 family, member A1  1.14 0.06 0.61 
3457794 APOF  apolipoprotein F  -1.26 0.03 0.66 
3379326 CHKA  choline kinase alpha  1.13 0.06 0.98 
3379644 CPT1A  carnitine palmitoyltransferase 1A (liver)  -1.51 0.00 0.67 
3833992 CYP2S1  cytochrome P450, family 2, subfamily S, polypeptide 1  -1.15 0.11 0.22 
3015040 CYP3A43  cytochrome P450, family 3, subfamily A, polypeptide 43  -1.18 0.13 0.95 
3853658 CYP4F11  cytochrome P450, family 4, subfamily F, polypeptide 11  1.31 0.00 0.16 
3823340 CYP4F12  cytochrome P450, family 4, subfamily F, polypeptide 12  1.18 0.10 0.04 
2709235 DGKG  diacylglycerol kinase, gamma 90kDa  1.23 0.00 0.33 
2708720 EHHADH 
 enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A 
dehydrogenase  -1.22 0.03 0.97 
2781813 ELOVL6 
 ELOVL family member 6, elongation of long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3-like, yeast)  1.12 0.09 0.71 
3408018 ETNK1  ethanolamine kinase 1  1.11 0.11 0.38 
2451870 ETNK2  ethanolamine kinase 2  1.31 0.00 0.00 
2334740 FAAH  fatty acid amide hydrolase  -1.17 0.06 0.86 
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3774635 FASN  fatty acid synthase  -1.10 0.03 0.01 
3821995 GCDH  glutaryl-Coenzyme A dehydrogenase  -1.23 0.01 0.65 
3683276 GDE1  glycerophosphodiester phosphodiesterase 1  1.34 0.00 0.56 
3729014 GDPD1 
 glycerophosphodiester phosphodiesterase domain 
containing 1  1.40 0.08 0.99 
3306984 GPAM  glycerol-3-phosphate acyltransferase, mitochondrial  1.31 0.01 0.05 
2945518 GPLD1  glycosylphosphatidylinositol specific phospholipase D1  1.19 0.03 0.01 
3821015 LDLR  low density lipoprotein receptor  -1.20 0.00 0.57 
3299585 LIPA  lipase A, lysosomal acid, cholesterol esterase  1.23 0.04 0.87 
3595691 LIPC  lipase, hepatic  1.16 0.03 0.67 
3787855 LIPG  lipase, endothelial  1.53 0.00 0.01 
2708855 LIPH  lipase, member H  2.26 0.00 0.09 
3661718 LPCAT2  lysophosphatidylcholine acyltransferase 2  1.64 0.02 0.77 
2469910 LPIN1  lipin 1  1.13 0.03 0.35 
3796335 LPIN2  lipin 2  -1.13 0.01 0.85 
2737257 MTTP  microsomal triglyceride transfer protein  1.23 0.02 0.78 
3962219 NAGA  N-acetylgalactosaminidase, alpha-  1.12 0.06 0.66 
3065480 NAPEPLD  N-acyl phosphatidylethanolamine phospholipase D  1.32 0.02 0.33 
3294142 PLA2G12B  phospholipase A2, group XIIB  1.28 0.00 0.71 
3666124 PLA2G15  phospholipase A2, group XV  1.11 0.02 0.83 
3947952 PNPLA3  patatin-like phospholipase domain containing 3  1.18 0.02 0.10 
3434142 PRKAB1  protein kinase, AMP-activated, beta 1 non-catalytic subunit  1.12 0.07 0.90 
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3220673 PTGR1  prostaglandin reductase 1  1.43 0.00 0.80 
3352904 SC5DL 
 sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, S. 
cerevisiae)-like  1.31 0.09 0.24 
3289235 SGMS1  sphingomyelin synthase 1  1.26 0.06 0.18 
2738664 SGMS2  sphingomyelin synthase 2  1.67 0.01 0.00 
2359885 SLC27A3  solute carrier family 27 (fatty acid transporter), member 3  -1.17 0.04 0.50 
3415763 SOAT2  sterol O-acyltransferase 2  -1.20 0.01 0.64 
3747966 SREBF1  sterol regulatory element binding transcription factor 1  -1.15 0.03 0.78 
3967689 STS  steroid sulfatase (microsomal), isozyme S  1.52 0.00 0.04 
3137901 TTPA  tocopherol (alpha) transfer protein  1.96 0.00 0.08 
Acute phase response 
2460296 AGT 
 angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8)  1.14 0.02 0.01 
3221800 AMBP  alpha-1-microglobulin/bikunin precursor  1.12 0.00 0.36 
3442475 C1R  complement component 1, r subcomponent  1.48 0.00 0.00 
3403168 C1S  complement component 1, s subcomponent  1.39 0.00 0.17 
2902958 C4B  complement component 4B (Chido blood group)  -1.14 0.04 0.69 
2377165 C4BPA  complement component 4 binding protein, alpha  -1.19 0.12 0.54 
3223776 C5  complement component 5  -1.20 0.08 0.74 
2902844 CFB  complement factor B  -1.23 0.01 0.72 
3851020 ECSIT  ECSIT homolog (Drosophila)  -1.24 0.01 0.64 
2790626 FGA  fibrinogen alpha chain  1.24 0.01 0.04 
2790652 FGG  fibrinogen gamma chain  1.40 0.06 0.40 
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3838094 FTL  ferritin, light polypeptide  1.29 0.11 0.63 
3830306 HAMP  hepcidin antimicrobial peptide  -1.41 0.01 0.99 
3667858 HP  haptoglobin  -1.28 0.02 0.82 
3360874 HPX  hemopexin  -1.35 0.01 0.92 
3000503 IGFBP1  insulin-like growth factor binding protein 1  -1.19 0.03 0.25 
3996551 IKBKG 
 inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase gamma  1.22 0.04 0.10 
2496962 IL1R1  interleukin 1 receptor, type I  1.19 0.12 0.82 
2657831 IL1RAP  interleukin 1 receptor accessory protein  -1.14 0.08 0.94 
2360257 IL6R  interleukin 6 receptor  -1.19 0.01 0.86 
2857416 IL6ST 
 interleukin 6 signal transducer (gp130, oncostatin M 
receptor)  1.20 0.13 0.25 
4027009 IRAK1  interleukin-1 receptor-associated kinase 1  -1.12 0.04 0.71 
2624178 ITIH3  inter-alpha (globulin) inhibitor H3  -1.42 0.00 0.84 
3160895 JAK2  Janus kinase 2 (a protein tyrosine kinase)  1.43 0.04 0.86 
3733065 MAP2K6  mitogen-activated protein kinase kinase 6  1.29 0.08 0.57 
2904946 MAPK13  mitogen-activated protein kinase 13  -1.15 0.08 0.92 
3832760 NFKBIB 
 nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, beta  -1.11 0.10 0.80 
2934682 PLG  plasminogen  1.46 0.01 0.11 
3442579 RBP5  retinol binding protein 5, cellular  -1.24 0.02 0.64 
2892341 RIPK1  receptor (TNFRSF)-interacting serine-threonine kinase 1  1.18 0.13 0.51 
3549757 SERPINA3 
 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3  1.23 0.00 0.41 
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2444529 SERPINC1  serpin peptidase inhibitor, clade C (antithrombin), member 1  1.23 0.06 0.91 
3937743 SERPIND1 
 serpin peptidase inhibitor, clade D (heparin cofactor), 
member 1  1.10 0.01 0.66 
3016148 SERPINE1 
 serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1  -1.30 0.00 0.23 
3331355 SERPING1  serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  1.41 0.01 0.03 
3757840 STAT3 
 signal transducer and activator of transcription 3 (acute-
phase response factor)  1.10 0.01 0.32 
3783565 TTR  transthyretin  1.12 0.01 0.82 
Oxidative stress response 
3646164 DNAJA3  DnaJ (Hsp40) homolog, subfamily A, member 3  -1.11 0.01 0.62 
2656569 DNAJB11  DnaJ (Hsp40) homolog, subfamily B, member 11  1.18 0.12 0.94 
2343289 DNAJB4  DnaJ (Hsp40) homolog, subfamily B, member 4  1.25 0.13 0.66 
3018866 DNAJB9  DnaJ (Hsp40) homolog, subfamily B, member 9  1.27 0.06 0.25 
3487432 DNAJC15  DnaJ (Hsp40) homolog, subfamily C, member 15  1.17 0.12 0.11 
3497270 DNAJC3  DnaJ (Hsp40) homolog, subfamily C, member 3  1.38 0.01 0.95 
2340350 DNAJC6  DnaJ (Hsp40) homolog, subfamily C, member 6  1.14 0.06 0.87 
2382970 EPHX1  epoxide hydrolase 1, microsomal (xenobiotic)  1.29 0.00 0.33 
2957700 GCLC  glutamate-cysteine ligase, catalytic subunit  1.21 0.03 0.70 
3568603 GPX2  glutathione peroxidase 2 (gastrointestinal)  1.24 0.00 0.26 
2957462 GSTA4  glutathione S-transferase alpha 4  1.19 0.11 0.60 
3662387 HERPUD1 
 homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member 1  1.14 0.02 0.03 
3944129 HMOX1  heme oxygenase (decycling) 1  1.34 0.00 0.83 
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3696666 NQO1  NAD(P)H dehydrogenase, quinone 1  1.10 0.07 0.17 
3917851 SOD1  superoxide dismutase 1, soluble  1.13 0.13 0.27 
3429460 TXNRD1  thioredoxin reductase 1  1.22 0.01 0.59 
3952880 TXNRD2  thioredoxin reductase 2  -1.19 0.00 0.77 
Hepatic fibrosis or hepatic stellate activation 
2863964 ARSB   arylsulfatase B  1.14 0.09 0.44 
2351063 CSF1  colony stimulating factor 1 (macrophage)  1.10 0.11 0.26 
2974330 CTGF  connective tissue growth factor  -1.22 0.02 0.15 
3002640 EGFR 
 epidermal growth factor receptor (erythroblastic leukemia 
viral (v-erb-b) oncogene homolog, avian)  1.12 0.02 0.17 
3229338 FCN1  ficolin (collagen/fibrinogen domain containing) 1  -1.20 0.04 0.79 
3132016 FGFR1  fibroblast growth factor receptor 1  1.49 0.00 0.05 
3310041 FGFR2  fibroblast growth factor receptor 2  1.53 0.00 0.00 
3704513 GALNS   galactosamine (N-acetyl)-6-sulfate sulfatase  1.21 0.01 0.00 
2835792 GM2A   GM2 ganglioside activator  1.10 0.09 0.10 
2675120 HYAL3   hyaluronoglucosaminidase 3  1.13 0.08 0.12 
4025339 IDS   iduronate 2-sulfatase  1.26 0.03 0.01 
3918574 IFNAR1  interferon (alpha, beta and omega) receptor 1  1.25 0.08 0.02 
3918447 IFNAR2  interferon (alpha, beta and omega) receptor 2  1.32 0.05 0.35 
3610804 IGF1R  insulin-like growth factor 1 receptor  1.13 0.01 0.89 
3654175 IL4R  interleukin 4 receptor  -1.19 0.00 0.99 
2724308 KLB   klotho beta  1.20 0.01 0.50 
2340433 LEPR  leptin receptor  1.40 0.03 0.00 
3304012 MGEA5   meningioma expressed antigen 5 (hyaluronidase)  1.23 0.02 0.21 
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3388830 MMP3  matrix metallopeptidase 3 (stromelysin 1, progelatinase)  -1.30 0.11 0.96 
3962219 NAGA   N-acetylgalactosaminidase, alpha-  1.12 0.06 0.66 
3721795 NAGLU   N-acetylglucosaminidase, alpha-  -1.12 0.01 0.65 
2791197 PDGFC  platelet derived growth factor C  1.18 0.11 0.63 
2881239 PDGFRB  platelet-derived growth factor receptor, beta polypeptide  -1.31 0.00 0.99 
3087703 PDGFRL  platelet-derived growth factor receptor-like  1.15 0.11 0.62 
3773340 SGSH   N-sulfoglucosamine sulfohydrolase  -1.10 0.05 0.73 
3908358 SULF2   sulfatase 2  1.51 0.00 0.01 
3863021 TGFB1  transforming growth factor, beta 1  1.23 0.00 0.28 
2615360 TGFBR2  transforming growth factor, beta receptor II (70/80kDa)  1.12 0.02 0.97 
2422722 TGFBR3  transforming growth factor, beta receptor III  1.31 0.00 0.80 
3976341 TIMP1  TIMP metallopeptidase inhibitor 1  1.24 0.01 0.18 
3772661 TIMP2  TIMP metallopeptidase inhibitor 2  1.28 0.05 0.30 
3943504 TIMP3  TIMP metallopeptidase inhibitor 3  1.25 0.00 0.14 
Cell cycle or Apoptosis 
3191724 ABL1  c-abl oncogene 1, receptor tyrosine kinase  1.12 0.00 0.59 
3838067 BAX  BCL2-associated X protein  -1.13 0.15 0.17 
3261165 BTRC  beta-transducin repeat containing  1.12 0.01 0.44 
3338192 CCND1  cyclin D1  1.12 0.06 0.21 
3828112 CCNE1  cyclin E1  1.31 0.02 0.06 
3145107 CCNE2  cyclin E2  1.28 0.08 0.50 
3551303 CCNK  cyclin K  1.24 0.07 0.68 
3458783 CDK4  cyclin-dependent kinase 4  -1.14 0.03 0.49 
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3061319 CDK6  cyclin-dependent kinase 6  1.15 0.14 0.13 
2905169 CDKN1A  cyclin-dependent kinase inhibitor 1A (p21, Cip1)  1.10 0.07 0.37 
3042001 CYCS  cytochrome c, somatic  -1.26 0.09 1.00 
2897576 E2F3  E2F transcription factor 3  1.19 0.07 0.23 
3257098 FAS  Fas (TNF receptor superfamily, member 6)  1.36 0.03 0.19 
3421300 MDM2  Mdm2 p53 binding protein homolog (mouse)  1.19 0.06 0.09 
Nuclear receptor transcribed genes 
3218528 ABCA1  ATP-binding cassette, sub-family A (ABC1), member 1  1.21 0.00 0.04 
3060182 ABCB1  ATP-binding cassette, sub-family B (MDR/TAP), member 1  1.17 0.14 1.00 
3060117 ABCB4  ATP-binding cassette, sub-family B (MDR/TAP), member 4  1.17 0.08 0.06 
3475879 ABCB9  ATP-binding cassette, sub-family B (MDR/TAP), member 9 1.16 0.11 0.08 
3665029 CES3  carboxylesterase 3  -1.17 0.02 0.56 
3910429 CYP24A1  cytochrome P450, family 24, subfamily A, polypeptide 1  -1.30 0.00 0.60 
3502437 F10  coagulation factor X  -1.20 0.02 0.64 
2473149 NCOA1  nuclear receptor coactivator 1  1.12 0.11 0.72 
3887635 NCOA3  nuclear receptor coactivator 3  1.24 0.00 0.06 
2402883 NR0B2  nuclear receptor subfamily 0, group B, member 2  -1.29 0.01 0.89 
2659393 OSTalpha  organic solute transporter alpha  -1.32 0.00 0.45 
3738629 SLC16A3 
 solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4)  -1.30 0.00 0.22 
2907887 SLC22A7 
 solute carrier family 22 (organic anion transporter), member 
7  1.14 0.10 0.38 
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3866785 SULT2A1 
 sulfotransferase family, cytosolic, 2A, 
dehydroepiandrosterone (DHEA)-preferring, member 1  -1.17 0.10 0.87 
3381817 UCP2  uncoupling protein 2 (mitochondrial, proton carrier)  -1.34 0.00 0.97 
2772341 UGT2B4  UDP glucuronosyltransferase 2 family, polypeptide B4  2.17 0.00 0.84 
3160175 VLDLR  very low density lipoprotein receptor  1.41 0.01 0.28 
Signaling molecules 
3000342 ADCY1  adenylate cyclase 1 (brain)  1.27 0.00 0.00 
2677723 ARHGEF3  Rho guanine nucleotide exchange factor (GEF) 3  1.25 0.00 0.01 
2359993 CREB3L4  cAMP responsive element binding protein 3-like 4  -1.16 0.00 0.79 
2480383 EPAS1  endothelial PAS domain protein 1  -1.13 0.01 0.59 
3210808 GNAQ  guanine nucleotide binding protein (G protein), q polypeptide  1.17 0.03 0.59 
2903782 ITPR3  inositol 1,4,5-triphosphate receptor, type 3  -1.18 0.01 0.89 
4001785 MAP3K15  mitogen-activated protein kinase kinase kinase 15  1.21 0.02 0.16 
2496727 MAP4K4  mitogen-activated protein kinase kinase kinase kinase 4  1.14 0.03 0.55 
2644565 MRAS  muscle RAS oncogene homolog  1.20 0.02 0.46 
2580955 NMI  N-myc (and STAT) interactor  1.63 0.00 0.02 
3382861 PAK1  p21 protein (Cdc42/Rac)-activated kinase 1  1.63 0.00 0.00 
3559192 PRKD1  protein kinase D1  1.46 0.00 0.00 
3091301 PTK2B  PTK2B protein tyrosine kinase 2 beta  -1.13 0.03 0.29 
3568616 RAB15  RAB15, member RAS onocogene family  1.47 0.00 0.17 
2436985 SHC1 
 SHC (Src homology 2 domain containing) transforming 
protein 1  1.15 0.02 0.01 
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Alcohol metabolism 
3169331 ALDH1B1  aldehyde dehydrogenase 1 family, member B1  1.13 0.01 0.11 
3432090 ALDH2  aldehyde dehydrogenase 2 family (mitochondrial)  -1.12 0.06 0.71 
3337329 ALDH3B1  aldehyde dehydrogenase 3 family, member B1  -1.32 0.00 0.80 
3571727 ALDH6A1  aldehyde dehydrogenase 6 family, member A1  -1.60 0.00 0.65 
2975257 ALDH8A1  aldehyde dehydrogenase 8 family, member A1  -1.22 0.09 0.69 
Transcription factors 
3945914 ATF4 
 activating transcription factor 4 (tax-responsive enhancer 
element B67)  -1.11 0.06 0.21 
3858993 CEBPA  CCAAT/enhancer binding protein (C/EBP), alpha  -1.14 0.02 0.94 
3888613 CEBPB  CCAAT/enhancer binding protein (C/EBP), beta  1.12 0.02 0.89 
3134013 CEBPD  CCAAT/enhancer binding protein (C/EBP), delta  -1.16 0.10 0.99 
3836266 FOSB  FBJ murine osteosarcoma viral oncogene homolog B  -1.26 0.14 0.85 
3561703 FOXA1  forkhead box A1  -1.15 0.01 0.16 
3510858 FOXO1  forkhead box O1  -1.12 0.01 0.63 
2891556 FOXQ1  forkhead box Q1  -1.20 0.05 0.57 
3539070 HIF1A 
 hypoxia inducible factor 1, alpha subunit (basic helix-loop-
helix transcription factor)  1.13 0.13 0.72 
3754797 HNF1B  HNF1 homeobox B  -1.14 0.04 1.00 
3886453 HNF4A  hepatocyte nuclear factor 4, alpha  1.12 0.01 0.01 
2516967 HOXD1  homeobox D1  -1.33 0.00 0.41 
2907730 SRF 
 serum response factor (c-fos serum response element-
binding transcription factor)  -1.11 0.04 0.76 
3458337 STAT6 
 signal transducer and activator of transcription 6, interleukin-
4 induced  -1.20 0.00 0.68 
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Chromatin regulation 
2544662 DNMT3A  DNA (cytosine-5-)-methyltransferase 3 alpha  -1.11 0.03 0.01 
3882012 DNMT3B  DNA (cytosine-5-)-methyltransferase 3 beta  1.25 0.00 0.01 
3945006 H1F0  H1 histone family, member 0  -1.15 0.05 0.82 
3048869 H2AFV  H2A histone family, member V  -1.13 0.11 0.50 
2611504 HDAC11  histone deacetylase 11  -1.32 0.01 0.66 
3758845 HDAC5  histone deacetylase 5  -1.12 0.02 0.89 
3976848 HDAC6  histone deacetylase 6  -1.16 0.01 0.94 
2947073 HIST1H1B  histone cluster 1, H1b  1.18 0.00 0.76 
2946353 HIST1H1D  histone cluster 1, H1d  1.31 0.05 0.78 
2900074 HIST1H2BN  histone cluster 1, H2bn  1.13 0.11 0.04 
2946324 HIST1H3D  histone cluster 1, H3d  1.11 0.07 0.06 
2899233 HIST1H3E  histone cluster 1, H3e  1.14 0.12 0.12 
2946383 HIST1H4H  histone cluster 1, H4h  1.31 0.01 0.01 
2509740 MBD5  methyl-CpG binding domain protein 5  1.43 0.00 0.00 
3656855 MYST1  MYST histone acetyltransferase 1  -1.15 0.02 0.02 
3252382 MYST4  MYST histone acetyltransferase (monocytic leukemia) 4  1.19 0.11 0.68 
Genes associated with alcoholism 
3521174 ABCC4  ATP-binding cassette, sub-family C (CFTR/MRP), member 4  1.14 0.01 0.75 
3606304 AKAP13  A kinase (PRKA) anchor protein 13  1.22 0.01 0.47 
3927226 APP  amyloid beta (A4) precursor protein  1.13 0.00 0.15 
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3673684 CDT1  chromatin licensing and DNA replication factor 1  -1.22 0.00 0.05 
3603436 CHRNA5  cholinergic receptor, nicotinic, alpha 5  1.36 0.02 0.06 
2772968 COX18 
 COX18 cytochrome c oxidase assembly homolog (S. 
cerevisiae)  -1.23 0.01 0.77 
3720228 CRKRS  Cdc2-related kinase, arginine/serine-rich  1.19 0.02 0.29 
3652424 EEF2K  eukaryotic elongation factor-2 kinase  1.11 0.01 0.90 
3260383 ENTPD7  ectonucleoside triphosphate diphosphohydrolase 7  1.12 0.01 0.04 
2948587 FLOT1  flotillin 1  -1.15 0.01 1.00 
3199511 FREM1  FRAS1 related extracellular matrix 1  1.82 0.00 0.07 
2469825 GREB1  GREB1 protein  1.24 0.01 0.00 
3636391 HOMER2  homer homolog 2 (Drosophila)  1.27 0.01 0.27 
3349660 HTR3B  5-hydroxytryptamine (serotonin) receptor 3B  2.13 0.00 0.27 
3779362 IMPA2  inositol(myo)-1(or 4)-monophosphatase 2  -1.24 0.01 0.68 
3817733 JMJD2B  jumonji domain containing 2B  -1.17 0.00 0.77 
3517793 KLF12  Kruppel-like factor 12  1.30 0.00 0.18 
2667809 OSBPL10  oxysterol binding protein-like 10  1.17 0.01 0.31 
2698996 PCOLCE2  procollagen C-endopeptidase enhancer 2  1.88 0.00 0.01 
3358361 PDDC1  Parkinson disease 7 domain containing 1  -1.16 0.02 0.41 
2361401 PMF1  polyamine-modulated factor 1  -1.19 0.02 0.75 
2480168 PRKCE  protein kinase C, epsilon  1.20 0.00 0.00 
3213847 SHC3 
 SHC (Src homology 2 domain containing) transforming 
protein 3  1.31 0.02 0.64 
2902884 SKIV2L  superkiller viralicidic activity 2-like (S. cerevisiae)  -1.16 0.02 0.88 
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3369366 SLC1A2 
 solute carrier family 1 (glial high affinity glutamate 
transporter), member 2  1.17 0.01 0.53 
2610544 SLC6A11 
 solute carrier family 6 (neurotransmitter transporter, GABA), 
member 11  1.23 0.01 0.79 
3751794 SLC6A4 
 solute carrier family 6 (neurotransmitter transporter, 
serotonin), member 4  1.20 0.00 0.01 
3318666 SMPD1  sphingomyelin phosphodiesterase 1, acid lysosomal  1.18 0.03 0.90 
2378662 TRAF5  TNF receptor-associated factor 5  1.84 0.00 0.04 
3316375 TSPAN4  tetraspanin 4  -1.20 0.00 0.92 
3896976 TXNDC13  thioredoxin domain containing 13  1.23 0.00 0.00 
3815328 WDR18  WD repeat domain 18  -1.19 0.01 0.87 
3989089 ZBTB33  zinc finger and BTB domain containing 33  1.27 0.01 0.15 
3971923 ZFX  zinc finger protein, X-linked  1.16 0.00 0.80 
3078478 ZNF786  zinc finger protein 786  1.20 0.03 0.67 
 
Table 13. Differentially expressed genes within pathways that were significantly affected by chronic alcohol 
exposure.  Pathways significantly affected by ethanol were identified by Ingenuity Pathway analysis (Table 12). Pathways 
(and genes in them) with related functions were grouped into broader categories. For example, Glycolysis/ 
Gluconeogenesis and Citrate cycle are grouped under carbohydrate metabolism. Fold change (E/C) is ethanol/ control. 
Differentially expressed genes (FDR ≤ 15% and difference ≥ 10%) within the key pathways discussed in the text are 
shown. Other genes are listed in Appendix. 
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4.a. Validation of differential gene expression results by qRT-PCR 
Quantitative real time RT-PCR assays (Taqman gene expression assays) 
were carried out to confirm differential gene expression changes that were 
observed in microarray data. Genes were selected from the key pathways that 
were affected by chronic ethanol treatment. Even small expression changes in 
the array data were confirmed by these assays. For example SREBF1 decreased 
in expression by 15% in the array data and was confirmed to be decreased by 
19% in qRT-PCR (Figure 18). A total of thirteen genes out of fourteen genes 
testes were confirmed with fold changes very similar to that observed in the array 
data (Figure 18).  
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Figure 18. qRT-PCR validation of differential gene expression. Genes from 
key pathways affected by chronic alcohol exposure were validated by qRT-PCR. 
Fold change is the ratio of expression under ethanol treatment over control 
treatment. For all genes p-value ≤ 5 x 10-6. For comparison, fold changes 
observed in array data are shown.  
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5. Effects of chronic alcohol exposure on RNA splicing  
Effects of ethanol on splicing were explored using Affymetrix GeneChip® 
Human Exon 1.0 ST Arrays. Two-way ANOVA generated p-values (and FDRs 
calculated using this p-value) were used to identify genes that were differentially 
alternatively spliced due to chronic ethanol exposure. Some of these genes were 
also differentially expressed. Of the 10,222 genes that were analyzed many 
genes were differentially alternatively spliced after treatment with ethanol (Table 
14). 
 
 
 Number of genes 
 FDR 15% FDR 10% FDR 3% 
Total Alternatively spliced1 1323 948 458 
Alternatively spliced only2 687 559 323 
Differentially expressed and 
Alternatively spliced3 
636 389 135 
 
Table 14. Effects of chronic ethanol exposure on splicing at different false 
discovery rates. 1Irrespective of the differential expression FDR. 2Alternative 
splicing without differential expression at that FDR. 3Both alternative splicing and 
differential expression. FDR was calculated by the method of Benjamini and 
Hochberg (1995).
 109 
 
Due to the complexity of identifying true alterative splicing events 
(discussed in Introduction), FDR ≤ 3% was used for detecting genes that were 
differentially alternatively spliced upon chronic ethanol treatment. A total of 458 
(4.5%) of the detected genes were differentially alternatively spliced at an FDR ≤ 
3%. To detect true events, the effects of alcohol on each probe set was 
visualized in the context of the gene using a custom track in the UCSC genome 
browser (Kent et al., 2002). Multiple factors were considered during this 
inspection. How is the expression of each probe set affected by ethanol? If a 
probe set changes in expression with ethanol, is this effect different from how the 
other probe sets in the gene are affected? To aid in this analysis, a one-way 
ANOVA was carried out on probe sets. The fold change obtained for each probe 
set along with the p-value (which indicates if the effect is significant) from one-
way ANOVA were used to identify probe sets that were probably alternatively 
spliced in a gene. The analysis was restricted to genes with a minimum of three 
present probe sets.  
In many genes, probe sets at the 5’ end of the transcript were either called 
absent or exhibited a decrease in expression with ethanol treatment (Figure 19). 
A pattern was also noticed at the 3’ end of the transcripts, with an increase in the 
expression in the presence of ethanol. Examples of these edge effects are 
shown in Figure 19. In most cases it was difficult to distinguish between edge 
effects and true alternate promoter and alternate poly(A) events and we therefore 
focused on other alternate events such as putative cassette exons. However, in 
some cases multiple probe sets indicated the presence of an alternate promoter 
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(for example, in MBD5, KANK1). We considered these alternate promoters to be 
probably differential alternative events.
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Figure 19. 5’ and 3’ edge effects in exon array data.  Both UCSC genes and 
Refseq tracks are shown. In these tracks exons are represented as boxes, and 
intervening introns as lines. Arrows on introns show the direction of transcription. 
The alternative splicing events track, which displays all known alternative splicing 
events, is also shown. Probe set FC E/C is a custom track that displays fold 
change, ethanol/ control, for each probe set from the data in this study. (A) An 
example of 5’ edge effect; affected probe set indicated by an arrow (B) An 
example of 3’ effect, indicated by an arrow. 5’ edge effect is also observed in this 
gene.   
 
 
A
B
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A total of 458 genes that were alternatively spliced were visually inspected 
and grouped into three categories (described in detail in Materials and Methods, 
section 9) 1. Probably differentially alternatively spliced, if a probe set has a 
significant fold change between ethanol and control, and behaves differently from 
the remaining probe sets in the gene; 2. Probably not differentially alternatively 
spliced if there was no indication of differential alternative splicing or if only edge 
effects were observed; 3. Uncertain if the changes appear to be probably 
differentially alternatively spliced but it is difficult to conclude if the alternative 
event is real. An example of each category is shown in Figure 20. 142 genes 
(31%) appeared to be probably alternatively spliced while 199 (43%) genes were 
probably not alternatively spliced. The remaining genes were grouped into the 
uncertain category. In genes that were detected as probably alternatively spliced 
probe sets that are probably differentially spliced are listed in Table 15.
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Figure 20. Examples of different groups of alternatively spliced genes.  
USCS genome browser images with exon array custom track are shown. (A) An 
example of a gene that was grouped as probably differentially alternatively 
spliced is shown. One half of the probe sets have lower fold change than the 
other half, suggesting expression of a shorter form of the transcript with ethanol. 
(B) Gene classified as Uncertain. Among the probe sets that were significantly 
affected, some (indicated by blue arrows) had a smaller fold change while others 
(indicated by black arrows) had a much higher fold change; some remained 
unaffected. Thus it was difficult to say if the gene was alternatively spliced or not. 
(C) Gene that was classified as probably not differentially alternatively spliced by 
looking at the expression of probe sets in the gene. Only three probe sets were 
significantly affected by ethanol but were similar in expression to each other.  
C
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From the 142 genes that appeared probably differentially alternative 
spliced, 317 probe sets were matched to known alternative splicing or promoter 
or termination events from the data available in the UCSC genome browser. Of 
these only 39 probe sets appeared to be affected by ethanol. 26 of these probe 
sets were cassette exons. 
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Probe set 
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3308034 3307939 ABLIM1  actin binding LIM protein 1  0.00 0.04 2.10 1.13   
2796582 2796553 ACSL1  acyl-CoA synthetase long-chain family member 1  0.00 0.00 2.66 1.42   
3716956 3716950 ADAP2  ArfGAP with dual PH domains 2  0.00 0.02 1.56 1.21 Cassette Exon 
3716961 3716950 ADAP2  ArfGAP with dual PH domains 2  0.00 0.02 1.85 1.21   
3263610 3263555 ADD3  adducin 3 (gamma)  0.02 0.13 1.53 1.15   
3940676 3940631 ADRBK2  adrenergic, beta, receptor kinase 2  0.00 0.02 2.35 1.25   
3509892 3509885 ALG5 
 asparagine-linked glycosylation 5, 
dolichyl-phosphate beta-
glucosyltransferase homolog (S. 
cerevisiae)  
0.00 0.06 2.05 1.12   
3704741 3704717 ANKRD11  ankyrin repeat domain 11  0.01 0.02 2.03 1.17   
3282143 3282117 ANKRD26  ankyrin repeat domain 26  0.01 0.19 1.84 1.24   
3282161 3282117 ANKRD26  ankyrin repeat domain 26  0.01 0.19 1.66 1.24   
3282188 3282117 ANKRD26  ankyrin repeat domain 26  0.01 0.19 2.23 1.24   
3985233 3985218 ARMCX5  armadillo repeat containing, X-linked 5  0.02 0.07 1.44 1.18   
3261950 3261923 AS3MT  arsenic (+3 oxidation state) methyltransferase  0.00 0.15 -1.83 -1.06   
3137642 3137530 ASPH  aspartate beta-hydroxylase  0.01 0.02 1.50 1.16 Cassette Exon 
2950757 2950753 BAK1  BCL2-antagonist/killer 1  0.01 0.55 1.37 -1.04   
2950763 2950753 BAK1  BCL2-antagonist/killer 1  0.01 0.55 -1.66 -1.04   
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2996330 2996321 BBS9  Bardet-Biedl syndrome 9  0.00 0.05 2.09 1.39   
2996339 2996321 BBS9  Bardet-Biedl syndrome 9  0.00 0.05 2.26 1.39   
3025504 3025500 BPGM  2,3-bisphosphoglycerate mutase  0.00 0.53 -1.69 1.06 Cassette Exon 
3732463 3732448 BPTF  bromodomain PHD finger transcription factor  0.00 0.11 2.33 1.21 
Cassette 
Exon 
3393845 3393834 C11orf60  chromosome 11 open reading frame 60  0.02 0.01 1.93 1.42   
3393857 3393834 C11orf60  chromosome 11 open reading frame 60  0.02 0.01 2.16 1.42   
3471832 3471819 C12orf30  chromosome 12 open reading frame 30  0.00 0.47 2.00 1.05   
3588702 3588658 C15orf41  chromosome 15 open reading frame 41  0.00 0.01 1.79 1.15   
3442492 3442475 C1R  complement component 1, r subcomponent  0.00 0.00 1.91 1.48   
3442494 3442475 C1R  complement component 1, r subcomponent  0.00 0.00 2.53 1.48   
2377258 2377229 CD55 
 CD55 molecule, decay accelerating 
factor for complement (Cromer 
blood group)  
0.02 0.07 -1.38 1.17 Cassette Exon 
3964164 3964154 CERK  ceramide kinase  0.01 0.05 1.50 1.09   
2685924 2685908 CLDND1  claudin domain containing 1  0.00 0.10 2.04 1.15 Cassette Exon 
3261992 3261971 CNNM2  cyclin M2  0.00 0.06 -1.08 1.13   
3452866 3452865 COL2A1  collagen, type II, alpha 1  0.00 0.02 1.83 1.25   
3452867 3452865 COL2A1  collagen, type II, alpha 1  0.00 0.02 2.52 1.25   
3924402 3924372 COL6A1  collagen, type VI, alpha 1  0.00 0.23 1.55 1.12   
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3855119 3855104 CRLF1  cytokine receptor-like factor 1  0.00 0.02 -1.26 1.14   
3284910 3284882 CUL2  cullin 2  0.02 0.14 2.74 1.20   
2837366 2837266 CYFIP2  cytoplasmic FMR1 interacting protein 2  0.00 0.04 1.73 1.13   
2903043 2903034 CYP21A2  cytochrome P450, family 21, subfamily A, polypeptide 2  0.00 0.02 2.35 1.19   
3526553 3526544 DCUN1D2 
 DCN1, defective in cullin 
neddylation 1, domain containing 2 
(S. cerevisiae)  
0.00 0.01 2.00 1.20 Cassette Exon 
2429199 2429147 DENND2C  DENN/MADD domain containing 2C  0.02 0.25 2.06 1.21 
Alt Three 
Prime 
3449809 3449760 DENND5B  DENN/MADD domain containing 5B  0.01 0.15 1.71 1.11 
Alt Five 
Prime 
3438704 3438617 EP400  E1A binding protein p400  0.00 0.14 2.72 1.07   
3883731 3883690 EPB41L1  erythrocyte membrane protein band 4.1-like 1  0.00 0.01 -1.15 1.20 
Cassette 
Exon 
3260855 3260829 FAM178A  family with sequence similarity 178, member A  0.00 0.08 1.77 1.24   
3260884 3260829 FAM178A  family with sequence similarity 178, member A  0.00 0.08 1.71 1.24   
3260885 3260829 FAM178A  family with sequence similarity 178, member A  0.00 0.08 1.75 1.24   
3884894 3884892 FAM83D  family with sequence similarity 83, member D  0.00 0.45 -1.34 -1.02   
3536809 3536786 FBXO34  F-box protein 34  0.01 0.13 1.26 1.12   
3310204 3310041 FGFR2  fibroblast growth factor receptor 2  0.00 0.00 2.75 1.53   
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2678828 2678714 FHIT  fragile histidine triad gene  0.01 0.07 -1.37 1.12   
3355064 3355056 FOXRED1  FAD-dependent oxidoreductase domain containing 1  0.00 0.05 1.47 -1.11 
Bleeding 
Exon 
3183263 3183238 FSD1L  fibronectin type III and SPRY domain containing 1-like  0.01 0.18 2.13 1.15   
2836609 2836518 GALNT10 
 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 
(GalNAc-T10)  
0.00 0.05 1.72 1.12   
3468153 3468103 GNPTAB 
 N-acetylglucosamine-1-phosphate 
transferase, alpha and beta 
subunits  
0.00 0.01 2.10 1.29   
3438161 3438061 GPR133  G protein-coupled receptor 133  0.01 0.34 -1.44 1.04 Cassette Exon 
3334428 3334415 GPR137  G protein-coupled receptor 137  0.01 0.19 1.52 1.10   
3050476 3050462 GRB10  growth factor receptor-bound protein 10  0.03 0.19 1.38 1.05   
2469862 2469825 GREB1  GREB1 protein  0.00 0.01 1.90 1.24   
3267040 3267036 GRK5  G protein-coupled receptor kinase 5  0.01 0.05 2.07 1.17   
2927734 2927722 HEBP2  heme binding protein 2  0.03 0.83 -1.28 -1.01   
3258934 3258910 HELLS  helicase, lymphoid-specific  0.03 0.31 1.67 1.12 Cassette Exon 
2610128 2610094 IL17RC  interleukin 17 receptor C  0.02 0.63 -1.42 -1.03   
2610086 2610056 IL17RE  interleukin 17 receptor E  0.00 0.60 -1.74 1.04   
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3272344 3272205 INPP5A  inositol polyphosphate-5-phosphatase, 40kDa  0.02 0.40 -1.51 -1.03 
Bleeding 
Exon 
3339471 3339423 INPPL1  inositol polyphosphate phosphatase-like 1  0.00 0.07 1.36 1.05   
3159484 3159483 KANK1  KN motif and ankyrin repeat domains 1  0.00 0.02 -1.19 1.08 
Alt 
Promoter 
3159513 3159483 KANK1  KN motif and ankyrin repeat domains 1  0.00 0.02 3.21 1.08 
Cassette 
Exon 
3159526 3159483 KANK1  KN motif and ankyrin repeat domains 1  0.00 0.02 1.91 1.08   
3687311 3687308 KCTD13  potassium channel tetramerisation domain containing 13  0.01 0.09 1.69 1.09   
3117386 3117384 KHDRBS3 
 KH domain containing, RNA 
binding, signal transduction 
associated 3  
0.00 0.05 -1.44 1.18   
2764216 2764192 KIAA0746  KIAA0746 protein  0.01 0.00 2.45 1.56   
3239168 3238962 KIAA1217  KIAA1217  0.00 0.01 1.77 1.25 Cassette Exon 
3239170 3238962 KIAA1217  KIAA1217  0.00 0.01 1.71 1.25 Cassette Exon 
3737294 3737274 KIAA1618  KIAA1618  0.00 0.03 2.47 1.07   
3886104 3886072 L3MBTL  l(3)mbt-like (Drosophila)  0.01 0.04 2.11 1.18   
2674065 2674047 LAMB2  laminin, beta 2 (laminin S)  0.01 0.15 -1.51 -1.09   
3402854 3402836 LEPREL2  leprecan-like 2  0.00 0.27 1.75 1.06   
2352526 2352501 LRIG2  leucine-rich repeats and immunoglobulin-like domains 2  0.01 0.55 1.69 1.04   
3600255 3600212 LRRC49  leucine rich repeat containing 49  0.01 0.21 -1.75 1.28   
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2814812 2814756 MAP1B  microtubule-associated protein 1B  0.00 0.01 1.58 1.24   
3723725 3723687 MAPT  microtubule-associated protein tau  0.01 0.00 2.39 1.47   
3807768 3807753 MBD1  methyl-CpG binding domain protein 1  0.01 0.14 1.42 1.06 
Cassette 
Exon 
3807800 3807753 MBD1  methyl-CpG binding domain protein 1  0.01 0.14 1.41 1.06   
2509748 2509740 MBD5  methyl-CpG binding domain protein 5  0.00 0.00 1.20 1.43 
Alt 
Promoter 
2509755 2509740 MBD5  methyl-CpG binding domain protein 5  0.00 0.00 2.12 1.43 
Alt 
Promoter 
3611221 3611126 MEF2A  myocyte enhancer factor 2A  0.02 0.11 2.06 1.15 Cassette Exon 
3834786 3834778 MEGF8  multiple EGF-like-domains 8  0.00 0.12 2.21 1.09   
3945116 3945084 MICALL1  MICAL-like 1  0.01 0.47 2.54 1.05   
3453679 3453592 MLL2  myeloid/lymphoid or mixed-lineage leukemia 2  0.03 0.04 1.46 1.09   
3939483 3939470 MMP11  matrix metallopeptidase 11 (stromelysin 3)  0.02 0.61 1.48 1.05   
4027609 4027585 MPP1  membrane protein, palmitoylated 1, 55kDa  0.02 0.01 1.51 1.15 
Cassette 
Exon 
2692888 2692883 MUC13  mucin 13, cell surface associated  0.00 0.00 1.03 2.99   
3431233 3431220 MVK  mevalonate kinase  0.02 0.35 1.68 1.04   
3341235 3341221 MYO7A  myosin VIIA  0.00 0.25 1.48 1.04   
3722722 3722700 NAGS  N-acetylglutamate synthase  0.01 0.16 -1.65 -1.15   
3485325 3485292 NBEA  neurobeachin  0.00 0.01 2.46 1.47   
3485354 3485292 NBEA  neurobeachin  0.00 0.01 3.20 1.47   
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3776154 3776139 NDC80  NDC80 homolog, kinetochore complex component (S. cerevisiae)  0.02 0.11 2.07 1.20   
3468771 3468743 NT5DC3  5'-nucleotidase domain containing 3  0.00 0.01 1.94 1.25   
3382895 3382861 PAK1  p21 protein (Cdc42/Rac)-activated kinase 1  0.00 0.00 1.18 1.63   
3175284 3175274 PCSK5  proprotein convertase subtilisin/kexin type 5  0.00 0.00 2.01 1.35   
3407496 3407453 PDE3A  phosphodiesterase 3A, cGMP-inhibited  0.02 0.32 2.12 1.10   
3755379 3755359 PIP4K2B  phosphatidylinositol-5-phosphate 4-kinase, type II, beta  0.03 0.16 1.44 1.06   
2977650 2977621 PLAGL1  pleiomorphic adenoma gene-like 1  0.01 0.00 2.33 1.44 Cassette Exon 
2640646 2640579 PLXNA1  plexin A1  0.00 0.40 -1.30 1.04   
3426598 3426502 PLXNC1  plexin C1  0.00 0.00 1.92 1.34   
2694842 2694817 PLXND1  plexin D1  0.03 0.73 1.31 -1.01   
3878439 3878429 POLR3F  polymerase (RNA) III (DNA directed) polypeptide F, 39 kDa  0.00 0.12 2.03 1.17   
3976654 3976639 PORCN  porcupine homolog (Drosophila)  0.03 0.78 1.64 -1.02   
2948431 2948425 PPP1R10  protein phosphatase 1, regulatory (inhibitor) subunit 10  0.02 0.00 -1.00 1.24   
2948433 2948425 PPP1R10  protein phosphatase 1, regulatory (inhibitor) subunit 10  0.02 0.00 -1.00 1.24   
3134053 3134034 PRKDC  protein kinase, DNA-activated, catalytic polypeptide  0.01 0.57 1.21 1.04   
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3185569 3185558 PRPF4  PRP4 pre-mRNA processing factor 4 homolog (yeast)  0.01 0.50 1.23 1.04   
3771474 3771464 QRICH2  glutamine rich 2  0.00 0.02 2.20 1.17   
2369994 2369950 QSOX1  quiescin Q6 sulfhydryl oxidase 1  0.01 0.08 1.63 1.12   
3580293 3580234 RAGE  renal tumor antigen  0.01 0.05 2.75 1.23   
2843588 2843579 RMND5B  required for meiotic nuclear division 5 homolog B (S. cerevisiae)  0.00 0.59 1.54 -1.05 
Bleeding 
Exon 
3221027 3220977 ROD1  ROD1 regulator of differentiation 1 (S. pombe)  0.00 0.52 1.99 1.04 
Cassette 
Exon 
3847294 3847252 SAFB2  scaffold attachment factor B2  0.01 0.59 1.47 1.04   
3832949 3832918 SAMD4B  sterile alpha motif domain containing 4B  0.01 0.22 1.50 1.07   
2829436 2829416 SEC24A  SEC24 family, member A (S. cerevisiae)  0.00 0.97 1.85 -1.01   
2622567 2622547 SEMA3F 
 sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3F  
0.01 0.02 1.50 1.13   
3764552 3764527 SEPT4  septin 4  0.00 0.05 2.00 1.20   
2738684 2738664 SGMS2  sphingomyelin synthase 2  0.00 0.01 2.42 1.67   
3557360 3557350 SLC22A17  solute carrier family 22, member 17  0.01 0.02 1.68 1.16 Cassette Exon 
3472326 3472312 SLC24A6 
 solute carrier family 24 
(sodium/potassium/calcium 
exchanger), member 6  
0.02 0.96 -1.35 -1.00   
2645287 2645275 SLC25A36  solute carrier family 25, member 36  0.03 0.38 1.45 1.12   
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2584925 2584904 SLC38A11  solute carrier family 38, member 11  0.02 0.02 2.67 1.80   
2545588 2545549 SLC5A6 
 solute carrier family 5 (sodium-
dependent vitamin transporter), 
member 6  
0.01 0.53 1.21 -1.03   
3751824 3751794 SLC6A4 
 solute carrier family 6 
(neurotransmitter transporter, 
serotonin), member 4  
0.01 0.00 1.76 1.20   
3262461 3262433 SLK  STE20-like kinase (yeast)  0.00 0.46 -1.55 1.05 Cassette Exon 
3592394 3592366 SPATA5L1  spermatogenesis associated 5-like 1  0.02 0.64 1.47 -1.04   
3140741 3140640 STAU2  staufen, RNA binding protein, homolog 2 (Drosophila)  0.01 0.05 2.39 1.28 
Cassette 
Exon 
3766288 3766284 STRADA  STE20-related kinase adaptor alpha  0.00 0.07 1.42 1.08 
Retained 
Intron 
3908375 3908358 SULF2  sulfatase 2  0.01 0.00 1.07 1.51   
2660827 2660800 SUMF1  sulfatase modifying factor 1  0.00 0.21 -1.53 1.07   
3283067 3282974 SVIL  supervillin  0.01 0.00 1.70 1.17 Cassette Exon 
3283123 3282974 SVIL  supervillin  0.01 0.00 1.92 1.17 Alt Promoter 
3968223 3968122 TBL1X  transducin (beta)-like 1X-linked  0.00 0.00 2.16 1.13   
4007736 4007734 TFE3  transcription factor binding to IGHM enhancer 3  0.01 0.04 1.29 1.17 
Cassette 
Exon 
3631259 3631214 TLE3  transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila)  0.03 0.01 1.94 1.23 
Cassette 
Exon 
3301869 3301857 TM9SF3  transmembrane 9 superfamily member 3  0.00 0.12 1.88 1.13   
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3502641 3502632 TMCO3  transmembrane and coiled-coil domains 3  0.00 0.02 1.62 1.13   
3909102 3909064 TMEM189-UBE2V1 
 TMEM189-UBE2V1 readthrough 
transcript  0.00 0.07 2.77 1.21 
Cassette 
Exon 
3107258 3107242 TMEM67  transmembrane protein 67  0.02 0.23 2.12 1.20 Cassette Exon 
3449083 3449068 TMTC1  transmembrane and tetratricopeptide repeat containing 1  0.01 0.02 2.13 1.27   
2317444 2317434 TPRG1L  tumor protein p63 regulated 1-like  0.01 0.40 1.50 1.06   
3634080 3634071 TSPAN3  tetraspanin 3  0.01 0.00 1.09 1.11   
3896997 3896976 TXNDC13  thioredoxin domain containing 13  0.00 0.00 1.07 1.23   
2962727 2962683 UBE2CBP  ubiquitin-conjugating enzyme E2C binding protein  0.00 0.68 1.37 1.04   
3311757 3311715 UROS  uroporphyrinogen III synthase  0.02 0.21 1.74 1.16 Alt Promoter 
2542699 2542651 WDR35  WD repeat domain 35  0.00 0.98 -1.25 -1.00   
3699223 3699178 WDR59  WD repeat domain 59  0.00 0.00 1.55 1.12 Alt Promoter 
3846617 3846594 ZBTB7A  zinc finger and BTB domain containing 7A  0.02 0.22 -1.32 1.04   
3571260 3571248 ZFYVE1  zinc finger, FYVE domain containing 1  0.01 0.02 1.79 1.17   
3907571 3907561 ZNF335  zinc finger protein 335  0.00 0.73 1.21 1.01   
3078504 3078493 ZNF425  zinc finger protein 425  0.01 0.21 2.35 1.24   
2564648 2564634 ZNF514  zinc finger protein 514  0.02 0.15 2.15 1.24   
3843919 3843906 ZNF8  zinc finger protein 8  0.00 0.03 1.75 1.15   
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3621172 3621160 ZSCAN29  zinc finger and SCAN domain containing 29  0.02 0.09 -1.27 1.13 
Alt Five 
Prime 
 
Table 15. Probe sets probably differentially alternatively spliced in response to chronic ethanol treatment. Probe 
sets that are probably alternatively spliced in response to chronic ethanol treatment are shown. Fold change (E/C) is 
ethanol/ control. Probe set fold change refers to the change in the expression of the indicated (Probe set ID) probe set 
with ethanol. Gene fold change refers to the difference in the expression of the gene, taking into consideration all the 
probe sets in the given transcript cluster (Transcript cluster ID). 
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5.a. Validation of differential alternative splicing  
Four genes, MBD5 (methyl CpG binding protein), CD55 (CD55 molecule, 
decay accelerating factor for complement), BPGM (2,3-bisphosphoglycerate 
mutase), and ACSL1(acyl-CoA synthetase long-chain family member 1) that 
were detected as differentially alternatively spliced were tested in validation 
studies. These genes were selected because they are associated with important 
functions like chromatin regulation and fatty acid metabolism. MBD5, CD55 and 
ACSL1 were also detected as differentially expressed. 
MBD5 was considered as probably alternatively spliced because of the 
presence of a possible alternative promoter, that leads to a shorter transcript (2.3 
kb) that shares five exons with the longer transcript (5.3 kb; Figure 20). While 
probe sets corresponding to only the long transcript had a mean fold change of 
1.3, the probe sets corresponding to both isoforms had an average 2.1-fold 
change with ethanol. To quantitate the fold change for each test exon, qRT-PCR 
reactions were carried out. For MBD5 primer pairs were designed to amplify 
regions with 1.3- and 2.1-fold change. A similar change in expression was also 
observed in qRT-PCR assays; 1.4-fold (± 0.12 standard error of the mean) and 
2.5 (± 0.4 standard error of the mean) increase in expression was observed for 
the corresponding regions. 
CD55, BPGM, and ACSL1 had what appeared to be differentially 
alternatively spliced cassette exon. In CD55 there was a -1.4-fold change in 
expression of probe set 2377258 with ethanol while other probe sets increased in 
expression. To test whether this exon is alternatively spliced, primers were 
 128 
 
designed to flank the exon and two products of 383 bp or 266 bp were expected. 
Two transcript isoforms were detected for CD55 (Figure 21). In qRT-PCR 
assays, a 0.7 ± 0.1, fold decrease in the expression of test exon with ethanol was 
observed. To determine if this decrease in expression is specific to this exon, 
another exon which did not appear to be alternatively spliced was also tested. A 
similar change in expression (0.7 ± 0.2) was observed for this exon also, 
indicating that CD55 does not undergo a true differential alternative splicing 
event. 
In BPGM one probe set (3025504) displayed a significant -1.7-fold 
decrease in expression while others did not have any significant change. The test 
exon was 320 bp long and thus products of 384 bp or 67 bp were expected if the 
exon was included or excluded from the transcript. In PCR multiple bands were 
seen, including bands that appeared to be of the expected size (Figure 21).  
In ACSL1 one probe set (2796582) increased in expression by 2.6-fold 
while others were increased on average 1.4 fold. To detect if isoforms of the 
gene with and without the cassette exon exist, primers were designed to amplify 
across the putative cassette exon, yielding either 232 bp or 181 bp products. 
Only one isoform was detected for ACSL1 and therefore it was not considered 
further (Figure 21).
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Figure 21. Detection of alternative isoforms for validation.  PCR was carried 
out with primers flanking the test exon to determine if the exon is alternatively 
spliced. cDNA from control (C) and ethanol (E) samples was used as the 
template. Size of the DNA ladder is indicated on the left. For BPGM, two bands 
that appeared to be of the expected size are indicated by an asterix. 
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IV.DISCUSSION 
 
1. Regulation of ADHs by distal cis-regulatory regions 
Cis-regulatory regions play a critical role in the regulation of the gene 
expression. Because polymorphisms in regulatory sequences may affect the 
genetic risks for alcoholism, understanding the regulation of ADH expression is 
important. The known cis-regulatory elements in the ADH cluster do not 
completely account for expression levels of all ADH genes in the liver. We sought 
to identify distal regulatory regions in the ADH cluster. Sequence conservation 
implies an important functional role. Therefore, to discover putative distal 
regulatory regions, sequence conservation in the non-coding regions of the ADH 
cluster extending from the 3’ end of ADH1A to the transcriptional start site of 
ADH5 was studied. We chose to restrict our search to the intergenic regions, 
although regulatory regions could also be present in the intron sequences.  
Eight conserved regions were identified and tested in the context of the 
ADH4 basal promoter in human hepatoma cells (HepG2). Most were negative 
regulatory regions that decreased the activity of the promoter by at least 40% 
(Figure 7). The greatest effect was observed with 4E, a 1504 bp region 13 kb 
upstream of the ADH4 translational start site. 4E increased the activity of its 
cognate ADH4 promoter 50-fold in HepG2 cells (Figure 8). In preliminary studies, 
this enhancer activity was observed to be distance and orientation dependent 
(data not shown). 4E also enhanced the activity of the ADH1B promoter by 180-
fold. In HepG2 cells the ADH1B proximal promoter has weaker activity than 
ADH4 promoter. This probably explains the larger increase in activity observed 
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with the ADH1B promoter. 4E also enhanced the activity of another strong 
promoter, SV40 early promoter, 56-fold. 
The 4E enhancer was not functional in a non-hepatic cell line, H1299 lung 
carcinoma cells, suggesting that it has cell-type specificity (Table 7). By deletion 
analysis, it was observed that the enhancer activity was present in a 565 bp 
region, 4E3 (Figure 9). Six putative transcription factor binding sites were 
identified in 4E3 by sequence homology, and their roles were tested by 
electrophoretic mobility shift assays (EMSA) and site directed mutagenesis. Sites 
1, 2, 3, 4, and 6 were confirmed to be FOXA binding sites by EMSA with 
competitor oligonucleotides and by supershift assays (Figure 11). Oligo 3, which 
spans sites 3, 4, and 5, produced multiple high molecular weight bands, but the 
FOXA specific complex was the most prominent (Figure 12). Site 5, which 
overlaps with the site 4 by two nucleotides, was predicted to be a HNF-1A site. 
While none of the bands were disrupted by HNF-1A competitor, a stronger FOXA 
specific complex was detected. It is possible that HNF-1A binds weakly to site 5 
and this binding interferes with the binding of the FOXA to the overlapping site 4. 
Site-directed mutagenesis studies showed the greatest effect on enhancer 
function when either site 1 or site 4 was mutated, with activity decreasing to 40% 
of the wild type (Figure 13). Mutating multiple sites affected activity more 
dramatically. All combinations of multiple mutants tested displayed approximately 
a multiplicative reduction in activity compared to the respective single mutants, 
suggesting that each site is acting independently (Figure 13). When sites 1, 2, 4 
and 6 were mutated, activity decreased to 10% of the wild type. In a genome-
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wide mapping of DNase I hypersensitive sites in HepG2 cells (Crawford et al., 
2006b) , a hypersensitive peak was detected across the region of transcription 
factor binding sites that we characterized in 4E3 (UCSC Open chromatin track, 
March 2006, NCBI36/hg 18 assembly). This indicates that the site identified here 
is accessible to transcription factors in vivo. 
FOXA and HNF-1A proteins are liver-enriched factors that regulate many 
liver-specific genes. Thus, it is not surprising that they are utilized to enhance the 
expression of ADH genes that are expressed at highest levels in the liver. FOXA 
proteins can function as pioneer factors and bind to highly compacted chromatin, 
alter the chromatin structure and enhance transcription. Evidence of such 
regulation was observed in the expression of the albumin gene during 
development (Cirillo and Zaret, 1999). This could be a possible mechanism by 
which FOXA activates ADH4 expression from the 4E3 enhancer.  
Among the other seven putative distal regulatory regions that were tested, 
six regions repressed the activity of the 4Basal promoter. Highest repression was 
observed with the region between ADH4 and ADH5, with the promoter activity 
decreasing by 76% (Figure 7). A similar decrease in activity was observed with 
fragment 6-4-a, the region immediately upstream (relative to the translational 
start site of ADH4) of 4E. Fragments 1A-6-c and 1A-6-a also decreased the 
activity while1A-6-b did not have any significant effect. 1A-6-a, 1A-6-b and 1A-6-c 
were overlapping fragments that span 4.1 kb on genomic sequence. It is possible 
that fragmenting this 4.1 kb region decreased the functional effect of the region. 
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A more comprehensive analysis with more overlap between fragments is 
necessary to understand the role of this region. 
It is noteworthy that a strong enhancer is flanked by negative regulatory 
regions. Because 4E3 functions on heterologous promoters in vitro, including the 
ADH1B and SV40 promoters, it is conceivable that in the absence of intervening 
boundary elements this enhancer could act on the ADH6 promoter 60 kb away or 
other ADH promoters in the cluster. One possible function of the negative 
regulatory regions maybe to modulate the function of the 4E3 enhancer. Another 
possibility is that these regions play an important role in other tissues. A more 
detailed study is necessary to understand the role of these regions in the 
regulation of ADH expression. In summary, multiple distal cis-regulatory regions 
in the ADH cluster that could regulate the expression of ADH genes were 
identified.  
 
2. Regulatory variations and effects on function 
Several variations in genes encoding alcohol dehydrogenases have been 
associated with the risk for alcoholism (Birley et al., 2009; Edenberg and Foroud, 
2006; Edenberg et al., 2006; Reich et al., 1998; Williams et al., 1999). Although 
the most widely-studied ADH variations affect the sequence of the encoded 
enzymes, one (rs1800759) is known to affect regulation of gene expression 
(Edenberg et al., 1999). The expression level of ADH enzymes could affect the 
flux through the alcohol metabolic pathway and thereby influence the effects of 
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alcohol and the risk for alcoholism. As part of this dissertation, haplotypes of two 
cis-regulatory regions in ADH cluster were tested.  
Because of its enhancer function, variations in the 4E3 region could 
greatly affect the expression levels of ADH4. There are three SNPs in this region, 
rs7678936 (G/T), rs7678890 (T/G) and rs11401494 (del/T). Three haplotypes 
were tested. Haplotype 2 (T, T, del) and haplotype 3 (G, G, del) were less active 
(0.6-fold) than Haplotype1 (G, T, del), so it was not possible to attribute the effect 
to a single SNP. rs11401494 had a small effect on the function of the enhancer. 
The three SNPs are not present in any of the transcription factor binding sites 
identified in this study, however, rs7678936 is adjacent to a putative FOXA site 
and rs7678890 is adjacent to site 5 (HNF-1A). 
It would be of interest to determine whether these variations will contribute 
to differential susceptibility to alcoholism. From allele frequencies, rs7678936 
(G/T) and rs7678890 (T /G) appear to be in linkage disequilibrium, meaning the 
rs7678936 G allele travels with the rs7678890 T allele. The GT haplotype is at a 
fifty percent frequency in African populations (YRI, LWK, MIKK) whereas it 
appears to have reached higher frequencies in European (CEU) and have 
become fixed in Asian populations (CHB, JPT) or populations with Asian 
ancestry (CHD, GIH). Therefore, the role of these variations in the risk for 
alcoholism will be more important in populations of African descent. 
The effect of variations was also investigated in the ADH1B proximal 
promoter region because there is evidence of association of two SNPs 
(rs1229982 and rs1159918) in this region with the risk for alcoholism in a 
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European-American population (Edenberg et al., 2006). We tested five 
haplotypes and observed that the presence of the C allele of rs1229982 reduced 
the activity of the promoter by 30%. Although the magnitude of the effect is small, 
it could be of significance considering alcoholism is a complex disease in which 
multiple genes contribute to the disease. This functional effect supports our 
hypothesis that variations in the regulatory polymorphisms could be associated 
with the disease and vice versa. The frequency of the rs1229982 C/C genotype 
is high in some populations such as CHB, JPT. It would be of interest to study 
the effect of this SNP on the risk for alcoholism in these populations. 
In this study, we did not detect a functional effect for rs1159918 and other 
SNPs that were tested in this region. One possible explanation for the absence of 
functional effect even though it was associated with alcoholism is that it is in 
linkage disequilibrium (LD) with another SNP that is associated with the risk for 
alcoholism. From the available HapMap LD data in the ADH cluster, only 
rs6810842 (r2 = 0.949) is in LD with rs1159918 in the CEU population. This SNP 
was, however, tested in this study and was not observed to have any functional 
effect, hinting at a possibility of another SNP associated with alcoholism.  
In view of the effect of variations on the enhancer activity and also on the 
promoter activity that was observed in this study, it is important to consider the 
presence of variations in a test region when studying cis-regulatory regions. 
Testing a haplotype which has much lower activity could mislead one to ignore 
the function of the region. The small magnitude of effect that was observed with 
the negative regulatory regions in this study could be one such example. Thus, it 
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is necessary to study other haplotypes in test regions to completely appreciate 
the function of these regions. 
In summary, results from this study support our hypothesis that variations 
could have a functional effect on the expression levels of ADH, and that these 
could be associated with alcoholism.  
 
3.  Effects of alcohol on gene expression  
The effects of extended alcohol exposure on global gene expression in a 
human hepatoma cell line, HepG2 were studied. HepG2 cells do not express 
class I ADH genes but express ADH4 at moderate levels (Tian and Edenberg, 
2005). They also do not express cytochrome P450 2E1 (CYP2E1). Thus, this 
model system helped to identify the direct effects of alcohol and also effects due 
to limited metabolism of alcohol. An advantage was to identify effects of alcohol 
directly on human hepatocyte-like cells in the absence of potential signaling from 
neighboring cells, such as hepatic stellate cells and Kupffer cells which are 
known to play a role in alcohol induced liver injury (Siegmund and Brenner, 2005; 
Thurman, 1998; Wheeler et al., 2001). 
 HepG2 cells were cultured in the presence of 75 mM ethanol for 9 days. 
The legal limit of 0.08% blood alcohol level corresponds to 17.4 mM ethanol. 
Alcoholic beverages range from approximately 4.5% ethanol (900 mM) for beer 
to 12% ethanol (2 M) for wine to 41.1% ethanol in spirits (7M). Because 80% of 
alcohol is absorbed in the small intestine and most of alcohol is carried to the 
liver via portal vein, liver is exposed to high concentrations of alcohol (Swift, 
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2003). Prolonged exposure of HepG2 cells to ethanol led to a decrease in the 
number of viable cells relative to untreated cells. This decrease in cell number 
could be due to a prolonged lag phase, or slow cell growth or due to cell death. 
Ethanol has been shown to have apoptotic effects in HepG2 cells and 
hepatocytes (Higuchi et al., 1996; Neuman et al., 1993; Neuman et al., 1999). 
However, we did not observe visible differences in morphology between cells in 
ethanol and control conditions, and also did not notice non-adherent (dead) cells 
in the presence of ethanol. 
 Significant differences in gene expression between control and ethanol 
treated cells were observed. Many of these were small changes (10 to 30%). 
Statistical power obtained from eight arrays used for each condition along with 
multiple probe sets that target each gene, allowed us to detect these small 
changes. We were able to validate changes as small as 15% in qRT-PCR 
studies 
Chronic ethanol treatment of HepG2 cells had an effect on the expression 
of genes in key metabolic pathways and stress response pathways. Some of the 
pathways that may be key to understanding different aspects of alcohol induced 
liver disease are discussed below. Effects of alcohol on genes involved in 
chromatin regulation and genes associated with alcoholism are also discussed. 
 
3.a. Acute phase response 
Liver responds to infection, inflammation, injury to tissue, or malignancy, 
with the acute phase response. Acute phase response is characterized by 
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increase or decrease in the levels of multiple proteins (Ceciliani et al., 2002; 
Gabay and Kushner, 1999). Several genes involved in the acute phase response 
were affected by ethanol (Table 13). Interleukin 6 (IL-6) and IL-1 are the primary 
mediators of acute phase response in the liver; although the genes encoding 
these mediators were not detected in our data, the genes encoding their 
receptors and signal transducers were affected by ethanol. IL6R decreased in 
expression whereas IL1R1 increased. The signal transducer membrane proteins 
(IL6ST and IL1RAP) associated with these receptors were also affected. The 
intracellular signal transducer of IL-6, Janus kinase 2 (JAK2) increased in 
expression by 43% while transcription factor Signal transducer and activator of 
transcription 3 (STAT3) increased modestly. Positive acute phase proteins 
(protein that increase in expression in acute phase response) like fibrinogens 
(FGG, FGA), angiotensiongen (AGT), SERPINs (A3, D1, G1) increased in 
expression by ethanol (Table 13). Increase in the expression of FGG was 
confirmed by qRT-PCR validation. We observed a 1.9-fold change in FGG 
expression, larger than that observed using arrays (1.4- fold; Figure 18).  
Chronic ethanol exposure had an opposite effect on some positive acute 
phase proteins: heptoglobin (HP), hemopexin (HPX), hepcidin antimicrobial 
peptide (HAMP), complement C4 binding protein (C4BPA) decreased in 
expression. Decrease in the expression of C4BPA and HAMP proteins with 
ethanol was observed in other studies (Bykov et al., 2007; Ohtake et al., 2007). 
Recent evidence suggests that the decrease in the expression of hepcidin 
antimicrobial peptide along with the increase in the expression of ferritin probably 
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leads to the iron overload (Chick et al., 1987; Ohtake et al., 2007). In our chronic 
alcohol exposure model HAMP and ferritin light chain (FTL) were changed by -
1.41- and 1.29-fold, respectively (Table 13). Similar observations were made in 
the serum levels of ferritin and hepcidin antimicrobial peptide in alcoholics (Chick 
et al., 1987; Ohtake et al., 2007). Reactive oxygen species, possibly from 
parenchymal and non-parenchymal cells, have been implicated in the 
downregulation of hepcidin expression (Harrison-Findik et al., 2006). In a mouse 
model this effect was shown to be independent of Kupffer cells (Harrison-Findik 
et al., 2009). Similar findings in our model system indicate that oxidative stress 
generated in hepatocytes could be sufficient to change the expression of 
hepcidin. Therefore, these results indicate that chronic alcohol exposure 
modulates the receptivity of hepatocytes to the acute phase response, and also 
the expression of acute phase reactant proteins.  
 
3.b. Nrf2 oxidative stress response pathway  
Alcohol metabolism generates reactive oxygen species and creates a 
state of oxidative stress in hepatocytes (Albano, 2006; Bailey et al., 1999; Wu 
and Cederbaum, 2009). In response to oxidative stress, the transcription factor 
Nuclear factor-eythroid 2-related factor 2 (Nrf2) regulates expression of multiple 
genes involved in antioxidant defenses (Itoh et al., 1997; McMahon et al., 2001). 
Increase in the levels of Nrf2 transcript and protein were observed in animal 
livers and HepG2 cells expressing CYP2E1 and exposed to alcohol (Gong and 
Cederbaum, 2006). Deletion of Nrf2 in mice was shown to aggravate alcohol 
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induced liver damage (Lamle et al., 2008). In our data we did not observe an 
increase in the expression of Nrf2. However, many Nrf2 transcribed genes were 
differentially expressed. This could be due to the activation of Nrf2 instead of an 
increase in the levels of expression. Under non stress conditions, kelchlike ECH-
associated protein 1 (Keap1) sequesters Nrf2 and targets it for ubiquitination. 
When there is oxidative stress, Keap1 dissociates from Nf2, leading to a 
functional Nrf2 (Itoh et al., 1999; Itoh et al., 2003).  
One of the Nrf2 transcribed genes that was affected by chronic alcohol 
exposure is the catalytic subunit (GCLC) of the glutamate cysteine ligase (GCL). 
This enzyme carries out the rate-limiting step of glutathione (GSH) synthesis (Lu, 
1999). With chronic ethanol exposure there was a 20% increase in the 
expression of the enzyme. This increase in expression was also confirmed by 
qRT-PCR (Figure 18). In addition to GCL activity, the synthesis of GSH is also 
regulated by the availability of cysteine (Lu, 1999). SLC7A11, one of the subunits 
of amino acid transport system χc- involved in the uptake of cystine (Bannai, 
1986), was differentially expressed (1.54-fold). Although it is not an Nrf2 
transcribed gene, the increase in SLC7A11 could be an additional response of 
the cell to maintain the cellular GSH levels.  
Ethanol also affected other Nrf2 transcribed antioxidant enzymes: 
glutathione s-transferase alpha 4 (GSTA4), glutathione peroxidase 2 (GPX2), 
superoxide dismutase 1 (SOD1), thioredoxin reductase 2 (TXNRD2) increased in 
expression. Multiple genes belonging to the DNAJ/Hsp40 family of chaperone 
proteins were upregulated with ethanol. DNAJ members stimulate the ATP 
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hydrolysis of Hsp70 proteins, and are thus essential for the activity of Hsp70 
proteins (Qiu et al., 2006). In summary, limited metabolism of alcohol and direct 
alcohol exposure generates an oxidative stress response in HepG2 cells.   
 
3.c. Amino acid metabolism 
Several genes involved in the metabolism of amino acids were 
downregulated by ethanol. Genes encoding urea cycle enzymes arginase 
(ARG2) and arginosuccinate lyase (ASL) decreased in expression. Multiple 
enzymes in argenine proline metabolism were affected by ethanol. Glycine 
amidinotransferase (GATM) and guanidinoacetate N-methyltransferase (GAMT) 
mediate the conversion of argenine to creatine and were downregulated with 
ethanol. Two key enzymes involved in the synthesis of polyamine putrescine 
were affected by ethanol. Ornithine decarboxylase (ODC) that converts ornithine 
to putrescine (Russell and Snyder, 1968) increased in expression by 15%. In 
contrast agmatinase (AGMAT) which also leads to the synthesis of putrescine 
from argmatine (Russell and Snyder, 1968), decreased in expression by the 
same magnitude. Opposing effects of alcohol on ODC activity during liver 
regeneration have been reported earlier. After partial hepatectomy, acute 
exposure to alcohol inhibited ODC activity where as chronic exposure to alcohol 
increased activity (Diehl et al., 1988; Diehl et al., 1990; Poso and Poso, 1980). 
Our data suggest that the increase in the expression of ODC could be one 
possible factor in the increase in the activity of ODC after chronic ethanol 
treatment. 
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Two enzymes involved in methionine metabolism were also affected by 
ethanol. An increase in expression was observed for Betaine-homocysteine 
methyltransferases (BHMT, BHMT2) which carry out the folate independent 
conversion of homocysteine to methionine (Finkelstein and Martin, 1984). For 
BHMT the array data was validated by qRT-PCR. Another pathway of 
homocysteine catabolism is transsulfuration of homocysteine to cystathione and 
is catalyzed by cystathionine β-synthase (CBS) (Finkelstein and Mudd, 1967). In 
our data CBS was downregulated by a modest 12%. This increase in the 
expression of BHMTs and decrease in CBS expression could be an adaptive 
response to maintain the levels of essential amino acid methionine in the cells. In 
addition to being a part of proteins, methionine also acts as a precursor to methyl 
group donor, S-adenosyl methionine (SAM). SAM acts as a methyl-group donor 
for methyltransferase-catalyzed reactions.  
 
3.d. Carbohydrate metabolism  
Effects of alcohol on the activity of enzymes involved in carbohydrate 
metabolism have been recognized for many years. Alcohol alters NADH/NAD+ 
ratio and this affects the activity of many enzymes in glycolysis, citrate cycle. In 
our data we saw a decrease in the expression of many genes involved in 
carbohydrate metabolism (Badawy, 1977). Two key regulatory proteins in the 
glycolytic pathway, hexokinase (HK2) and phosphofructokinase (PFKL) were 
decreased in expression due to ethanol treatment. The ethanol induced change 
in HK2 expression was validated by qRT-PCR (Figure 18). TCA cycle enzyme, 
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oxoglutarate dehydrogenase (OGDH) was decreased by 1.24-fold while isocitrate 
dehydrogenase (IDH3B) decreased modestly. Both these enzymes are inhibited 
by NADH, and carry out key regulatory steps in TCA cycle. Phosphoenol 
pyruvate carboxykinase (PCK) catalyzes the formation of phosphoenolpyruvate 
from oxaloacetate and is an important control point in gluconeogenesis. The 
cytosolic form, PCK1, decreased by 1.35-fold; we further confirmed this by qRT-
PCR (Figure 18). Pyruvate carboxylase (PC) that catalyzes the carboxylation of 
pyruvate to oxaloacetate, decreased. In addition to pyruvate, various precursors 
like lactate, amino acids and glycerol, enter the gluconeogenic pathway. To enter 
into the gluconeogenic pathway, glycerol has to be phosphorylated by glycerol 
kinase (GK) (Walker et al., 1993). There was a -1.33-fold change in the 
expression of glycerol kinase, indicating an additional mechanism by which 
alcohol inhibits hepatic gluconeogenesis. These results indicate that alcohol not 
only modulates the activity of some enzymes involved in the carbohydrate 
metabolism, it also affects their expression at the level of transcription.  
 
3.e. Lipid metabolism 
Key genes involved in the fatty acid beta-oxidation pathway were affected 
by ethanol. Acyl-CoA synthetases (ACS) are involved in the activation of fatty 
acids (Soupene and Kuypers, 2008). With chronic ethanol treatment, acyl-CoA 
synthetases ACSL1, ACSS2 were differentially expressed by 1.42 and -1.18-fold, 
respectively. CPT1A transports fatty acyl-coA esters across the mitochondrial 
inner membrane and its deficiency results in a decreased rate of fatty acid beta-
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oxidation (Aoyama et al., 1998; Zammit, 2008). CPT1A decreased by 50% in 
HepG2 cells exposed to ethanol and this decrease was confirmed by qRT-PCR 
(Figure 18). Acyl-CoA dehydrogenase, short chain (ACADS) is one of enzymes 
which carry out the first step in the beta-oxidation of fatty acids (Kelly et al., 
1993). It was downregulated by 24%. In peroxisomal oxidation of fatty acids, this 
reaction is catalyzed by Acyl-CoA oxidase, palmitoyl, ACOX1(Reddy and 
Hashimoto, 2001). ACOX1 also decreased in expression. In summary, many of 
the enzymes involved in the oxidation of fatty acids were expressed at lower 
levels when HepG2 cells were exposed to ethanol. 
Ethanol also had a modest (15% decrease) effect on the expression of 
serum response regulatory binding factor 1 (SREBF1). We confirmed array 
results with qRT-PCR (Figure 18). SREBF1 transcribes many genes that 
participate in fatty acid synthesis, including fatty acid synthase. Our data 
contradicts previous findings where an increase in protein and mRNA expression 
and the activity of SREBF1 was observed (You et al., 2002). Acetaldehyde was 
shown to be responsible for the increase in the transcription from SREBF1 
promoters. It is possible the decrease in expression in our data is because 
limited metabolism of alcohol in HepG2 cells does not generate enough 
acetaldehyde to trigger an increase in the expression of SREBF1. 
Exposure of cells to ethanol for 9-days also affected many genes in the 
glycerolipid or glycerophospholipid metabolism. Glycerol-3-phosphate 
acyltransferase, mitochondrial (GPAM) and 1-acylglycerol-3-phosphate O-
acyltransferase 3 (AGPAT) were increased by 1.31- and 1.48-fold. GPAM is 
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involved in the first step of de novo synthesis of triglycerides and 
glycerophospholipids (Dircks and Sul, 1997). Overexpression of this protein in 
mice was shown to increase serum and liver triglycerides, while decreasing fatty 
acid β-oxidation and steatosis (Linden et al., 2006). AGPAT3 belongs to the 
family of lysophosphotaide acyl transferases that are involved in acylation of 
glycerol-3-phosphate to 1-acyl glycerol-3-phsphate. AGPAT3 is localized to the 
golgi membrane and over expression of this protein inhibits the formation of Golgi 
membrane tubules and protein trafficking (Schmidt and Brown, 2009).  
Lipins are 1, 2-diacylglycerol-3-phosphate (phosphatidate) phosphatases. 
Lipin 1 (LPIN1) increased in expression whereas LIPN2 decreased with ethanol. 
Both are expressed in the liver (Donkor et al., 2007). In addition to phosphatase 
activity, LIPN1 also has transcriptional coactivator activity (Finck et al., 2006). It 
associates with PPARα and PPARγ coactivator-1α and modulates the 
expression of many enzymes involved in fatty acid oxidation and synthesis.  
In summary, genes encoding multiple enzymes involved in fatty acid 
metabolism and triglyceride synthesis were affected upon chronic alcohol 
exposure. These effects could partly explain the development of alcohol induced 
fatty liver. Action of ethanol on LIPN1 could be a new mechanism by which 
alcohol affects fatty acid metabolism in the liver. By affecting proteins like 
AGPAT3 which regulates golgi membrane, alcohol could lead to more cellular 
damage. 
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3.f. Genes involved in chromatin regulation 
Recent studies indicate that ethanol affects epigenetic modifications of 
histones and DNA (Bonsch et al., 2006; Bonsch et al., 2004; Lee and Shukla, 
2007; Park et al., 2005; Shukla and Aroor, 2006). In HepG2 cells cultured in 
ethanol for 9 days, a 1.25-fold increase in the expression of DNMT3B, one of the 
de novo DNA methyl transferases, was observed. A similar increase (1.31-fold) 
of DNMT3B expression was observed in validation assays. In addition to 
DNMT3, methyl-CpG binding domain protein 5 (MBD5) expression was also 
increased by 43%. The MBD family of proteins binds to methylated CpG regions 
in the DNA leading to transcriptional repression.  
Effects of alcohol on DNA methylation are controversial. A 40% decrease 
in global DNA methylation was reported in the livers of rats fed ethanol for 9-
weeks (Lu et al., 2000). In chronic alcoholics, however, a hypermethylation of 
DNA in peripheral blood cells with a decrease in the expression of DNMT3B was 
reported (Bonsch et al., 2006; Bonsch et al., 2004). In our experiment with 
HepG2 cells, global DNA methylation levels were not measured.  
Genes encoding histone deacetylases and histone acetylases were 
affected by ethanol exposure. HDAC5, HDAC6 and HDAC11 decreased in 
expression. Histone acetylase MYST4 increased in expression by 20% where as 
MYST1 decreased modestly (11%). HDAC5 (Zhang et al., 2002) and HDAC11 
(Villagra et al., 2009) proteins are involved in the regulation of transcription, while 
HDAC6 is a cytoplasmic protein associated with microtubules (Zhang et al., 
2008b).  
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In a study that examined the acute effects of alcohol on histone 
modifications in isolated rat hepatocytes and rat liver, ethanol was shown to 
increase the acetylation of histone 3 (H3), lysine 9 (K9) acetylation (Park et al., 
2005). As acetylation of histones is regulated by histone acetylases and 
deacetylases, it is possible that this effect is brought about by modulating the 
expression of histone deacetylases and acetylases as was observed in our data.  
 
3.g. Genes associated with alcoholism 
Alcoholism is a genetic disorder and multiple genes have been associated 
with this disease. Forty four genes that were differentially expressed in our data 
have been previously associated with alcoholism in humans (Bierut et al., 2010; 
Edenberg and Foroud, 2006; Hill et al., 2004; Kalsi et al., 2009). Some of these 
genes, including Insulin-like growth factor 1 receptor (IGF1R), Cholinergic 
receptor, nicotinic, alpha 5 (CHRNA5), 5-hydroxytryptamine (serotonin) receptor 
3B (HTR3B) play a role in alcohol induced liver injury in the liver, or act as 
receptors in the brain. We confirmed the effect on expression of HTR3B by qRT-
PCR (Figure 18). Knowledge that ethanol affects the transcription of the genes 
associated with the disease provides mechanistic insight into why these genes 
are associated with the disease.  
 
4. Effects of alcohol on alternative splicing  
Recently it has been predicted that 92 to 94% of genes in the human 
genome encode alternative isoforms (Wang et al., 2008) and there is increasing 
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evidence that alternative isoforms could lead to disease (Garcia-Blanco et al., 
2004; Orengo and Cooper, 2007). For the first time, the effects of chronic ethanol 
exposure on alternative isoforms were explored in this study using Affymetrix 
human Exon arrays. Due to the inherent difficulties associated with exon array 
data analysis, a stringent FDR was used. Resulting genes were also visually 
inspected to identify true alternative splicing events. Only 31% of the genes that 
passed a 3% FDR filter were probably alternatively spliced. One of the main 
causes for many probably not alternatively spliced are the 5’ and 3’ edge effects 
that were observed in most of the genes. There was a decrease in the 
expression of 5’ probe set with ethanol whereas there was an increase in the 
expression of 3’ probe set. Bemmo et al. (2008) reported that probe sets at the 5’ 
and 3’ ends of the transcript behave differently and termed this “edge bias.” They 
attributed the 5’ effects to high GC content at the 5’ end of the transcript and the 
3’ effects could be due to the random amplification protocol. Whistler et al. (2010) 
reported that approximately 75% of false positives are due to this edge bias 
effect (Whistler et al., 2010). Other reasons for false positives include saturated 
or non-responsive probe sets (Bemmo et al., 2008; Whistler et al., 2010).  
In validation studies, four genes were tested. Three of the tested events 
appeared to be cassette exons, whereas one was an alternative promoter. Of the 
three cassette exons, only two (BPGM and CD55) were confirmed to be 
alternatively spliced. For BPGM the decrease in the expression of the test exon 
was confirmed by qRT-PCR assays. For CD55, although a decrease in the 
expression of the test exon was observed, a similar decrease in the remaining 
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part of the transcript was also observed. This observation suggests that this is 
not a true ethanol affected differential alternative splicing. However, the fraction 
of the transcript with the test exon in the RNA was very small (as indicated by the 
density of the band in Figure 21). It is possible that the assays carried out are not 
sensitive to detect a 40% fold change at low concentrations of the transcript.  
Another gene that was validated for differential alternative splicing was 
MBD5. In MBD5, probe sets in one half of the transcripts were increased in 
expression by 1.3-fold and probe sets in the second half of the transcript were 
increased approximately by 2-fold. Although no alternative isoforms are reported 
in the Refseq database, a shorter isoform is reported in the UCSC gene track. 
The expression of shorter isoform (2.5 kb) was increased by 2.1-fold upon 
ethanol treatment. This was validated by qRT-PCR assay. Not much is known 
about the function of this protein. A haploinsufficiency in this gene was reported 
to be the cause of a 2q23.1 microdeletion syndrome that leads to intellectual 
disabilities, seizures and speech impairment (Williams et al., 2010). Interestingly, 
the short isoform lacks the 70 amino acid methyl binding domain that is present 
in all MBD proteins. So, further studies are required to understand the function of 
short form of the transcript. 
BPGM encoded 2,3-Bisphophoglycero mutase enzyme catalyzes both the 
synthesis and degradation of 2,3-diphosphoglycerate (2,3-DPG), which 
modulates the affinity of hemoglobin to oxygen (Joulin et al., 1988). The function 
of the alternative forms of this protein is not known. BPGM is mainly expressed in 
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erythrocytes. It will be interesting to study if chronic alcohol exposure has the 
same effect on BPGM alternative splicing in erythrocytes.   
In summary, identification of differential alternative splicing due to alcohol 
exposure is very complicated. It requires a great deal of manual analysis of the 
data and validation studies to identify true differential alternative isoforms.   
 
5. Future directions 
As part of this dissertation multiple cis-regulatory regions in the 360 kb 
ADH cluster have been identified. In this study 4E3, a strong distal enhancer of 
ADH4 was identified. All experiments were carried out by transient transfections 
in human hepatocyte-like cells. Transient transfection assays cannot duplicate 
the full regulatory complexity present in vivo, including additional cis-regulatory 
regions and the complexity of chromatin structure. Future studies could study this 
region in an animal model. A transgenic mouse model of human ADH4 can be 
generated by integrating a bacterial artificial chromosome (BAC) carrying human 
ADH4 along with its neighboring non-coding sequences into mouse genome. The 
animal model can be used to answer many questions regarding the function of 
4E3. The magnitude of enhancer activity of 4E3 along with its contribution to 
tissue specificity in all tissues can be determined. The mechanism of activation 
can also be examined. If FOXA mediated physical interaction of the promoter 
and enhancer and DNA looping occurs, it can be identified using chromosome 
conformation capture technique (3C) (Dekker et al., 2002). 3C technique involves 
formaldehyde crosslinking of interacting chromatin regions, restriction digestion, 
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intermolecular ligation and subsequent PCR. If FOXA proteins function as 
pioneer factors at 4E3 enhancer in the embryonic stage, chromatin 
immunoprecipitation technique can be used to investigate chromatin profile 
before and after activation.  
The most interesting question that arises with genes that are present in a 
cluster in genome is whether they are regulated by a locus control region (LCR). 
By definition, LCRs are regulatory regions that regulate the expression of multiple 
genes in a cluster. It will be interesting to study the role of 4E3 on regulation of 
other ADH genes in the cluster. This also can be studied in an animal model if 
other ADH genes are included in the BAC.  
The function of negative regulatory regions identified in this study in cells 
other than hepatic cells has not been explored. It is possible that these could play 
a greater functional role in non-liver tissues. Tissue specificity of these regions 
can be studied in non-hepatic cells or in an animal model. 
Variations play an important role in the risk for alcoholism. Two variations 
in the 4E3 enhancer were observed to affect the enhancer activity. These could 
play a significant role in alcoholism. Therefore, association studies have to be 
carried out to determine their affect on the risk for alcoholism.  
In our study of the effects of chronic ethanol treatment of HepG2 cells, we 
observed many hallmark effects of alcohol on gene expression along with some 
new effects. Because these cells are acting as a good model system for alcohol 
effects, it is possible to further explore other effects of alcohol. Effects of alcohol 
on global methylation can be studied using chromatin immunoprecipitation with 
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anti-methyl cytosine antibody combined with high throughput techniques like 
sequencing or microarrays. Effects of alcohol on histone modifications can also 
be studied in a similar approach.  
To identify effects of alcohol on alternative isoforms an alternative 
approach like RNA-sequencing (RNA-seq) can be employed. RNA-seq data 
allow detection of alternative isoforms using the reads at the splicing junctions.  
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APPENDIX 
 
Genes differentially expressed with chronic ethanol exposure.  
All differentially expressed genes (FDR ≤ 3, fold change ≥ 10%), excluding genes 
listed in Table 13. 
 
 
Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
3230610 ABCA2 -1.11 0.02 0.29 
2708287 ABCC5 1.33 0.01 0.05 
3682182 ABCC6 -1.14 0.03 0.33 
2777276 ABCG2 1.38 0.02 0.45 
3500772 ABHD13 1.17 0.02 0.98 
3528759 ABHD4 1.27 0.00 0.76 
3282268 ACBD5 -1.10 0.00 0.64 
2459837 ACTA1 -1.23 0.01 0.25 
2566021 ACTR1B -1.24 0.01 0.98 
3907011 ADA 1.13 0.02 0.48 
3011492 ADAM22 1.31 0.01 0.45 
2358393 ADAMTSL4 -1.42 0.00 0.87 
3716950 ADAP2 1.21 0.02 0.00 
3320123 ADM -1.18 0.00 0.82 
3336801 ADRBK1 -1.15 0.01 0.14 
3940631 ADRBK2 1.25 0.02 0.00 
3554360 ADSSL1 -1.30 0.02 0.97 
3039791 AGR2 2.36 0.01 0.52 
3903361 AHCY -1.12 0.00 0.86 
3293187 AIFM2 -1.18 0.01 0.47 
3868160 AKT1S1 1.22 0.00 0.84 
3838522 ALDH16A1 -1.26 0.01 0.87 
3646542 ALG1 1.17 0.00 0.66 
3391093 ALG9 1.13 0.01 0.83 
3427032 AMDHD1 1.20 0.00 0.85 
2696309 AMOTL2 -1.27 0.00 0.92 
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Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
2445982 ANGPTL1 1.58 0.02 0.93 
3299970 ANKRD1 -1.58 0.00 0.41 
3704717 ANKRD11 1.17 0.02 0.01 
2754673 ANKRD37 -1.27 0.01 0.98 
3651672 ANKS4B -1.22 0.01 0.92 
2487082 ANTXR1 1.35 0.00 0.00 
2487412 ANXA4 -1.35 0.01 0.39 
3295032 AP3M1 1.12 0.01 0.09 
3015241 AP4M1 -1.24 0.01 0.44 
2766893 APBB2 1.15 0.01 0.33 
2622196 APEH -1.20 0.03 0.62 
3356115 APLP2 1.10 0.02 0.07 
3945572 APOBEC3C -1.31 0.01 0.85 
3945614 APOBEC3F -1.32 0.00 0.85 
3469319 APPL2 1.15 0.01 0.10 
3203569 AQP3 -1.30 0.02 0.56 
3022409 ARF5 -1.15 0.03 0.96 
3371928 ARFGAP2 -1.11 0.02 0.21 
2746693 ARHGAP10 1.50 0.01 0.13 
3289189 ASAH2 1.68 0.00 0.04 
3743371 ASGR1 -1.17 0.01 0.13 
3137530 ASPH 1.16 0.02 0.01 
2315951 ATAD3A -1.20 0.02 0.91 
2726072 ATP10D 1.54 0.01 0.34 
3464983 ATP2B1 1.16 0.02 0.07 
3863087 ATP5SL -1.12 0.02 0.71 
3974556 ATP6AP2 1.16 0.02 0.25 
3514736 ATP7B 1.12 0.01 0.06 
3834046 AXL -1.18 0.00 0.13 
2669930 AXUD1 -1.16 0.02 0.75 
3908963 B4GALT5 1.11 0.02 0.07 
3803120 B4GALT6 1.42 0.01 0.11 
3240452 BAMBI 1.28 0.01 0.02 
3910360 BCAS1 1.29 0.00 0.34 
3447694 BCAT1 1.13 0.03 0.11 
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Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
3656829 BCKDK -1.23 0.01 0.88 
2713382 BDH1 -1.25 0.02 0.93 
2608725 BHLHE40 -1.37 0.00 0.99 
3346548 BIRC3 1.67 0.03 0.43 
3882190 BPIL1 1.14 0.01 0.94 
2903343 BRD2 1.10 0.01 0.22 
3436544 BRI3BP 1.16 0.02 0.59 
2375664 BTG2 1.18 0.02 0.04 
2899340 BTN2A2 1.26 0.02 0.97 
2899413 BTN3A3 1.25 0.01 0.85 
3286776 C10orf10 -1.30 0.00 0.47 
3252690 C10orf11 1.25 0.02 0.19 
3308378 C10orf82 1.20 0.01 0.45 
3334847 C11orf2 -1.27 0.01 0.99 
3393834 C11orf60 1.42 0.01 0.02 
3396144 C11orf61 1.23 0.02 0.13 
3332938 C11orf79 1.13 0.02 0.42 
3474787 C12orf27 1.27 0.02 0.53 
3410384 C12orf35 1.39 0.02 0.71 
3472000 C12orf51 1.19 0.03 0.39 
3572461 C14orf1 1.16 0.01 0.31 
3578069 C14orf139 1.40 0.01 0.21 
3573933 C14orf145 1.53 0.03 0.07 
3573994 C14orf145 1.28 0.01 0.66 
3578089 C14orf49 1.17 0.00 0.46 
3588658 C15orf41 1.15 0.01 0.00 
3652271 C16orf52 1.18 0.01 0.19 
3688424 C16orf58 -1.17 0.00 0.60 
3678542 C16orf89 1.33 0.02 0.26 
3744324 C17orf68 -1.15 0.02 0.47 
3864597 C19orf61 1.21 0.01 0.99 
3820310 C19orf66 -1.17 0.01 0.47 
2437273 C1orf2 1.15 0.02 0.01 
2361697 C1orf66 -1.22 0.01 0.38 
2359736 C1orf77 -1.11 0.02 0.99 
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Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
3960005 C1QTNF6 1.51 0.01 0.10 
3442514 C1RL 1.14 0.01 0.09 
3890109 C20orf108 -1.10 0.02 0.12 
3904594 C20orf117 1.12 0.01 0.42 
3901665 C20orf3 1.11 0.02 0.90 
2621949 C3orf60 -1.31 0.01 0.53 
2882834 C5orf4 -1.11 0.03 0.86 
2986146 C6orf122 1.73 0.01 0.00 
2950798 C6orf125 -1.24 0.00 0.97 
2902736 C6orf48 -1.22 0.01 0.43 
2931700 C6orf97 -1.51 0.00 0.52 
2337786 C8A -1.22 0.02 0.98 
3130823 C8orf41 1.13 0.02 0.79 
3168210 C9orf127 1.22 0.03 0.83 
3186207 C9orf91 1.18 0.01 0.31 
3168066 CA9 -1.74 0.00 0.13 
3392332 CADM1 1.26 0.00 0.20 
3456353 CALCOCO1 1.23 0.01 0.17 
3772775 CANT1 1.19 0.01 0.35 
3449368 CAPRIN2 1.37 0.02 0.44 
3591838 CASC4 1.15 0.01 0.62 
4005859 CASK 1.30 0.02 0.20 
3456630 CBX5 -1.57 0.00 0.69 
3226737 CCBL1 -1.18 0.02 0.98 
3767531 CCDC46 1.64 0.02 0.20 
2881860 CCDC69 1.20 0.02 0.07 
2674138 CCDC71 -1.16 0.01 0.85 
2948821 CCHCR1 -1.16 0.01 0.98 
3753956 CCL16 -1.17 0.01 0.98 
3625326 CCPG1 1.41 0.03 0.42 
2936657 CCR6 -1.24 0.01 0.90 
3601229 CD276 1.12 0.01 0.42 
3708858 CD68 -1.16 0.01 0.74 
2881370 CD74 1.19 0.00 0.45 
2895841 CD83 1.24 0.02 0.66 
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Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
3402315 CD9 1.20 0.00 0.19 
4025771 CD99L2 1.16 0.00 0.58 
2324084 CDA 1.37 0.01 0.48 
3666409 CDH1 -1.19 0.00 0.67 
3970642 CDKL5 1.37 0.02 0.30 
3396770 CDON 1.22 0.00 0.00 
3863669 CEACAM1 1.14 0.01 0.80 
3350908 CEP164 1.13 0.02 0.26 
3190420 CERCAM 1.27 0.01 0.78 
3906160 CHD6 1.14 0.02 0.02 
4014251 CHM 1.15 0.03 0.39 
2662435 CIDEC -1.29 0.01 0.88 
3815649 CIRBP -1.14 0.02 0.83 
3469687 CKAP4 1.13 0.01 0.00 
3007960 CLDN4 1.21 0.02 0.87 
2949330 CLIC1 1.18 0.03 0.00 
3577940 CLMN 1.20 0.02 0.75 
3381063 CLPB 1.15 0.01 0.60 
2395890 CLSTN1 1.15 0.02 0.94 
3129065 CLU 1.27 0.00 0.33 
2836856 CNOT8 -1.21 0.02 0.61 
3452865 COL2A1 1.25 0.02 0.00 
3892974 COL9A3 1.14 0.03 0.00 
3543935 COQ6 -1.23 0.00 0.13 
3662723 COQ9 -1.13 0.01 0.86 
2768197 CORIN 1.38 0.02 0.24 
3378830 CORO1B -1.16 0.01 0.48 
3512843 CPB2 1.33 0.00 0.22 
2842255 CPLX2 1.24 0.01 0.99 
2711604 CPN2 1.16 0.02 0.43 
3421446 CPSF6 1.17 0.00 0.37 
2477073 CRIM1 -1.11 0.01 0.53 
3855104 CRLF1 1.14 0.02 0.00 
3934245 CSTB -1.16 0.02 0.60 
2527786 CTDSP1 -1.28 0.01 0.57 
 158 
 
Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
2954355 CUL7 -1.12 0.01 0.72 
3986230 CXorf57 1.32 0.02 0.15 
2515240 CYBRD1 1.74 0.00 0.01 
3120051 CYC1 -1.23 0.01 0.92 
3771642 CYGB 1.19 0.01 0.08 
4031068 CYorf15B 1.39 0.03 0.96 
2903034 CYP21A2 1.19 0.02 0.00 
2344888 CYR61 -1.50 0.00 0.48 
3940001 CYTSA 1.14 0.02 0.40 
2854445 DAB2 1.28 0.03 0.94 
2673830 DALRD3 -1.25 0.00 0.95 
3723071 DBF4B 1.16 0.01 0.10 
2999710 DBNL -1.23 0.01 0.05 
3526544 DCUN1D2 1.20 0.01 0.00 
3113280 DEPDC6 1.36 0.00 0.20 
3937183 DGCR8 1.22 0.00 0.43 
3567187 DHRS7 1.25 0.01 0.82 
3235373 DHTKD1 -1.13 0.00 0.85 
3598613 DIS3L 1.17 0.01 0.60 
3133325 DKK4 2.03 0.00 0.93 
3296386 DLG5 1.24 0.00 0.32 
3552083 DLK1 1.13 0.01 0.75 
2515471 DLX1 1.83 0.00 0.05 
3624145 DMXL2 1.29 0.01 0.64 
3820758 DNM2 -1.23 0.00 0.84 
3303165 DNMBP 1.16 0.00 0.95 
3068097 DOCK4 1.24 0.01 0.77 
3850725 DOCK6 -1.14 0.00 0.00 
3522398 DOCK9 1.43 0.01 0.00 
2424524 DPYD 1.36 0.02 0.11 
3802924 DSC3 2.17 0.00 0.11 
3783529 DSG2 1.13 0.03 0.45 
3552847 DYNC1H1 1.12 0.02 0.13 
3695199 DYNC1LI2 1.14 0.01 0.11 
3521372 DZIP1 1.31 0.02 0.22 
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Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
3463112 E2F7 1.27 0.01 0.09 
2612371 EAF1 -1.11 0.02 0.42 
3980380 EDA 1.24 0.02 0.52 
2830861 EGR1 -1.20 0.02 0.09 
4021433 ELF4 1.17 0.02 0.07 
3679959 EMP2 1.17 0.01 0.79 
3345427 ENDOD1 1.32 0.02 0.21 
3150579 ENPP2 2.41 0.00 0.01 
3883690 EPB41L1 1.20 0.01 0.00 
3713794 EPN2 1.11 0.03 0.14 
3015778 EPO -1.33 0.01 0.31 
3400413 ERC1 1.20 0.00 0.98 
3648995 ERCC4 1.13 0.01 0.01 
2462329 ERO1LB 1.49 0.01 0.00 
3445768 ERP27 1.55 0.01 0.42 
2395177 ERRFI1 -1.18 0.00 0.90 
3921068 ETS2 -1.15 0.00 0.53 
3541937 EXDL2 1.18 0.02 0.84 
3566304 EXOC5 1.14 0.00 0.86 
3328389 EXT2 1.24 0.00 0.00 
3502411 F7 -1.17 0.02 0.68 
3979101 FAAH2 1.27 0.02 0.14 
3226253 FAM102A 1.30 0.00 0.06 
3278813 FAM107B -1.18 0.02 0.89 
3471538 FAM109A -1.16 0.01 0.30 
2523354 FAM117B 1.26 0.02 0.01 
3355021 FAM118B 1.20 0.01 0.44 
3225952 FAM129B -1.14 0.01 1.00 
2777487 FAM13A1 -1.52 0.00 0.96 
2867145 FAM172A 1.30 0.01 0.36 
3798778 FAM38B 1.31 0.03 0.54 
3798829 FAM38B2 1.17 0.01 0.20 
2658785 FAM43A -1.20 0.03 0.79 
2634058 FAM55C 1.32 0.01 0.17 
3803290 FAM59A 1.24 0.01 0.43 
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Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
3665550 FAM65A -1.13 0.01 0.71 
3152558 FAM84B 1.28 0.02 0.02 
2904663 FANCE -1.22 0.01 0.62 
2742581 FAT4 1.26 0.02 0.04 
3576749 FBLN5 1.61 0.00 0.00 
3623031 FBN1 1.52 0.00 0.00 
3230530 FBXW5 -1.16 0.01 0.15 
3809621 FECH 1.14 0.03 0.37 
2338487 FGGY -1.19 0.01 1.00 
3125993 FGL1 1.33 0.02 0.72 
2568687 FHL2 -1.25 0.01 0.84 
3401099 FKBP4 1.14 0.03 0.01 
2360468 FLAD1 -1.11 0.03 0.58 
3527864 FLJ10357 -1.12 0.00 0.85 
3898355 FLRT3 1.34 0.01 0.88 
3544625 FLVCR2 1.15 0.01 0.85 
3227159 FNBP1 1.16 0.00 0.42 
3190061 FPGS -1.20 0.01 0.08 
2732655 FRAS1 1.23 0.01 0.67 
3421579 FRS2 1.17 0.02 0.75 
3661152 FTO 1.11 0.01 0.94 
3608398 FURIN 1.15 0.01 0.56 
3130757 FUT10 1.16 0.01 0.80 
3847462 FUT6 1.13 0.02 0.00 
3830189 FXYD1 -1.65 0.00 0.39 
3110272 FZD6 1.39 0.01 0.97 
2745547 GAB1 1.18 0.03 0.03 
3623683 GABPB1 1.16 0.01 0.24 
2401581 GALE -1.18 0.01 0.99 
2511045 GALNT13 1.41 0.03 0.64 
3454892 GALNT6 1.24 0.00 0.36 
3706439 GARNL4 -1.19 0.00 0.29 
2474594 GCKR 1.30 0.01 0.52 
3663228 GINS3 1.19 0.01 0.76 
3471005 GIT2 1.17 0.02 0.10 
 161 
 
Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
3759335 GJC1 1.59 0.00 0.12 
2989537 GLCCI1 1.58 0.02 0.83 
3422855 GLIPR1 1.81 0.00 0.14 
3451246 GLT8D3 1.24 0.02 0.32 
3468103 GNPTAB 1.29 0.01 0.00 
3191338 GPR107 1.23 0.00 0.22 
3475782 GPR109A -1.60 0.02 0.99 
3475794 GPR109B -1.56 0.00 0.94 
2386747 GPR137B 1.35 0.03 0.04 
3662851 GPR97 -1.22 0.01 0.33 
3683377 GPRC5B 1.61 0.00 0.00 
3830002 GRAMD1A -1.17 0.02 0.95 
2584712 GRB14 1.48 0.01 0.87 
2469157 GRHL1 -1.18 0.03 0.92 
3755903 GSDMB 1.32 0.03 0.19 
3574074 GTF2A1 1.15 0.03 0.13 
3192525 GTF3C4 1.11 0.03 0.37 
2954771 GTPBP2 -1.12 0.02 0.53 
3257750 HECTD2 1.43 0.02 0.13 
3396249 HEPACAM 1.44 0.00 0.43 
3354380 HEPN1 1.41 0.02 0.74 
2735459 HERC3 -1.24 0.01 0.96 
3096575 HGSNAT 1.31 0.03 0.19 
3260666 HIF1AN 1.15 0.02 0.46 
3325907 HIPK3 1.16 0.03 0.99 
2948926 HLA-B 1.30 0.01 0.09 
3881282 HM13 1.16 0.01 0.00 
3351841 HMBS -1.12 0.03 0.20 
3815493 HMHA1 -1.38 0.01 0.16 
3557268 HOMEZ 1.18 0.00 0.48 
3851720 HOOK2 -1.15 0.02 0.15 
3667890 HPR -1.33 0.00 0.48 
3711262 HS3ST3B1 1.11 0.02 0.06 
3721815 HSD17B1 -1.15 0.02 0.07 
3671076 HSD17B2 -1.22 0.01 1.00 
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Differential 
Alternative 
splicing 
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2903488 HSD17B8 -1.21 0.02 0.58 
3656737 HSD3B7 -1.18 0.03 0.84 
3934187 HSF2BP 1.34 0.00 0.06 
3308397 HSPA12A 1.30 0.00 0.00 
3925439 HSPA13 1.22 0.03 0.09 
3394123 HYOU1 1.11 0.00 0.64 
3766621 ICAM2 1.18 0.03 0.04 
2957499 ICK 1.21 0.01 0.68 
2948630 IER3 -1.31 0.01 0.90 
2403261 IFI6 1.35 0.01 0.00 
3257246 IFIT1 1.80 0.02 0.11 
3629610 IGDCC3 1.24 0.00 0.40 
3359134 IGF2 1.14 0.02 0.49 
3918535 IL10RB 1.26 0.02 0.42 
3339261 IL18BP 1.18 0.02 0.13 
2359817 INTS3 1.21 0.01 0.19 
3430776 ISCU 1.15 0.01 0.41 
2438482 ISG20L2 1.21 0.01 0.41 
3573123 ISM2 -1.23 0.00 0.55 
3656223 ITGAL -1.33 0.00 0.79 
3276337 ITIH5 1.59 0.00 0.00 
3488985 ITM2B 1.21 0.01 0.66 
3577160 ITPK1 -1.20 0.01 0.75 
3897505 JAG1 -1.27 0.00 0.99 
3357237 JAM3 1.22 0.02 0.13 
2333429 JMJD2A 1.13 0.02 0.43 
2459296 JMJD4 -1.18 0.01 0.97 
2415084 JUN -1.14 0.01 0.11 
3854877 JUND -1.24 0.01 0.87 
3470793 KCTD10 1.20 0.03 0.72 
3867092 KDELR1 1.10 0.02 0.97 
3572041 KIAA0317 1.19 0.02 0.13 
3905073 KIAA0406 1.14 0.01 0.36 
2764192 KIAA0746 1.56 0.00 0.01 
3203990 KIAA1161 1.23 0.02 0.87 
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3604147 KIAA1199 1.14 0.00 0.15 
3238962 KIAA1217 1.25 0.01 0.00 
3655628 KIF22 -1.12 0.03 0.39 
3464747 KITLG 1.66 0.01 0.96 
2724308 KLB 1.20 0.01 0.50 
3147508 KLF10 1.35 0.00 0.04 
2469213 KLF11 1.25 0.01 0.55 
3803418 KLHL14 1.35 0.01 0.03 
3757108 KRT19 -1.18 0.01 0.45 
2925510 L3MBTL3 1.66 0.00 0.05 
2371065 LAMC1 1.22 0.00 0.20 
3631498 LARP6 1.33 0.01 0.43 
2828796 LEAP2 -1.29 0.03 0.67 
3841474 LENG8 1.14 0.00 0.49 
3577078 LGMN 1.16 0.01 0.99 
3866898 LIG1 -1.13 0.02 0.90 
3463727 LIN7A -1.34 0.01 0.59 
3965936 LMF2 -1.14 0.03 0.19 
3416996 LOC440104 1.20 0.02 0.06 
3651509 LOC81691 -1.40 0.01 0.51 
3847356 LONP1 -1.20 0.00 0.72 
2393711 LRRC47 -1.13 0.02 0.16 
3016791 LRWD1 -1.13 0.03 0.60 
3529877 LTB4R2 1.33 0.01 0.01 
3402444 LTBR 1.14 0.01 0.28 
3098977 LYN 1.25 0.03 0.38 
2866590 LYSMD3 1.21 0.01 0.86 
3362826 LYVE1 1.60 0.02 0.78 
4013359 MAGT1 1.14 0.01 0.85 
3633347 MAN2C1 -1.18 0.01 0.42 
3444906 MANSC1 1.57 0.00 0.56 
2814756 MAP1B 1.24 0.01 0.00 
4002081 MAP7D2 1.23 0.00 0.48 
3723687 MAPT 1.47 0.00 0.01 
3286921 MARCH8 1.16 0.01 0.60 
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3702293 MBTPS1 1.12 0.00 0.05 
3394264 MCAM 1.27 0.01 0.13 
3502259 MCF2L 1.11 0.01 0.00 
3329343 MDK 1.23 0.01 0.90 
3844822 MED16 -1.21 0.01 0.48 
3223551 MEGF9 1.20 0.02 0.14 
3618333 MEIS2 1.25 0.00 0.29 
2909263 MEP1A 2.07 0.00 0.21 
3604236 MESDC1 1.14 0.01 0.97 
3796244 METTL4 1.25 0.01 0.09 
3416895 METTL7B 1.21 0.00 0.16 
3638204 MFGE8 1.60 0.00 0.00 
3304012 MGEA5 1.23 0.02 0.21 
3320717 MICAL2 1.14 0.01 0.44 
3256560 MINPP1 1.18 0.01 0.88 
3845647 MKNK2 -1.14 0.00 0.86 
3434525 MLEC 1.19 0.02 0.01 
3699080 MLKL 1.25 0.01 0.89 
3528864 MMP14 1.19 0.02 0.34 
3845681 MOBKL2A -1.24 0.01 0.18 
3064501 MOGAT3 -1.42 0.00 0.79 
3708874 MPDU1 -1.23 0.00 1.00 
4027585 MPP1 1.15 0.01 0.02 
2365958 MPZL1 1.18 0.00 0.71 
3738205 MRPL12 -1.14 0.02 0.82 
3675101 MRPL28 -1.14 0.01 0.99 
3771120 MRPL38 -1.12 0.02 0.99 
2902633 MSH5 -1.24 0.02 0.65 
3942179 MTMR3 1.16 0.00 0.20 
3697183 MTSS1L 1.11 0.03 0.13 
2692883 MUC13 2.99 0.00 0.00 
2896484 MYLIP -1.23 0.01 0.84 
2692447 MYLK 1.11 0.01 0.91 
3458248 MYO1A 1.19 0.01 0.20 
3752709 MYO1D 1.18 0.02 0.58 
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3624607 MYO5A 1.69 0.00 0.00 
3417809 NAB2 -1.22 0.01 0.93 
3229628 NACC2 -1.13 0.02 0.54 
3721795 NAGLU -1.12 0.01 0.65 
3181460 NANS 1.17 0.02 0.65 
3675369 NARFL -1.13 0.02 0.80 
2559619 NAT8 1.48 0.02 0.65 
3770390 NAT9 -1.26 0.00 0.75 
3485292 NBEA 1.47 0.01 0.00 
3649811 NDE1 -1.15 0.01 0.95 
3154317 NDRG1 -1.15 0.01 0.50 
3555736 NDRG2 -1.14 0.01 0.26 
2379068 NENF 1.19 0.02 0.06 
3601051 NEO1 1.36 0.00 0.33 
3690154 NETO2 1.33 0.00 0.97 
3340410 NEU3 1.12 0.02 0.34 
3942062 NF2 1.17 0.00 0.56 
2603987 NGEF -1.18 0.03 0.98 
3564071 NIN 1.37 0.01 0.04 
3956909 NIPSNAP1 -1.24 0.00 0.63 
3182984 NIPSNAP3B 1.32 0.02 0.66 
3660075 NKD1 1.13 0.01 0.67 
3708553 NLGN2 1.21 0.01 0.31 
4030371 NLGN4Y 1.46 0.02 0.67 
3203582 NOL6 -1.11 0.03 0.61 
2431112 NOTCH2 1.22 0.01 0.56 
3146012 NPAL2 1.54 0.02 0.48 
3891048 NPEPL1 1.13 0.01 0.04 
3774029 NPLOC4 1.12 0.01 0.61 
2738378 NPNT 1.37 0.00 0.65 
3632492 NPTN 1.23 0.02 0.99 
2612175 NR2C2 1.13 0.02 0.44 
3225096 NR6A1 1.15 0.00 0.57 
3770588 NT5C -1.21 0.01 0.79 
3304624 NT5C2 1.25 0.01 0.84 
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3468743 NT5DC3 1.25 0.01 0.00 
2915828 NT5E 1.53 0.01 0.80 
3681674 NTAN1 1.10 0.02 0.41 
3322251 NUCB2 1.37 0.02 0.58 
3751463 NUFIP2 1.15 0.02 1.00 
3376155 NXF1 1.19 0.00 0.21 
3432438 OAS1 1.19 0.01 0.66 
2912980 OGFRL1 1.81 0.02 0.31 
2609904 OGG1 -1.24 0.01 0.68 
3981120 OGT 1.15 0.03 0.61 
3319119 OLFML1 2.14 0.00 0.36 
3942531 OSBP2 1.37 0.02 0.44 
3549517 OTUB2 1.28 0.01 0.33 
3335952 PACS1 1.15 0.00 0.65 
3815116 PALM 1.21 0.02 0.08 
3457696 PAN2 -1.12 0.03 0.16 
2392528 PANK4 -1.11 0.03 0.77 
2910218 PAQR8 -1.12 0.03 0.14 
2699059 PAQR9 1.33 0.02 0.79 
2708229 PARL -1.19 0.01 0.68 
2639054 PARP14 1.26 0.03 0.84 
3629567 PARP16 1.24 0.03 0.32 
3368054 PAX6 1.20 0.03 0.40 
3887165 PCIF1 -1.13 0.02 0.74 
3175274 PCSK5 1.35 0.00 0.00 
3727712 PCTP 1.26 0.01 0.82 
2487696 PCYOX1 1.24 0.01 0.66 
3262198 PDCD11 1.10 0.02 0.69 
2589017 PDE11A 1.41 0.01 0.68 
3089535 PDLIM2 -1.20 0.01 0.17 
3766796 PECAM1 1.47 0.01 0.00 
2318656 PER3 -1.12 0.01 0.10 
3957445 PES1 -1.12 0.01 0.64 
3753690 PEX12 1.21 0.02 0.98 
2390518 PGBD2 1.17 0.01 0.66 
 167 
 
Transcript 
cluster ID Gene  
Gene 
Fold-
Change 
(E/C) 
Differential 
gene 
expression 
FDR 
Differential 
Alternative 
splicing 
FDR 
2953751 PGC -1.43 0.00 0.63 
4001556 PHKA2 -1.23 0.00 0.38 
3259978 PI4K2A 1.14 0.03 0.05 
3301914 PIK3AP1 1.24 0.00 0.18 
2905404 PIM1 -1.32 0.01 0.97 
3173673 PIP5K1B 1.23 0.02 0.15 
3732230 PITPNC1 1.44 0.01 0.10 
3822723 PKN1 -1.13 0.01 0.98 
3190683 PKN3 -1.16 0.01 0.90 
3922975 PKNOX1 1.19 0.01 0.04 
2977621 PLAGL1 1.44 0.00 0.01 
3828067 PLEKHF1 1.17 0.01 0.73 
2479433 PLEKHH2 1.46 0.02 0.01 
3845782 PLEKHJ1 -1.27 0.01 0.52 
3759849 PLEKHM1 1.21 0.00 0.50 
2453370 PLXNA2 1.23 0.00 0.00 
3426502 PLXNC1 1.34 0.00 0.00 
3746574 PMP22 1.51 0.00 0.61 
3073013 PODXL 1.16 0.01 0.02 
3881786 POFUT1 1.20 0.02 0.91 
3572982 POMT2 1.17 0.01 0.32 
3820342 PPAN -1.14 0.01 0.55 
2948425 PPP1R10 1.24 0.00 0.02 
3838004 PPP1R15A -1.31 0.00 0.98 
2518488 PPP1R1C 1.20 0.02 0.01 
3272761 PRAP1 1.24 0.02 0.89 
3838809 PRMT1 -1.13 0.02 0.26 
3874751 PRNP 1.19 0.00 0.93 
3973692 PRRG1 1.21 0.03 0.11 
3717737 PSMD11 1.11 0.02 0.85 
2353717 PTGFRN 1.12 0.02 0.00 
3402736 PTMS 1.32 0.01 0.50 
3871192 PTPRH -1.15 0.00 0.99 
3329983 PTPRJ 1.25 0.01 0.04 
3081862 PTPRN2 1.23 0.00 0.00 
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3757917 PTRF 1.18 0.01 0.68 
3157817 PUF60 -1.17 0.02 0.84 
2315739 PUSL1 -1.20 0.01 0.41 
3923498 PWP2 -1.13 0.00 1.00 
3625440 PYGO1 1.74 0.02 0.53 
3771464 QRICH2 1.17 0.02 0.00 
3820727 QTRT1 -1.19 0.01 0.65 
2888648 RAB24 -1.15 0.03 0.88 
3384321 RAB30 1.26 0.02 0.57 
3189617 RALGPS1 1.45 0.01 0.09 
3497659 RAP2A 1.35 0.00 0.50 
2675208 RASSF1 -1.19 0.01 0.65 
3315952 RASSF7 -1.31 0.02 0.33 
2546054 RBKS -1.29 0.00 0.70 
3472468 RBM19 1.11 0.00 0.03 
3976519 RBM3 -1.16 0.03 0.50 
3696226 RBM35B -1.47 0.00 0.52 
2766788 RBM47 1.46 0.00 0.00 
3378411 RBM4B 1.21 0.01 1.00 
3390542 RDX 1.29 0.02 0.81 
3168309 RECK 1.55 0.00 0.14 
2765865 RELL1 1.11 0.00 0.51 
2407786 RHBDL2 1.48 0.03 0.49 
3710870 RICH2 1.42 0.01 0.00 
3397877 RICS 1.14 0.02 0.77 
3878836 RIN2 1.33 0.03 0.05 
3861658 RINL -1.15 0.01 0.75 
3933205 RIPK4 -1.13 0.02 0.72 
3821908 RNASEH2A -1.11 0.02 0.51 
2562867 RNF103 1.36 0.01 0.54 
3844704 RNF126 -1.21 0.02 0.89 
2647458 RNF13 1.13 0.00 0.90 
2897172 RNF144B -1.20 0.02 0.72 
3704352 RNF166 -1.11 0.02 0.50 
2924253 RNF217 1.20 0.03 0.26 
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2333907 RNF220 -1.15 0.01 1.00 
2339872 ROR1 1.55 0.00 0.10 
2435261 RORC -1.17 0.01 0.53 
3230440 
RP11-
216L13.5 -1.57 0.00 0.58 
2321466 
RP1-
21O18.1 -1.13 0.01 0.88 
3978819 RRAGB 1.37 0.02 0.78 
2964231 RRAGD 2.15 0.00 0.01 
2675763 RRP9 -1.20 0.01 0.41 
3691326 SALL1 1.34 0.00 0.02 
3556454 SALL2 -1.19 0.02 0.49 
3909777 SALL4 1.62 0.01 0.07 
3252534 SAMD8 1.14 0.01 0.52 
3904691 SAMHD1 1.40 0.01 0.48 
2594089 SATB2 1.27 0.00 0.33 
3844978 SBNO2 -1.19 0.02 0.94 
3602004 SCAMP5 1.16 0.01 0.36 
3605780 SCAND2 1.27 0.01 0.12 
3091475 SCARA3 1.41 0.00 0.28 
2898934 SCGN 1.38 0.01 0.98 
3414969 SCN8A 1.31 0.01 0.29 
3441885 SCNN1A 1.19 0.02 0.91 
3728037 SCPEP1 1.29 0.00 0.27 
2592532 SDPR -1.40 0.00 0.72 
3790479 SEC11C 1.30 0.03 0.18 
3942350 SEC14L2 1.32 0.00 0.05 
3574207 SEL1L 1.16 0.02 0.82 
2622547 SEMA3F 1.13 0.02 0.01 
2872047 SEMA6A 1.52 0.00 0.45 
2328273 SERINC2 -1.33 0.00 0.93 
3549708 SERPINA4 1.18 0.01 0.83 
3549740 SERPINA5 1.30 0.00 0.46 
3387259 SESN3 3.26 0.00 0.62 
3687277 SEZ6L2 1.13 0.03 0.19 
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3250863 SGPL1 1.17 0.01 0.07 
3982811 SH3BGRL 1.56 0.01 0.12 
4001850 SH3KBP1 1.15 0.02 0.95 
3205659 SHB -1.26 0.00 0.68 
3708919 SHBG -1.24 0.02 0.77 
2875491 SHROOM1 -1.16 0.00 0.47 
3920171 SIM2 1.19 0.02 0.01 
3542847 SIPA1L1 1.14 0.00 0.89 
3873629 SIRPA 1.94 0.00 0.01 
3494706 SLAIN1 1.62 0.03 0.32 
3617312 SLC12A6 1.12 0.02 0.42 
3907987 SLC13A3 1.15 0.02 0.18 
3522327 SLC15A1 1.47 0.02 0.02 
2921402 SLC16A10 1.15 0.01 0.13 
2427469 SLC16A4 1.28 0.03 0.75 
3768412 SLC16A6 -1.53 0.00 0.13 
2485636 SLC1A4 1.21 0.01 0.22 
2353337 SLC22A15 -1.23 0.02 0.30 
3557350 SLC22A17 1.16 0.02 0.01 
2877861 SLC23A1 -1.20 0.02 0.77 
3598430 SLC24A1 1.10 0.02 0.16 
3738224 SLC25A10 -1.23 0.01 0.99 
3742384 SLC25A11 -1.17 0.03 0.58 
3990762 SLC25A14 1.21 0.01 0.75 
3561532 SLC25A21 1.59 0.01 0.34 
3251023 SLC29A3 1.14 0.02 0.98 
3887452 SLC2A10 1.14 0.02 0.72 
2701927 SLC33A1 1.18 0.02 0.50 
3354443 SLC37A2 -1.20 0.01 0.25 
3394092 SLC37A4 -1.34 0.01 0.21 
2584904 SLC38A11 1.80 0.02 0.02 
3542063 SLC39A9 1.11 0.03 0.72 
3469180 SLC41A2 1.38 0.02 0.13 
3183111 SLC44A1 1.15 0.03 0.26 
3820612 SLC44A2 1.60 0.00 0.01 
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3895330 SLC4A11 -1.14 0.01 0.97 
3988165 SLC6A14 2.07 0.01 0.69 
3087659 SLC7A2 -1.19 0.02 0.39 
3684100 SLC7A5P1 -1.27 0.01 0.40 
3340449 SLCO2B1 -1.18 0.02 0.94 
3892812 SLCO4A1 -1.12 0.00 0.08 
3945877 SMCR7L 1.14 0.02 0.04 
3713195 SMCR8 1.22 0.02 0.17 
3740838 SMG6 1.11 0.02 0.65 
3134511 SNAI2 1.59 0.00 0.14 
2824089 SNORA13 -1.19 0.01 0.98 
3833757 SNRPA -1.11 0.02 0.98 
3899346 SNX5 -1.11 0.01 0.41 
3035702 SNX8 -1.15 0.01 0.59 
2920085 SOBP 1.31 0.00 0.08 
3352948 SORL1 -1.16 0.00 0.98 
3733590 SOX9 1.16 0.00 0.85 
3883441 SPAG4 -1.32 0.00 0.92 
2882098 SPARC 1.84 0.00 0.02 
2411575 SPATA6 1.33 0.03 0.64 
3413950 SPATS2 1.22 0.01 0.83 
3293840 SPOCK2 1.51 0.00 0.00 
3455973 SPRYD3 -1.10 0.02 0.78 
3876990 SPTLC3 1.29 0.01 0.01 
3984468 SRPX2 1.22 0.01 0.04 
3894322 SRXN1 1.15 0.02 0.73 
3470597 SSH1 1.20 0.02 0.20 
3154398 ST3GAL1 -1.13 0.02 0.82 
3846709 STAP2 -1.16 0.01 0.43 
3381317 STARD10 1.19 0.01 0.60 
3980078 STARD8 1.39 0.00 0.00 
2999485 STK17A -1.24 0.01 0.75 
2951916 STK38 1.26 0.02 0.87 
3189932 STXBP1 1.34 0.02 0.03 
3558418 STXBP6 1.18 0.01 0.05 
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3261765 SUFU 1.14 0.03 0.20 
3908358 SULF2 1.51 0.00 0.01 
3417184 SUOX 1.16 0.01 0.94 
3282974 SVIL 1.17 0.00 0.01 
3375396 SYT7 1.26 0.02 0.14 
3094778 TACC1 1.20 0.02 0.14 
3361021 TAF10 -1.15 0.02 0.15 
2950214 TAP1 1.14 0.02 0.68 
3773241 TBC1D16 1.20 0.01 0.59 
3634458 TBC1D2B 1.28 0.01 0.16 
3968122 TBL1X 1.13 0.00 0.00 
3644249 TBL3 -1.13 0.03 0.19 
3472755 TBX3 1.15 0.03 0.42 
3063856 tcag7.1177 1.17 0.02 0.00 
3893910 TCEA2 1.16 0.01 0.02 
2622095 TCTA -1.26 0.00 0.89 
3264299 TECTB 1.36 0.00 0.33 
2845829 TERT -1.19 0.02 0.97 
2731757 THAP6 1.15 0.03 0.37 
3589458 THBS1 -1.19 0.00 0.79 
3956854 THOC5 1.19 0.00 0.35 
3816611 THOP1 -1.22 0.01 0.60 
2708498 THPO -1.15 0.00 0.50 
3558012 TINF2 -1.13 0.01 0.42 
3631214 TLE3 1.23 0.01 0.03 
3176209 TLE4 1.29 0.02 0.23 
3448481 TM7SF3 1.16 0.01 0.66 
3502632 TMCO3 1.13 0.02 0.00 
3182229 TMEFF1 1.65 0.01 0.18 
3412345 TMEM117 1.18 0.01 0.38 
3194613 TMEM141 -1.38 0.00 0.68 
3987029 TMEM164 1.36 0.00 0.12 
2526971 TMEM169 1.32 0.02 0.57 
4025500 TMEM185A 1.19 0.00 0.42 
3745525 TMEM220 -1.28 0.02 0.41 
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3675116 TMEM8 -1.16 0.02 0.81 
3449068 TMTC1 1.27 0.02 0.01 
3425134 TMTC3 1.29 0.02 0.04 
3645555 TNFRSF12A -1.28 0.02 0.80 
3481410 TNFRSF19 1.13 0.02 0.13 
2956052 TNFRSF21 1.15 0.01 0.03 
2444283 TNFSF4 -1.36 0.03 0.77 
2599153 TNS1 -1.35 0.00 1.00 
3748026 TOM1L2 1.15 0.02 0.07 
3954331 TOP3B 1.14 0.01 0.76 
3191147 TOR1B 1.12 0.01 0.27 
3145149 TP53INP1 1.32 0.00 0.95 
3597338 TPM1 1.12 0.02 0.04 
3644541 TRAF7 -1.14 0.02 0.42 
3677752 TRAP1 -1.13 0.02 0.90 
3819104 TRAPPC5 1.18 0.01 0.64 
2748061 TRIM2 1.56 0.01 0.57 
3763656 TRIM25 1.14 0.00 0.66 
3978579 TRO 1.28 0.01 0.21 
2991150 TSPAN13 1.18 0.01 0.01 
3634071 TSPAN3 1.11 0.00 0.01 
3418492 TSPAN31 -1.11 0.02 0.94 
3978169 TSPYL2 1.25 0.03 0.21 
3891342 TUBB1 -1.27 0.00 0.65 
3959593 TXN2 1.17 0.02 0.10 
3217736 TXNDC4 1.21 0.01 0.51 
2356115 TXNIP 1.26 0.01 0.95 
3195139 UAP1L1 -1.30 0.01 0.93 
2947877 UBD 1.50 0.01 0.24 
3431143 UBE3B 1.13 0.00 0.38 
2319560 UBE4B 1.14 0.00 0.08 
3758967 UBTF 1.11 0.02 0.46 
3486025 UFM1 1.14 0.00 0.19 
3438527 ULK1 1.13 0.02 0.01 
3770979 UNC13D -1.17 0.02 0.99 
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2936731 UNC93A -1.99 0.00 0.94 
3379269 UNC93B1 -1.17 0.01 1.00 
3597603 USP3 1.21 0.01 0.03 
3685051 USP31 -1.10 0.02 0.78 
3990566 UTP14A 1.18 0.03 0.21 
2949380 VARS -1.14 0.02 0.35 
2818517 VCAN 1.38 0.02 0.05 
3351806 VPS11 -1.14 0.01 0.10 
3569374 VTI1B 1.28 0.02 0.84 
2760371 WDR1 -1.10 0.03 0.77 
3976716 WDR13 -1.24 0.01 0.61 
3569926 WDR22 1.18 0.02 0.44 
3933817 WDR4 -1.12 0.02 0.72 
3699178 WDR59 1.12 0.00 0.00 
3591704 WDR76 1.17 0.03 0.53 
3722084 WNK4 1.11 0.03 0.84 
3715109 WSB1 -1.25 0.00 0.00 
3848437 XAB2 -1.13 0.02 0.84 
3956589 XBP1 1.12 0.01 0.00 
3687452 YPEL3 1.13 0.02 0.44 
3075566 ZC3HAV1 1.29 0.01 0.06 
3703665 ZCCHC14 1.18 0.02 0.30 
3307120 ZDHHC6 1.25 0.01 0.12 
3668898 ZFP1 1.33 0.01 0.72 
3620590 ZFP106 1.15 0.02 0.18 
3860410 ZFP82 1.35 0.03 0.51 
3571248 ZFYVE1 1.17 0.02 0.01 
3151473 ZHX1 1.24 0.01 0.11 
3906062 ZHX3 1.17 0.01 0.68 
3645881 ZNF174 1.25 0.03 0.98 
3359751 ZNF195 1.31 0.03 0.33 
3835544 ZNF227 1.24 0.02 0.10 
3835467 ZNF234 1.23 0.00 0.76 
3954525 ZNF280B 1.19 0.02 0.06 
3902081 ZNF337 1.23 0.02 0.52 
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3129304 ZNF395 -1.13 0.01 0.39 
3831698 ZNF420 1.23 0.01 0.01 
3821410 ZNF440 1.38 0.02 0.32 
3184896 ZNF483 1.89 0.02 0.40 
3826601 ZNF493 1.31 0.00 0.17 
3819968 ZNF559 1.16 0.00 0.33 
3842301 ZNF581 -1.18 0.01 0.43 
3856075 ZNF682 1.41 0.02 0.90 
3840372 ZNF701 1.24 0.02 0.73 
3851374 ZNF709 1.44 0.02 0.46 
4023006 ZNF75D 1.40 0.02 0.46 
2904528 ZNF76 -1.23 0.02 0.77 
3908831 ZNFX1 1.17 0.02 0.68 
3029129 ZYX -1.21 0.00 0.62 
3741875 ZZEF1 1.14 0.01 0.02 
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